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Résumé 
 
Le CD40 est un membre de la famille des récepteurs du facteur de nécrose tumorale ("Tumour 
necrosis factor", TNF), initialement identifié sur des cellules de carcinome de la vessie. 
L'interaction du CD40 avec son ligand (CD40L) est d'une importance cruciale pour le 
développement des cellules B et de la commutation d'isotype au cours de la réponse immunitaire 
acquise. L'expression du complexe CD40/CD40L était initialement cru d'être limiter aux cellules 
du système immunitaire, mais aujourd'hui il est bien connu que ce complexe est également 
exprimé sur les cellules du système circulatoire et vasculaire, et est impliqué dans diverses 
réactions inflammatoires; de sorte que le CD40L est maintenant considéré comme une molécule 
thrombo-inflammatoire prédictive des événements cardiovasculaires. Les plaquettes expriment 
constitutivement le CD40, alors que le CD40L n'est exprimé que suite à leur l'activation. Il est 
ensuite clivé en sa forme soluble (sCD40L) qui représente la majorité du sCD40L en circulation. 
Il fut démontré que le sCD40L influence l'activation plaquettaire mais son effet exact sur la 
fonction plaquettaire, ainsi que les mécanismes cellulaires et moléculaires sous-jacents à son 
action demeurent inconnus. Ainsi, ce projet a été entrepris dans le but d’adresser les objectifs 
spécifiques suivants: 1) évaluer les effets in vitro du sCD40L sur l'activation et l'agrégation 
plaquettaire; 2) identifier les récepteurs plaquettaires impliqués dans l’action du sCD40L; 3) 
élucider les voies signalétiques intracellulaires induits par le sCD40L; 4) évaluer les effets du 
sCD40L sur la formation de thrombus in vivo. 
 Nous avons trouvé que le sCD40L augmente fortement l'activation et l'agrégation des 
plaquettes en réponse à de faibles concentrations d'agonistes. Les plaquettes humaines traitées 
avec une forme mutante du sCD40L qui n'interagit pas avec le CD40, et les plaquettes de souris 
déficientes en CD40 ne furent pas en mesure d'induire de telles réponses, indiquant que le 
récepteur principal du sCD40L au niveau des plaquettes est le CD40. En plus, nous avons 
identifié la présence de plusieurs membres de la famille du facteur associé du récepteur du TNF 
("TNF receptor-associated factor", TRAF) dans les plaquettes et nous avons montré que 
seulement le TRAF2 s'associe avec le CD40 suite à la stimulation par le sCD40L. Nos résultats 
indiquent aussi que le sCD40L agisse sur les plaquettes au repos par l'entremise de deux voies 
signalétiques distinctes. La première voie implique l'activation de la petite GTPase Rac1 et de sa 
cible en aval, soit la protéine kinase p38 activée par le mitogène ("p38 mitogen-activated protein 
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kinase", p38 MAPK ), menant au changement de forme plaquettaire et à la polymérisation de 
l'actine; alors que la deuxième voie implique l'activation de la cascade signalétique du NF-kB. 
Par ailleurs, à la suite d'une lésion artérielle induite par le chlorure de fer, le sCD40L exacerbe la 
formation de thrombus et l'infiltration leucocytaire au sein du thrombus dans les souris du type 
sauvage, mais pas chez les souris déficientes en CD40. 
 En conclusion, ce projet a permis d'identifier pour la première fois deux voies 
signalétiques distinctes en aval du CD40 plaquettaire et a permis d'établir leur implication dans 
l'activation et l'agrégation plaquettaire en réponse au sCD40L. De manière plus importante, ce 
projet nous a permis d'établir un lien direct entre les niveaux élevés du sCD40L circulant et la 
formation de thrombus in vivo, tout en soulignant l'importance du CD40 dans ce processus. Par 
conséquent, l'axe CD40/CD40L joue un rôle important dans l'activation des plaquettes, les 
prédisposant à une thrombose accrue en réponse à une lésion vasculaire. Ces résultats peuvent 
expliquer en partie la corrélation entre les taux circulants élevés du sCD40L et l'incidence des 
maladies cardiovasculaires. 
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Abstract 
 
CD40 is a member of the tumour necrosis factor (TNF) receptor family, originally identified on 
human bladder carcinoma cells. Interaction of CD40 with its ligand (CD40L) is of crucial 
importance for B cell development and immunoglobulin isotype switching during the adaptive 
immune response. Expression of the CD40/CD40L dyad was initially thought to be restricted to 
cells of the immune system, but today it is known to be also expressed on cells of the circulatory 
and vascular systems, and have important implications in various inflammatory reactions, such 
that CD40L is now regarded as a thrombo-inflammatory molecule and a reliable predictor of 
cardiovascular events. Platelets constitutively express CD40, whereas CD40L is expressed upon 
activation and subsequently cleaved into its soluble form (sCD40L), accounting for the majority 
of circulating sCD40L. Soluble CD40L has been shown to influence platelet activation but its 
precise effect on platelet function, and the underlying cellular and molecular mechanisms remain 
undefined; hence the purpose of this project. The specific aims of this study are: 1) to evaluate 
the in vitro effects of sCD40L on platelet activation and aggregation; 2) to determine the 
receptor(s) on platelets involved in the action of sCD40L; 3) to elucidate the intracellular 
signalling pathways induced by sCD40L; and 4) to evaluate the in vivo effects of sCD40L on 
thrombus formation. 
 We have showed that sCD40L strongly enhances activation and aggregation of washed 
human platelets in response to sub-threshold concentrations of agonists. Human platelets treated 
with a mutated form of sCD40L that lacks CD40 binding, and platelets from CD40 deficient 
mice failed to elicit such responses, indicating that CD40 is the major platelet receptor for 
sCD40L. Moreover, we identified the presence of multiple members of the TNF receptor-
associated factor (TRAF) in platelets and showed that only TRAF2 associates with CD40 after 
sCD40L stimulation. Interestingly, sCD40L primes resting platelets through two distinct 
signalling pathways. The first pathway involves activation of the small GTPase Rac1 and its 
downstream target p38 mitogen-activated protein kinase, leading to platelet shape change and 
actin polymerization; whereas the second pathway involves activation of the NF-κB signalling 
cascade. Furthermore, sCD40L exacerbates thrombus formation and leukocyte infiltration within 
the thrombus mass in wild-type mice but not in CD40 deficient mice following ferric chloride-
induced arterial injury. 
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 In conclusion, we have identified for the first time two distinct signalling pathways 
downstream of platelet CD40, and established their implication in platelet activation and 
aggregation in response to sCD40L. Noticeably, we established a direct link between elevated 
levels of sCD40L and in vivo thrombus formation, while emphasizing the requirement of CD40 
in this process. Therefore, the CD40/CD40L dyad plays an important role in platelet priming that 
predisposes platelets to enhanced thrombus formation in response to vascular injury. These 
results may partly explain the correlation between elevated circulating levels of sCD40L and the 
incidence of cardiovascular diseases. 
 
Key words: platelets ■ thrombosis ■ signal transduction ■ CD40 ■ CD40L 
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1.1 Introduction 
Platelets were considered as "red cell dust" mere fifty years ago, but now they are viewed as 
sentinels of the vascular system, where they react to damage to the vascular wall by forming a 
haemostatic plug. Beyond their role in haemostasis, platelets have emerged as active players in 
inflammation as well as modulators of both the innate and adaptive immunity. Their involvement 
in all facets of atherosclerosis, which is now considered as a chronic inflammatory disease, is 
probably the most relevant example in which platelets are viewed as true thrombo-inflammatory 
cells. The initiation, development, and progression of the atherosclerotic plaque depend largely 
on the interaction of platelets with the endothelium and subsequent recruitment of leukocytes to 
the lesion site, which is mediated by a plethora of molecules expressed and secreted by platelets. 
The thrombotic events resulting from atherosclerotic plaque rupture rely mainly on the activation 
and aggregation of platelets, and their subsequent involvement in mediating activation of the 
coagulation cascade. 
 CD40 ligand (CD40L) is among the important inflammatory molecules expressed by 
activated platelets. This inflammatory mediator was initially thought to be exclusive to activated 
T lymphocytes, but now it is known to be expressed on a wide array of cells, including 
endothelial cells, macrophages, smooth muscle cells, and platelets.1 Interaction of CD40L with 
its cognate receptor, CD40, on B lymphocytes is of major importance in the immune response. 
The pioneering work by Henn et al.2, 3 demonstrated  the presence of the CD40 and CD40L dyad 
in platelets, as well as the role of platelet CD40L in inducing an inflammatory reaction in 
endothelial cells. Platelet CD40L has since been viewed as a key player in atherosclerosis 
development, and now a plethora of evidence point to multiple roles of platelet CD40L, 
including the stabilization of thrombus formation by sustaining platelet/platelet aggregates, 
activation of antigen presenting cells (APC), and differentiation and Ig isotype class switching in 
B cells.4-6 
 Platelets are estimated to account for more than 95% of circulating soluble CD40L 
(sCD40L).7 In addition, there is a close link between elevated levels of circulating sCD40L and 
clinical complications related to multiple vascular diseases, including acute coronary syndromes 
(ACS), peripheral arterial occlusive disease, hypercholesterolemia, and diabetes.8-12 Indeed, 
elevated levels of sCD40L are now considered as a risk factor for future cardiovascular events.13 
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Therefore, a better understanding of the interplay between CD40L and platelets could shed light 
on future diagnostic and preventive cardiovascular disease treatments. 
 
1.2 Origin and structure 
Platelets were first described by Osler in 1873 for their disk-like structure,14 then in 1881 
Bizzozero identified platelets anatomically and associated them with a haemostatic and 
experimental thrombotic role.15, 16 Bizzozero was also the first to identify bone marrow 
megakaryocytes without recognizing them as the precursors of platelets, which was later 
discovered by Wright in 1906.17, 18 Actually, platelets are not only recognized for their 
physiological haemostatic role, but also for their contribution in multiple pathological conditions 
such as vascular thrombosis, atherosclerosis, inflammation, immunity, oncology, coronary and 
cerebral-vascular diseases, diabetes and psychiatric diseases. 
 Platelets are derived from highly specialized cells called megakaryocytes, which have the 
sole purpose of generating platelets. Megakaryocytes develop from pluripotent hematopoietic 
stem cells that are characterized by their surface expression of CD34 and CD41, and have 
become committed to the megakaryocyte lineage as indicated by expression of CD61 (integrin 
β3, GPIIIa) and CD41 (integrin αIIb, GPIIb) according to the model in Figure 1.1.19 
 Although it is well established that platelets originate from megakaryocytes, the 
mechanisms by which they are formed and released remains controversial. Three models of 
platelet formation have been proposed: 1) cytoplasmic fragmentation, 2) platelet budding, and 3) 
pro-platelet formation. The cytoplasmic fragmentation model describes the formation of mature 
platelets within the megakaryocytes. These platelets are then released following the 
defragmentation of the megakaryocytic membrane.20, 21 However, this model lost support 
because of several inconsistent observations.  For instance, the platelet territories within the 
megakaryocytes do not exhibit structural characteristics of platelets. In the platelet budding 
model, platelets are formed by blebs pinching off from the megakaryocyte surface.22, 23 This 
model was also rejected because examination by electron microscopy revealed that these blebs 
lack platelet organelles. Accumulating evidence now support the current proposed pro-platelet 
formation model, in which megakaryocytes in the bone marrow form long cytoplasmic 
extensions through junctions in the lining of blood sinuses, thereby releasing barbell shaped pro-
platelets into the circulation that undergo further fragmentation into individual platelets.24, 25 
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Figure 1.1: Megakaryocytopoiesis. (CFU-GEMM: Colony-forming unit-granulocyte-erythroid-macrophage-
megakaryocyte; BFU-Meg: burst-forming unit-megakaryocyte; CFU-Meg: colony-forming unit-megakaryocyte. 
Michelson A. D. (2007). Platelets. Second Edition. Burlington: Academic Press. p. 24. 
 
 Platelets circulate in the blood at a concentration of 150-450 x 106 per mL in adults and 
have a life span averaging 10 days. Senescent platelets are removed from the circulation in the 
spleen, liver and the mononuclear phagocyte system. Platelets are disc shaped with an average 
dimension of 3 μm x 0.5 μm. They are anucleated cells and their cytoplasmic organelles, such as 
mitochondria, granules, lysosomes and residual membranes of the endoplasmic reticulum 
originate from megakaryocytes.26 The platelet structure is divided into three essential 
components: the plasma membrane, the cytoskeleton and the secretory granules. 
 The platelet plasma membrane is a smooth surface containing invaginations that form the 
open canalicular system (OCS). This system forms an elaborate circuit of plasma membrane 
allowing entry of certain molecules inside the cell. In addition, during platelet activation, the 
granules secrete their contents to the cell surrounding through fusion with the membrane of the 
OCS. Moreover, the OCS provides additional plasma membrane reserve that is used for platelet 
shape change and spreading. Finally, as for other cells, the plasma membrane is an anchoring site 
for multiple receptors and adhesion molecules.27 
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 The platelet cytoskeleton is formed by a monolayer of microtubule filaments underlining 
the plasma membrane, a spectrin membrane cytoskeleton and a cytoplasmic cytoskeleton formed 
by actin filaments (Figure 1.2).28-30 The microtubule filament confers the discoid shape to resting 
platelets while the spectrin membrane cytoskeleton, as well as the actin filaments, helps in 
maintaining the shape of resting platelets. In addition, the actin filaments constitute anchoring 
sites for different membrane glycoproteins (GP).31 As a whole, the platelet cytoskeleton harbours 
a site where multiple biochemical reactions, involved in platelet activation, occur.32 During 
platelet activation, there is reorganization of the cytoskeleton that allows platelets to change from 
their discoid structure into a spherical one containing multiple filopodia protrusions.33, 34 
 
   
Figure 1.2: Structure of platelet cytoskeleton. A) A monolayer of microtubule filaments surrounding the 
cytoplasmic cytoskeleton, which is formed by actin filaments. B) Structure of the membrane cytoskeleton formed by 
spectrin. C) Interaction between spectrin of the membrane cytoskeleton and actin filaments. D) Schematic of the 
membrane and cytoplamic cytoskeletons of platelets. Michelson A. D. (2007). Platelets. Second Edition. Burlington: 
Academic Press. p. 76. 
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 The cytoplasm of platelets is occupied by a large number of secretory granules (see 
section 1.4.3). Platelets contain three types of granules; alpha granules, dense granules and 
lysosomes, which contain a plethora of molecules that play an important role in platelet 
activation, adhesion and aggregation. 
 
1.3 Platelet receptors and adhesion molecules 
Platelets play a pivotal role in haemostasis by maintaining the integrity of the blood vessels. In 
order to accomplish this task, platelets contain multiple receptors and adhesion molecules that 
allow them to respond to external stimuli and to interact with the endothelium, the sub-
endothelial matrix and other platelets. Extensive research on the understanding of platelet 
receptors, adhesion molecules and the underlying signalling cascades shed light into the 
mechanisms by which platelets contribute not only to their physiological role in haemostasis but 
also to their pathological involvement in thrombosis. 
 Among the most important platelet receptors are the seven transmembrane domain 
receptors also known as G protein coupled receptors (GPCRs). Platelets express five types of 
GPCRs: the protease activated receptors (PARs), the purinergic receptors, the thromboxane 
receptors, the serotonin receptor (also known as the 5-hydroxytryptamine receptor; 5-HT 
receptor), and the adrenergic receptor. Human platelets contain PAR1, PAR4 and traces of 
PAR3, while mouse platelets contain PAR4 and PAR3.35-37 The purinergic receptors expressed 
on platelets are the ADP receptors P2Y2 and P2Y12, and the ATP receptor P2X1.38-40 The 
thromboxane receptors expressed by platelets are the two TP splice variants TPα and TPβ.41, 42 
The 5-HT and adrenergic receptors expressed by platelets are the 5-HT2A and α2A, respectively.43, 
44 
 In addition to the GPCRs, platelets also contain four types of adhesion molecules: the 
integrins, the immunoglobulins, the selectins and the sialomucins. The integrins include the 
integrin αIIbβ3 (GPIIb/IIIa), the integrin α2β1 (GPIa/IIa), the integrin αvβ3 (vitronectin receptor), 
the integrin α5β1 (fibronectin receptor) and the integrin α6β1 (laminin receptor). Among the 
immunoglobulins, platelets contain the GPVI, the Fc receptors (FcγRIIA and FcεRI), the 
intercellular adhesion molecule-2 (ICAM-2) and the platelet/endothelial adhesion molecule-1 
(PECAM-1). Among the selectins, platelets contain only P-selectin (CD62P) and among the 
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sialomucins, platelets express only GPIb/IX/V. In this section, only the most relevant receptors 
and adhesion molecules will be discussed. 
 
1.3.1 Protease activated receptors 
Activation of platelets by thrombin was first discovered by Wright and Minot in 1917.45 Now it 
is well established that thrombin is the most potent platelet activator.46 Platelets contain two 
types of thrombin receptors: GPIb/IX/V (see section 1.3.4) and PARs (PAR1, PAR3, and PAR4). 
There are four known ubiquitously expressed members of the PAR family (PAR1, PAR2, PAR3, 
and PAR4).47 PAR1 was first discovered in human platelets following cloning of a mRNA 
encoding this receptor in platelets.48 The presence of PAR3 in murine platelets was put into 
evidence by the delayed thrombin response of platelets derived from PAR3 deficient mice. The 
PAR4-activating peptide (AYPGKF-NH2) was shown to induce activation and aggregation of 
human platelets as well as platelets derived from PAR3 deficient mice, indicating the presence of 
PAR4 as a second PAR receptor in platelets.37 This section will focus on PAR1 and PAR4, since 
PAR3 does not induce signalling but is rather a cofactor for PAR4 in murine platelets, and PAR2 
is absent from platelets.49 
 PARs are seven transmembrane GPCRs that are irreversibly activated by serine proteases 
such as thrombin and trypsin, which cleave the receptors' amino terminal extracellular domain at 
a specific arginyl site, leading to unmasking of a previously cryptic tethered ligand domain that 
binds to a region in the second extracellular loop of the receptor, thereby inducing self activation 
of the receptor.48 Activation of PAR1 by thrombin rapidly transmits the signal across the plasma 
membrane to internally located G proteins. G12/13 activation by PAR1 allows them to bind Rho 
guanine-exchange factors (Rho GEFs) which are responsible for the change in platelet shape.50, 51 
Activation of Gi by PAR1 induces a rapid rise in intracellular Ca2+ due to inhibition of cyclic 
adenosine monophosphate (cAMP), while activation of Gq stimulates phospholipase Cβ (PLCβ)-
induced hydrolysis of membrane phosphoinositides (such as phophatidylinositol 4,5-
bisohosphate [PIP2]), thereby releasing inositol-1,4,5-triphosphate (IP3) and diacylglycerol 
(DAG).52, 53 DAG in turn activates protein kinase C (PKC), which causes phosphorylation of 
proteins such as the vasodilator-stimulated phosphoprotein (VASP).54 IP3 increases cytosolic 
levels of Ca2+ by binding to the IP3 receptor on the endoplasmic reticulum and triggering the 
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release of intracellular Ca2+ stores, and inhibits adenylyl cyclase, leading to decreased cAMP 
levels.52, 55      
 PAR4, on the other hand, is also coupled to G12/13 and Gq, but signalling through this 
receptor is different from that of PAR1. Following cleavage by thrombin, PAR4 generates a 
slower response than PAR1, therefore, providing the majority of the intracellular calcium flux.46, 
56 Moreover, unlike PAR1, PAR4 does not require additional signals from the P2Y12 receptor to 
sustain stable platelet-platelet aggregates.57, 58 
 It is now clear that thrombin acts on human platelets through both PAR1 and PAR4. It 
seems that thrombin cleavage of PAR1 initiates the signals necessary for platelet activation, 
while subsequent activation of PAR4 may be necessary to sustain the signalling events that 
optimize propagation of platelet activation. In addition, it has recently been shown in human 
platelets that PAR1 and PAR4 form a stable complex, which enables thrombin to act as a 
bivalent functional agonist.59 
 
1.3.2 Purinergic receptors 
ADP released form damaged blood vessels, red blood cells and secreted from platelet granules 
(in addition to ATP secreted from platelet granules) (see section 1.4.3) induces platelet activation 
through the purinergic receptors. These extracellular nucleotide receptors are subdivided into two 
groups: the P2X ligand-gated cation channels and the GPCR P2Y receptors.60 Up to date, seven 
members of the P2X receptors (P2X1 - P2X7) have been identified, and each member exhibits a 
distinct agonist profile.61 The P2Y group includes twelve members (P2Y1 - P2Y12).62, 63 It was 
thought that platelets express a single ADP receptor that was designated as the P2T receptor 
(thrombocyte P2), but now it is well known that platelets express three distinct purinergic P2 
receptor subtypes (P2Y1, P2Y12 and P2X1).64, 65 
 The P2Y1 is expressed in a wide range of tissues, including the heart, blood vessels, 
smooth muscle cells (SMC), neural tissues and platelets.66 About 150 copies of this receptor are 
expressed per platelet, which probably explains why ADP is a weak platelet agonist. 
Nonetheless, the P2Y1 receptor is crucial for the initiation of platelet activation induced by ADP 
or collagen.67, 68 The P2Y1 receptor is a 373 amino acid protein that exhibits the classical seven 
transmembrane GPCR structure. Given that P2Y1 is coupled to Gq, it triggers mobilization of 
calcium from internal stores resulting in platelet shape change and a weak, transient aggregation 
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in response to ADP, which were put into evidence through pharmacological inhibition and in a 
murine P2Y1 genetic deficient model.69-71 In addition, P2Y1 deficient mice exhibit a prolonged 
bleeding time, which is due to a defect in in vivo thrombus formation.72 
  The identity of the P2Y12 receptor on platelets was elusive for a long time, and it was 
designated as the P2YADP, P2YAC, P2Tac, P2T and P2Ycyc. Molecular cloning confirmed this 
receptor to be the novel P2Y12 receptor, which is uniquely and abundantly expressed on platelets, 
and to a minor extent in brain tissue.73 The P2Y12 receptor is a GPCR coupled to Gi and its 
activation by ADP induces inhibition of adenylyl cyclase. The important role of the P2Y12  
receptor is in the amplification of platelet aggregation induced by all known platelet agonist such 
as thrombin, collagen, thromboxane A2 (TxA2) and ADP.74 The P2Y12 is also involved in platelet 
dense granule secretion and TxA2 generation.75, 76 
 In platelets, it was initially thought that the P2X1 receptor was activated by ADP, but 
experiments with αβ-meATP (a specific P2X1 and P2X3 agonist) demonstrated an antagonistic 
effect of ADP in human platelets.77 As P2X1 is a ligand-gated cation channel, activation of this 
receptor by ATP induces a transient Ca2+ influx that is responsible for platelet shape change but 
not for aggregation.78 
 In summary, co-activation of the P2Y1 and P2Y12 receptors is necessary for normal ADP-
induced platelet aggregation.71 Hence the targeting of the P2Y12 receptor by the thienopyridine 
compounds ticlopidine and clopidogrel, which are used as antithrombotic drugs.79  On the other 
hand, the P2X1 receptor participates in collagen-induced platelet aggregation under shear 
conditions, which are a requirement for this receptor to fully play its role in thrombus 
formation.77 
 
1.3.3 Thromboxane receptors 
Thromboxane A2 is generated in platelets through the sequential enzymatic conversion of 
arachidonic acid, from the phospholipid bilayer, by the cyclooxygenase (COX-1 in platelets) and 
thromboxane synthase enzymes following activation by agonists, such as thrombin, collagen or 
ADP.80 Thus, TxA2 is considered as a secondary mediator that is involved in the second wave of 
platelet activation as well as in amplifying the response to more potent platelet agonists.81 In 
contrast to TxA2, prostacyclin (PGI2), which is also generated through the sequential enzymatic 
conversion of arachidonic acid (mainly by endothelial cells in the vasculature), inhibits platelet 
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function through the prostagladin I2 (IP) receptor.82 There is much discrepancy regarding the 
TxA2 receptors on platelets. Although cDNAs for both receptors TPα and TPβ splice variants 
have been shown to be present in platelets, only the TPα variant was demonstrated to be 
expressed on platelets using a specific splice variant antibody, which is probably due to a low 
level of expression of the TPβ variant.41, 42 
 The TPα receptor cDNA was cloned from human placenta from which a 343 amino acid 
sequence revealed that it belongs to the GPCR superfamily.83 The TPβ receptor cDNA was 
recently cloned from human endothelial cells from which a 407 amino acid sequence revealed 
that it is a splice variant of the TPα receptor.84 Therefore, the TPα and TPβ receptors differ only 
in their C-terminal domains where the 15 amino acid sequence in the carboxyl end of TPα is 
replaced by a 79 amino acid sequence in TPβ. The G proteins that are coupled to either TPα or 
TPβ in platelets remain unclear. Reports suggest that both TP receptors are coupled to Gq, Gi, G12 
or G13, and that signals from either TP receptor result in activating PLC, thereby releasing IP3 
and DAG.52, 85, 86 
 
1.3.4 GPIb/IX/V complex 
The importance of the GPIb/IX/V complex in haemostasis was put into evidence with the 
discovery of a rare but often severe bleeding disorder, Bernard-Soulier syndrome, where the 
complex is either absent, expressed at low levels or dysfunctional.87 The GPIb/IX/V complex is 
the second most abundant receptor on platelets, as compared to the αIIbβ3 integrin, with 
approximately 25 000 copies per platelet.88 The complex consists of GPIbα (CD42b) disulfide 
linked to GPIbβ (CD42c), non-covalently complexed with GPIX (CD42a) and GPV (CD42d) at 
a ratio of 2:2:2:1.87 The GPIb/IX/V complex does not have a built-in tyrosine kinase activity. It is 
not directly coupled to G proteins, and it does not contain phosphorylatable tyrosine residues that 
recruit signalling molecules. Nevertheless, it utilizes all these avenues to transmit signals by 
associating with other signalling molecules. Indeed, the cytoplasmic tail of GPIbα associates 
with 14-3-3ζ, calmodulin, phosphoinositide 3-kinase (PI3K), the Src family tyrosine kinases and 
filamin A (actin-binding protein).89-93 Interaction of the GPIb/IX/V complex with other proteins 
is mostly due to the globular domain of GPIbα, where it binds von Willebrand factor (vWF), 
thrombin, integrin αMβ2 (CD11b/CD18, macrophage antigen-1 [Mac-1]) on leukocytes, P-
selectin, coagulation factors XI and XII, and high molecular weight kininogen. 
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 Platelet adhesion under high shear depends on the interaction of GPIb/IX/V with 
multimeric vWF deposited on the sub-endothelial matrix. vWF is a large glycoprotein 
synthesized by endothelial cells and megakaryocytes and stored in platelet α-granules and 
Weibel-Palade bodies of endothelial cells.94, 95 Upon a damage to the vessel wall, vWF is 
secreted into the circulation in a form incapable of interacting with GPIb/IX/V. vWF then forms 
multimers on exposed collagen of the sub-endothelial matrix, thereby allowing its binding with 
the GPIb/IX/V complex, which then favours platelet adhesion, activation, secretion and 
aggregation. As mentioned earlier, the GPIb/IX/V complex can also interact with thrombin. In 
fact, it has been demonstrated that this complex is actually the high affinity receptor for thrombin 
on platelets. However,  it is still unclear if the GPIb/IX/V complex induces signals that activate 
platelets following its interaction with thrombin.96 On the other hand, interaction of GPIbα with 
thrombin allows it to act as a cofactor that localizes thrombin to the platelet surface to support 
thrombin cleavage of PAR1.97 Moreover, through interaction with Mac-1, the GPIbα subunit of 
the GPIb/IX/V complex favours recruitment of leukocytes to the site of injury where platelets are 
already adhered.98 Finally, the GPIb/IX/V complex seems to favour platelet rolling on the 
activated endothelium through its interaction with endothelial P-selectin.99 
 
1.3.5 GPVI 
GPVI is a valuable adhesion molecule that is uniquely expressed on platelets, and in addition to 
α2β1, is a major collagen receptor. Because of the low level of expression of GPVI on platelets as 
well as the difficulties in finding a suitable agonist (due to the second collagen receptor α2β1), it 
was difficult to determine the structure of this receptor. However, with the discovery of a 
specific GPVI agonist, the collagen-related peptide (CRP), it was possible to identify the 
structure of the receptor, which revealed that GPVI belongs to the immunoglobulin (Ig) 
superfamily with two Ig-like domains.100 GPVI was also shown to form a complex with the Fc 
receptor γ-chain (FcRγ) through a salt bridge at the Arg252 residue in the transmembrane domain 
of GPVI, which is responsible for stabilizing the complex in two Ig-like domains and one FcRγ 
configuration (Figure 1.3).101 Moreover, the two Ig-like domains of GPVI harbour the collagen 
binding site. Although the exact region that interacts with collagen is still unclear, it seems that 
there are more than one interaction site. The Ig-like domains also contain a high level of 
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glycosylation that allows GPVI to extend over the polysaccharide layer of the platelet surface, in 
a structure similar to GPIbα, thereby increasing its accessibility to collagen.102 
 
         
Figure 1.3: Schematic representation of the GPVI receptor. Mori M. et al. Thrombosis Research. 2004; 114:221-
233. 
 
 The FcRγ is essential for both expression and function of GPVI. Upon activation of 
GPVI by collagen, the immunoreceptor tyrosine-based activation motif (ITAM) within the FcRγ 
becomes phosphorylated by the Src kinases, Fyn and Lyn that are constitutively bound to the 
cytoplasmic tail of GPVI.103 In turn, the phosphorylated ITAM phosphorylates the tyrosine 
kinase Syk, which then induces the activating downstream signalling events, including activation 
of PKC and increase in intracellular Ca2+ by PLCγ2.102 
 It is now clear that GPVI is a major collagen receptor on platelets, but its physiological 
role is still unclear. There are two common haplotypes of GPVI known as GP6a and GP6b with 
observed frequencies of 0.85 and 0.13, respectively, that differ by 5 amino acid substitutions, 3 
in the extracellular domain (Ser199Pro, Lys217Glu, Thr229Ala) and 2 in the cytoplasmic 
domain (Gln297Leu and His302Asn).104 Although there is no difference in the expression level 
between the low- and high-frequency alleles, homozygosity for GP6b is associated with 
decreased functional responses of the receptor, as well as a reduced risk for recurrent 
cardiovascular events and mortality.104, 105 Moreover, it has been shown that in GPVI-deficient 
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patients and GPVI-depleted mice, there is a moderate increase in bleeding time and an 
impairment of platelet aggregation in response to collagen.106, 107 In addition, GPVI-deficient 
platelets exhibit decreased adhesion to collagen under flow conditions, which is abolished upon 
α2β1 blockade.108 Therefore, it seems that GPVI and α2β1 make each their contribution to the 
platelet response to collagen. 
 
1.3.6 α2β1 
The α2β1 is the first collagen receptor to be identified on platelets and serves mainly as an 
adhesion molecule.109 The crystal structure of the α2β1 integrin allowed identification of the 
structures of the α2 and β1 subunits. The extracellular domain of the α2 subunit has a β propeller-
like structure and a collagen-binding αI domain. The extracellular domain of the β1 subunit has 
an I domain-like fold, but it does not directly participate in collagen binding.110, 111 Interaction of 
collagen with the αI domain of the α2 subunit is dependent on the Mg2+ metal coordination site, 
named metal ion-dependent adhesion site (MIDAS), located in the bottom groove of the αI 
domain, while the αC helix in the αI domain seems to guide the collagen molecule into the 
groove in the right position, which is necessary for proper binding (Figure 1.4).112, 113 Signalling 
through the α2β1 integrin is similar to that induced by GPVI stimulation, which includes 
phosphorylation of the Src family kinases and the subsequent activation of PLC.114 Moreover, as 
for most integrins, the α2β1 integrin exists in two conformational configurations, an inactive 
conformation and an active one capable of bind collagen.111 
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Figure 1.4: Schematic representation of the α2β1 integrin. Heino J. Matrix Biology. 2000; 19:319-323. 
 
 It is now evident that α2β1 and GPVI are the two collagen receptors on platelets. 
However, their relative function in collagen-mediated platelet response is still unclear. The GPVI 
induced collagen response seems to be the most important. On the other hand, the α2β1 integrin is 
responsible for platelet adhesion to the exposed collagen surface in the sub-endothelium and in 
β1-deficient mice, the thrombi consist of loose platelet aggregates.115, 116 In addition, genetic or 
pharmacological depletion of GPVI highlight the capacity of α2β1 to mediate collagen signalling 
and haemostasis.108 
 
1.3.7 αIIbβ3 
The αIIbβ3 integrin is the most important and most abundant integrin on platelets, with 
approximately 80 000 copies per resting platelet and with important αIIbβ3 reserves within 
platelet α-granules and the OCS, which increase the integrin's surface expression by 25-50% 
upon platelet activation.117-119 The crucial importance of αIIbβ3 in primary haemostasis is 
evidenced by the bleeding disorder of patients with Glanzmann's disease, where genetic 
disorders in the αIIb and β3 gene result in functional abnormalities and/or prevention of surface 
expression of the αIIbβ3 integrin.120 The bleeding disorder is due to absence or improper 
haemostatic plug formation because of lack of platelet aggregation, which is mediated by the 
cross-linking of αIIbβ3 on adjacent platelets by soluble fibrinogen at low shear rate or vWF at 
high shear rate.121, 122 
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 The αIIb and β3 subunits of the αIIbβ3 integrin are both products of a single gene located on 
chromosome 17, giving rise to a 1008 and a 762 amino acid αIIb and β3 subunits, respectively.123 
The αIIb is proteolytically processed into a heavy and a light chain. The light chain contains a 20 
amino acid cytoplasmic tail, a transmembrane helix, and an extracellular segment that is 
disulfide linked to the heavy chain, which is entirely extracellular. Within the heavy chain, a 
large domain composed of a series of 60 amino acid repeats, which are arranged to form the 
seven blades of the β-propeller, extend outward from a central core. At the base of the β-
propeller there are four divalent cation (Ca2+) binding motifs.124-126 The β3 subunit contains a 48 
amino acid cytoplasmic tail and three major extracellular domains: the A domain, the PSI 
(plexin-semaphorin-integrin) domain, and four endothelial growth factor (EGF)-like domains 
(Figure 1.5).127 The PSI domain seems to be involved in integrin activation, because mutation of 
the cysteine linking it to the EGF-like domain, results in a constitutively active integrin.128 The A 
domain contains 2 or 3 divalent cations (Ca2+) sites, including a MIDAS motif that is highly 
involved in ligand binding. In addition, the A domain of the β3 subunit also contains two 
recognition sites, one for the γ-chain sequence and another for the RGD (arginine-glycine-
aspartic acid) sequence, which is present in ligands of the αIIbβ3 integrin, including fibrinogen, 
fibrin, vWF, vitronectin, fibronectin and autotaxin.121, 129-133 Finally, the EGF-like domains are 
formed by four cysteine rich loops (EGF-1 to EGF-4), which seem to have a regulatory function 
because a cysteine mutation within this region causes activation of the αIIbβ3 integrin.134, 135 
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Figure 1.5: Schematic representation of the αIIbβ3 integrin. Quinn M. J. et al. Arteriosclerosis, Thrombosis, and 
Vascular Biology. 2003; 23:945-952. 
 
 As most integrins, the αIIbβ3 integrin exist in two conformations; an inactive low affinity 
ligand binding conformation, and an active high affinity ligand binding one. Activating signals 
mediated by platelet agonists such as collagen and thrombin induce "inside-out" signals, which 
shifts the αIIbβ3 integrin from its inactive to active conformation. In the active conformation, 
ligand binding to αIIbβ3 stimulates "outside-in" signalling that promote firm platelet adhesion and 
spreading on the extracellular matrix, fibrin clot retraction, and development of platelet pro-
coagulant activity and microparticle generation.136-138 Moreover, there is a close association 
between αIIbβ3 and the platelet cytoskeleton, where the cytoskeleton is involved in regulating the 
structure and activation of the αIIbβ3 integrin. In resting platelets, the αIIbβ3 integrin is associated 
with the membrane cytoskeleton, which favours anchoring of the integrin to the plasma 
membrane, and upon platelet activation and ligation of the αIIbβ3 integrin with fibrinogen, the 
αIIbβ3 integrin associates with cytoplasmic actin, thereby stabilizing ligand/integrin interactions, 
which ultimately lead to stabilizing the platelet aggregates.139 The exact role of the αIIbβ3 integrin 
in platelet adhesion, aggregation and signalling will be discussed in more detail in section 1.4 of 
this chapter. 
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1.3.8 P-selectin 
P-selectin belongs to the selectin family, which is composed of three members that are named 
according to their main expression site: L-selectin is expressed in leukocytes, E-selectin is 
expressed on endothelial cells, and P-selectin is mainly found in platelets but also in endothelial 
cells.140-142 The human selectin family is encoded by genes located on chromosome 1, and all the 
members share a conserved structure consisting of an N-terminal Ca2+-dependent lectin 
recognition motif followed by an EGF-like motif, a series of short consensus repeats (SCRs), a 
transmembrane domain, and a short cytoplasmic tail.143 The main structurally differentiating 
factor between all members of the selectin family is the variation in the number of SCRs, with L-
selectin, E-selectin, and P-selectin having 2, 6 and 9 SCRs, respectively (Figure 1.6). 
 
       
Figure 1.6: Schematic representation of the selectin family members. Image is from the laboratory of Dr. Merhi.   
 
 In platelets, P-selectin is stored in the α-granules, and upon activation it is translocated to 
the plasma membrane, where approximately 10 000 copies of the molecule are then expressed on 
the surface of an activated platelet. This translates to a density of 350 molecules/μm2, which 
exceeds that of activated endothelial cells by approximately 10 fold.144 One of the major roles of 
platelet P-selectin is mediating interactions between platelets and leukocytes through their 
constitutively expressed high affinity P-selectin ligand, the P-selectin glycoprotein ligand-1 
(PSGL-1).145 Therefore, with such a high density of P-selectin molecules expressed on activated 
platelets, this interaction might have an even more important role in recruiting leukocytes to the 
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site of injury/inflammation than the interaction between endothelial P-selectin and leukocyte 
PSGL-1. In fact, it has been demonstrated that in P-selectin deficient mice, there is lack of 
leukocyte recruitment onto the platelet monolayer at the site of vessel injury.146 Moreover, the 
platelet/leukocyte interaction is of major importance not only in a physiological setting, but also 
in pathological ones such as in ischemia-reperfusion injury and in atherosclerosis.147, 148 
 P-selectin also has an important role in platelet/platelet interactions, as shown by its 
involvement in stabilizing platelet aggregates and thrombus formation; however, its ligands on 
platelets are still a matter of debate.149, 150 Although platelets express three potential ligands for 
platelet P-selectin; PSGL-1, GPIbα and sulfatides, sulfatides and GPIbα seem to be the most 
probable ligands. P-selectin and GPIbα but not PSGL-1 blockade, inhibits platelet rolling onto an 
activated endothelium and affects the stability of platelet aggregates, indicating a possible role 
for GPIbα as a P-selectin ligand on platelets.99, 149 By contrast, it has recently been shown that 
blocking antibodies against P-selectin and sulfatides, but not PSGL-1 or GPIbα inhibited platelet 
adhesion to P-selectin and platelet aggregation, indicating that sulfatides, and not PSGL-1 or 
GPIbα are the major P-selectin ligands on platelets.149, 151, 152 Such discrepancy in identifying the 
platelet P-selectin ligand could be attributed to the experimental settings. Furthermore, P-selectin 
expressed on activated platelets promotes fibrin and thrombus formation by recruiting tissue 
factor (TF) bearing monocytes and monocyte derived microparticles to the site of vessel 
injury.153, 154 
 
1.4 Platelet function 
As mentioned earlier in this chapter, platelets play a pivotal role in haemostasis by maintaining 
the integrity of blood vessels through the formation of a haemostatic plug that prevents blood 
loss. In order to accomplish such task, platelets respond to external stimuli mediated by the 
interaction of their receptors with the respective ligands. These interactions lead to a sequence of 
events consisting of adhesion, activation, secretion, and aggregation. In brief, GPIb/IX/V, GPVI, 
α2β1 integrin and αIIbβ3 integrin mediate platelet adhesion and activation, while αIIbβ3 is 
responsible for platelet aggregation, clot retraction and thrombus stability. 
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1.4.1 Platelet adhesion 
Under normal circumstances, platelets circulate in the blood in an inactive state unable to adhere 
or become activated, a process mediated by an important function of the endothelium. The 
endothelial cells not only create a physical barrier preventing platelet and sub-endothelial matrix 
contact, but also actively participate in inhibiting platelet activation by secreting inhibitory 
molecules such as nitric oxide (NO), PGI2, and nucleoside triphosphate diphosphohydrolase-1 
(NTPDase-1, CD39).82 On the other hand, damage to the vessel wall exposes the sub-endothelial 
matrix and activates endothelial cells, thereby initiating the haemostatic mechanism. Platelet 
adhesion at the site of vessel injury is initiated by platelet rolling on the activated endothelium, 
followed by firm adhesion of platelets to the components of the sub-endothelial matrix (collagen 
and vWF).155 
 
Platelet rolling on the activated endothelium 
Platelet rolling on the activated endothelium is the first step in initiating the haemostatic plug. 
Before adhering to the sub-endothelial matrix, circulating platelets undergo a deceleration 
process on activated, P-selectin (present in Weibel-Palade bodies) expressing endothelial cells 
neighbouring the injured vasculature.156 This process is mediated by the interaction of 
endothelial P-selectin with its yet unresolved ligand on platelets, albeit platelet PSGL-1 and the 
GPIb/IX/V complex could be the two possible candidates.99, 151 
 
Platelet adhesion to the sub-endothelial matrix 
At the site of the injured vasculature, following the rolling process onto the activated 
endothelium, platelets come to an arrest upon contact with the sub-endothelial matrix. The arrest 
is made possible by the interaction of platelet GPIb/IX/V, GPVI, α2β1 and αIIbβ3 with the 
components of the sub-endothelial matrix. The importance of the relative initial interactions of 
these receptors with their respective ligands is dependent on the shear force present at the site of 
injured vasculature. For instance, at high shear levels such as in stenotic arteries, initial tethering 
of platelets onto the sub-endothelial matrix fully depends on the weak interaction between the 
GPIb/IX/V complex and vWF, then followed by the firm adhesion of platelets to the exposed 
collagen matrix, which is GPVI and α2β1-dependent.157-159  By contrast, at low shear levels such 
as in the venous circulation, platelet adhesion to the sub-endothelial matrix depends on the 
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interactions of GPVI and α2β1 with collagen fibers, even though the GPIb/IX/V and vWF 
interaction is still present, it is of less importance.160 The αIIbβ3 integrin also participates in 
platelet adhesion by binding fibrinogen and vWF molecules present in the sub-endothelial 
matrix. Figure 1.7 summarizes the major events in platelet adhesion to the sub-endothelial 
matrix. 
 It is of interest to mention that circulating vWF molecules are not able to bind the 
GPIb/IX/V complex, but once in contact with collagen in the sub-endothelial matrix and in the 
presence of shear forces, the vWF molecule undergoes conformational change, which allows it to 
bind the GPIb/IX/V complex.161, 162 Although the vWF/GPIb/XI/V interaction is of a weak 
nature, at high shear levels, it occupies a crucial role in slowing down circulating platelets, which 
then favours GPVI and α2β1-dependent platelet arrest at the sites of injury. 
 
      
Figure 1.7: Platelet adhesion to the sub-endothelial matrix. Under normal conditions, platelet activation is prevented 
by the secreted endothelial mediators (NO, PGI2 and NTPDase-1). At the site of vessel lesion, platelet rolling, 
tethering, adhesion and activation is mediated by the interaction of platelet receptors/integrins with the components 
of the sub-endothelial matrix (see above text). Conde I. D. et al. Catheterization and Cardiovascular Interventions. 
2003; 60:236-246. 
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1.4.2 Platelet activation 
Interaction of GPIb/IX/V, GPVI, α2β1 and αIIbβ3 with components of the sub-endothelial matrix 
is not only responsible for platelet adhesion, but also mediates signals that induce platelet 
activation, secretion and aggregation. As mentioned in the previous section, ligation of 
GPIb/IX/V, GPVI and the α2β1 integrin with their respective ligands mainly induce activation of 
Src family kinases which ultimately activate PLC, specifically PLCγ2, leading to the generation 
of DAG and IP3, that activate PKCs and increase cytosolic Ca2+ levels, respectively. 
Furthermore, ligation of fibrinogen to the αIIbβ3 integrin also induces activation of the Src family 
kinases that activate PLCγ2, and the interaction of talin with the cytoplasmic tail of the β3 
subunit, which is involved in clot retraction.163 
 Following the initial wave of platelet activation induced by ligation of GPIb/IX/V, GPVI, 
α2β1 and αIIbβ3 with the components of the sub-endothelial matrix, activated platelets secrete 
secondary mediators such as TxA2 and ADP (see section 1.4.3) that recruit and activate 
additional circulating platelets at the site of vascular lesion. In addition, TF expressed on 
recruited monocytes, endothelial cells and activated platelets leads to the generation of thrombin 
at the site of injured vasculature, which also participates in recruitment and activation of 
additional platelets.154, 164, 165 Activation of platelets by TxA2, ADP and thrombin is mediated by 
ligation of these secondary mediators with their respective receptors; TPα and TPβ, the 
purinergic receptors, and PARs, which are coupled to G proteins (see section 1.3). Briefly, Gq 
and G12/13 lead to the generation of DAG and IP3 by PLCβ, and to the activation of the Rho 
GEFs, respectively. DAG in turn activates PKCs, which lead to protein phosphorylation, 
including VASP phosphorylation. VASP functions as an anti-capping protein, which is involved 
in crucial cellular functions, including shape change by directly modulating the actin ultra-
structure.166 IP3 binds to its receptor on the endoplasmic reticulum thereby inducing release of 
Ca2+ from intracellular stores. The Rho GEFs; RhoA, Rac1, and Cdc42 are regulators of 
signalling pathways that control actin organization by the formation of stress fibers, lamellipodia 
and filopodia.167 In summary, activation of platelets is mediated by two major signalling 
pathways, one including activation of PLC (PLCγ2 or PLCβ), and the second mediated by 
activation of G proteins through GPCRs. Figure 1.8 summarizes the major signalling pathways 
implicated in platelet activation. 
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Figure 1.8: The major signalling pathways implicated in platelet activation. Varga-Szabo D. et al. Arteriosclerosis, 
Thrombosis, and Vascular Biology. 2008; 28:403-412. 
 
 One of the early hallmarks of platelet activation is the morphological shape change 
induced by the reorganization of the platelet actin cytoskeleton, which transforms platelets from 
their disk-like structure into a spherical one containing multiple filopodia protrusions (Figure 
1.9).33, 34 The change in platelet shape as well as the formation of filopodia allows platelets to 
expand and cover a larger surface area at the site of vessel injury. Platelet activation also leads to 
the expression of P-selectin and the activation of the αIIbβ3 integrin (through an "inside-out" 
signalling mechanism), where they each make their contribution to platelet aggregation. 
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Figure 1.9: Scanning electron microscopy image of platelet shape change. Left: Resting platelet. Right: Activated 
platelet. Images are from the laboratory of Dr. Merhi. 
 
1.4.3 Platelet secretion 
Platelet activation is accompanied with secretion, where platelets secret a plethora of molecules 
stored in their granules, as well as newly enzymatically synthesised compounds, such as TxA2. 
Platelet secretion is an indispensible process linked to their pathophysiological role, including 
recruitment and activation of additional circulating platelets, initiation of thrombus formation, 
mediating intracellular adhesion and triggering cell proliferation and migration. Platelets contain 
three types of secretory granules; α-granules, dense granules and lysosomes, which are formed, 
pre-packaged, and sorted into pro-platelets during platelet formation from megakaryocytes.168  
 Megakaryocytes synthesise most of the protein contents present in platelet granules, and 
during the platelets' life span, platelets incorporate proteins into their existing granules through 
endocytosis. For instance, incorporation of fibrinogen is mediated by its interaction with the 
αIIbβ3 integrin, and its subsequent internalization and sorting into α-granules.169 The α-granules 
are the largest and most abundant granules in platelets with approximately 80 α-granules per 
platelet, and they contain coagulation proteins (e.g. fibrinogen, factor V), soluble adhesion 
molecules (e.g. vWF), growth factors (e.g. platelet derived growth factor [PDGF]), protease 
inhibitors (e.g. plasminogen activator inhibitor-1), and membrane adhesion molecules (e.g. P-
selectin and αIIbβ3).170 The dense granules are less abundant and less voluminous than α-granules, 
with about 3-8 dense granules per platelet; however, they contain substances indispensible for 
platelet activation, such as ADP, serotonin, Ca2+, and magnesium.171, 172 Although the contents of 
the α and dense granules differ from each other, recent studies have shown the presence of P-
selectin, αIIbβ3, and GPIb in both granules.173, 174 Finally, lysosomes contain enzymes that have a 
role in degrading and digesting multiple proteins.175, 176 Table 1.1 summarizes the major contents 
of platelet granules.177 
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Table 1.1: Platelet granule contents. 
 
α-granules Dense granules Lysosomes 
P-selectin 
αIIbβ3 integrin 
GPIb/IX/V 
GPVI 
αvβ3 integrin 
PECAM-1 
Stomatin 
PDGF 
EGF 
VEGF 
Transforming growth factor β (TGF-β) 
Albumin 
Fibrinogen 
Fibronectin 
Vitronectin 
Osteonectin 
vWF 
von Willebrand antigen II 
Thrombospondin 
Platelet factor-4 (PF4) 
IgG, IgA, IgM 
C1 inhibitor 
Plasminogen 
Plasminogen activator inhibitor-1 
Platelet-derived collagenase inhibitor 
High molecular weight kininogen 
Protein S 
α2-antitrypsin 
α2-macroglobulin 
α2-antiplasmin 
Multimerin 
Platelet basic protein 
β-thromboglobulin 
Histidine-rich glycoprotein 
Connective tissue-activating protein III 
Neutrophil-activating protein II 
Coagulation factor V 
Coagulation factor VIII 
GPIb 
αIIbβ3 integrin 
P-selectin 
CD107a (LAMP-1) 
CD107b (LAMP-2) 
CD63 (LAMP-3) 
Serotonin 
Histamine 
ATP 
ADP 
GTP 
GDP 
Pyrophosphate 
Calcium 
Magnesium 
Cathepsin D 
Cathepsin E 
Carboxypeptidase A 
Carboxypeptidase B 
Proline carboxypeptidase 
CD107a (LAMP-1) 
CD107b (LAMP-2) 
CD63 (LAMP-3) 
Acid phosphatase 
Arylsulphatase 
β-D-glucuronidase 
β-D-galactosidase 
β-D-fucosidase 
β-D-glucosidase 
α-D-mannosidase 
α-D-galactosidase 
α-L-arabinofuranosidase 
α-L-fucosidase 
 
 
 
 Activation of platelets by physiological agonist such as thrombin, ADP, TxA2 and 
collagen leads to intracellular signalling events that mediate platelet secretion, where platelets 
discharge their granule contents into the extracellular environment by exocytosis.172 Although 
most of the platelet physiological agonists can mediate α and dense granule secretion, it seems 
that only thrombin, the most potent agonist, is capable of inducing lysosome secretion.178 As 
mentioned earlier in this chapter, ligation of platelet agonists with their cognate receptors induces 
activation of two major signalling pathways (PLC and G protein activation), of which PLC 
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activation seems to be of significant importance for platelet secretion. The increase in cytosolic 
Ca2+ levels by IP3, as well as the activation of DAG following PLC mediated degradation of 
PIP2, leads to the activation of PKCs, which are crucial signalling molecules involved in platelet 
secretion. Platelets contain multiple PKCs (α, β1, β11, δ, ζ, η, and θ) and it seems that each of 
them has a specific role in platelet secretion, where they induce phosphorylation of intracellular 
signalling molecules implicated in the exocytotic machinery.172, 179-183 
 The molecular machinery involved in platelet secretion, which mediates granule fusion 
with surface connected membranes of the OCS or the plasma membrane, remained obscure for a 
long time.184, 185 However, insights into similarities between neuronal and platelet exocytosis, 
revealed molecular components of the secretory mechanism involved in both cell types.186 The 
molecular machinery responsible for membrane fusion during exocytosis is composed of the core 
soluble N-ethylmaleimide sensitive factor (NSF) associated protein receptor (SNARE) 
complexes. The SNAREs associated with granules are termed vesicular SNAREs (vSNARE), 
while those associated with target membranes (e.g. OCS and plasma membrane) are termed 
tSNAREs. In platelets, the identified vSNAREs include the vesicle-associated membrane 
proteins (VAMP) -2, -3, -7, and -8, while the identified tSNAREs include the syntaxins 2, 4, 7, 
and 11, and the soluble NSF-associated proteins (SNAP) -23, -25, and -29.187-193 Platelets also 
contain the Sec1 (platelet Sec1 protein, [PSP]) and Rab proteins that regulate SNARE 
function.183, 194 Platelet exocytosis is mediated by orchestrated steps involved in granule and 
plasma membrane fusion. Briefly, in resting conditions, PSP binds to tSNAREs and prevents 
formation of the SNARE complex required for membrane fusion. Upon platelet activation, the 
increase in cytosolic Ca2+ levels, as well as the activation of the PKCs, induces phosphorylation 
of PSP, which in turn relieves its inhibitory effects on SNARE complex formation.183 
Concurrently, NSF disassembles the cis-conformation of SNAREs on the same membrane 
thereby allowing formation of the trans-conformation of the SNAREs so that they are able to 
interact with their respective SNAREs on opposing membranes.195 Finally, the association of the 
vSNAREs and tSNAREs, in addition to the modulating role of Rab proteins, which facilitates 
docking of opposing membranes and modifies SNARE protein function, allow fusion of granule 
and plasma membranes thereby releasing the granule contents into the extracellular milieu.196-198 
 In addition to granule exocytosis, platelets also synthesize and secrete new molecules 
such as TxA2, upon activation. Platelet activation by physiological agonists such as thrombin, 
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ADP, and collagen induce activation of phospholipase A2, which is responsible for liberating 
arachidonic acid from the membrane lipid bilayer. Arachidonic acid is then converted into the 
prostaglandin TxA2 through sequential enzymatic modification by COX-1 and thromboxane 
synthase enzymes.199 
 
1.4.4 Platelet aggregation 
Platelet aggregation is the final step in primary haemostasis, where platelets cluster together to 
form a stable haemostatic plug following their adhesion and activation. Platelet aggregation is 
mediated by the cross-linking of αIIbβ3 integrins on adjacent platelets by soluble fibrinogen. 
However, in circulating quiescent platelets, the αIIbβ3 integrin is in an inactive conformation with 
a low affinity for fibrinogen. The subsequent activation of platelets by physiological agonists, 
such as thrombin, collagen, ADP, induces intracellular signals, which change the αIIbβ3 integrin 
from a low affinity inactive conformation to a high affinity active one through an "inside-out" 
signalling mechanism. Although activation of the αIIbβ3 integrin is a crucial step in determining 
platelet aggregation, the exact signalling mechanisms involved in its conformational changes 
have not been completely elucidated. Reconstruction of the αIIbβ3 activation pathway in Chinese 
hamster ovary (CHO) cells revealed the importance of talin (a major cytoskeleton actin binding 
protein) in the integrin's activation, and furthermore linked talin to upstream signalling 
partners.200 Platelet activation by physiological agonists leads to the activation of PKCs (see 
section 1.3), which in turn activate the Rap1 small guanosine triphosphatase. Activated Rap1 in 
turn interacts with talin and recruits it to the cytoplasmic tails of the αIIbβ3 integrin where it 
mediates their separation and hence activation of the integrin (Figure 1.10).200, 201 
 
          
Figure 1.10: Schematic representation connecting agonist stimulation to αIIbβ3 activation in platelets. Kasirer-Friede 
A. et al. Immunological Reviews. 2007; 218:247-264. 
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 As mentioned earlier in this chapter, following platelet activation and the subsequent 
activation of the αIIbβ3 integrin, ligand binding to αIIbβ3 stimulates "outside-in" signalling that 
promote firm platelet adhesion and spreading on the extracellular matrix, stabilization of platelet 
aggregates, fibrin clot retraction, and development of platelet pro-coagulant activity. Studies 
conducted on human platelets and CHO cells transfected with the αIIbβ3 integrin revealed three 
distinct "outside-in" signalling pathways derived from αIIbβ3 ligation, where the first is mediated 
by activation of the tyrosine kinase Syk, the second originates from the activation of the focal 
adhesion kinase (pp125FAK), and the third is initiated by phosphorylation of tyrosine residues in 
the cytoplasmic tail of the β3 subunit.202, 203 
 The cytoplasmic tail of the β3 subunit contains two conserved tyrosine residues (Y747 
and Y759), both of which become phosphorylated, probably by the Src kinase Fyn, following 
ligand binding to the αIIbβ3 integrin.203 The N-terminal tyrosine residue is within a conserved 
NPXY motif that mediates binding to proteins with phosphotyrosine binding domains, such as 
the adapter Dok2, which undergoes tyrosine phosphorylation downstream of the integrin.204, 205 
The second tyrosine falls within a similar NXXY motif, and has been shown to bind multiple 
signalling proteins, including Shc.206 The functional importance of these two conserved tyrosine 
residues is evidenced by the recurrent bleeding phenotype and the impaired clot retraction as 
seen in transgenic mice that have these two tyrosine residues of the β3 subunit mutated to 
phenylalanine.207 The molecular basis for this disorder was later attributed to the loss of myosin 
binding to the phosphorylated β3 tail; however, the contribution of Shc or Dok2 to this response 
is still unclear.208 
 Activation the Syk and pp125FAK signalling pathways result from clustering of the αIIbβ3 
integrin, albeit activation of the pp125FAK signalling pathway requires additional platelet 
stimulation by the secondary mediators, TxA2 and ADP.209, 210 The Syk signalling pathway leads 
to activation of the Rac exchange factor Vav-1 and the molecular adaptor SLP-76, that are 
implicated in cytoskeletal regulation downstream of the αIIbβ3 integrin, which leads to 
lamellipodia formation and platelet spreading.211, 212 In addition, Syk also activates PLCγ2, 
through a pathway that is likely to be dependent on SLP-76 and Vav, which also mediates 
platelet spreading.213, 214 Finally, little is known about the pp125FAK signalling pathway, but it 
seems that activation of pp125FAK mediates its interaction with Hic-5 protein, which is an adapter 
molecule implicated in platelet spreading.209 
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1.5 Pathological role of platelets 
It was previously thought that the major platelet role was in physiological haemostasis, in which 
they maintain the integrity of the blood vessels by limiting blood loss following vascular injury. 
Now, a plethora of evidence points to their involvement in multiple pathological conditions. As 
mentioned above, platelets are endowed with multiple molecules either present on their surface 
or secreted following platelet activation, which modulate the development and progression of a 
wide variety of diseases, including vascular thrombosis, atherosclerosis, inflammation, 
rheumatoid arthritis, lupus, cancer, coronary and cerebral-vascular diseases, diabetes and 
psychiatric diseases. This section will focus on the platelet contribution to development and 
progression of the following relevant pathologies: atherosclerosis, thrombosis and inflammation. 
 
1.5.1 Atherosclerosis 
Beyond their role in haemostasis and thrombosis, platelets are critically involved in the onset of 
atherosclerosis, which is now considered as a chronic inflammatory disease.215, 216 Their 
involvement in the initiation, progression and stability of the atherosclerotic plaque has recently 
been put into evidence thanks to new intra-vital microscopy techniques and to the development 
of appropriate atherosclerosis animal models. For instance, it has been shown that in 
hypercholesterolemic rabbits and apolipoprotein E (ApoE) deficient mice (an atherosclerosis 
mouse model characterized by high levels of circulating cholesterol), platelets adhere to 
atherosclerotic-prone sites before lesions are detectable, suggesting that platelets are among the 
first (if not the first) vascular cells to be recruited to the lesion site.217, 218 
 Although the first steps that initiate formation of the atherosclerotic plaque are still 
unclear, it seems that activation of endothelial cells could be the culprit. Mechanoreceptors on 
endothelial cells respond to variations in shear force that is generated by flowing blood at 
atherosclerotic-prone sites (arterial branching points), thereby mediating a change in cell 
morphology, gene expression profiles and increases in adhesiveness.219-221 Therefore, activation 
of endothelial cells increases surface expression of adhesion molecules, specifically P-selectin 
and αvβ3, which have been shown to be required for platelet recruitment to atherosclerotic-prone 
sites. Recruitment of platelets to atherosclerotic sites is mediated by a two step process, where 
the initial contact between platelets and activated endothelial cells is mediated by the weak 
interaction of platelet GPIb/IX/V or PSGL-1 and endothelial P-selectin. This weak interaction is 
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then followed by a firm adhesion of platelets on the activated endothelium through the cross-
linking of αIIbβ3 on platelets with αvβ3 on endothelial cells by fibrinogen.222-225 
 Following adhesion to the activated endothelium, platelets favour atherosclerotic plaque 
development by three different processes. The first is inducing  an inflammatory reaction in the 
endothelium through the release of the pro-inflammatory compounds interleukin-1β (IL-1β) and 
CD40L, which induce a pro-atherogenic phenotype of endothelial cells. This is characterized by 
expression of adhesion molecules (P-selectin, E-selectin, ICAM-1, vascular cell adhesion 
molecule-1 [VCAM-1] and αvβ3), and secretion of chemokines (macrophage chemotactic 
protein-1 [MCP-1]) and matrix degrading enzymes (matrix mettaloproteinases-9 [MMP-9]).2, 3, 
226-228 Secondly, platelets also contribute to the pro-atherogenic environment by releasing growth 
factors (PDGF, EGF, TGF-β, and fibroblast growth factor [FGF]), chemokines (PF4, platelet 
activating factor [PAF], macrophage inflammatory protein-1α [MIP-1α], and regulated upon 
activation normal T-cell expressed and released [RANTES]), and matrix degrading enzymes 
(MMP-2).216, 229-233 Finally, adherent platelets favour recruitment, activation, secretion and 
transmigration of leukocytes at the atherosclerotic site.229, 234 Effectively, as mentioned earlier in 
this chapter (see section 1.3.8) platelets have a much higher level of expression of P-selectin than 
activated endothelial cells, which has been shown to greatly influence leukocyte recruitment to 
the atherosclerotic site.  In the absence of adherent platelets, leukocyte recruitment to the lesion 
site is markedly reduced.235 Moreover, secreted chemokines (RANTES and MCP-1) by adherent 
platelets favour leukocyte homing toward the lesion site.2, 236 Figure 1.11 summarizes the platelet 
involvement in atherosclerotic plaque formation. 
 Development of coronary artery diseases, such as unstable angina, acute myocardial 
infarction, and stable coronary-artery disease, as well as peripheral vascular diseases, are tightly 
linked to the progression and complications related to atherosclerosis.237-239 Moreover, rupture of 
the atherosclerotic plaque exposes pro-thrombotic substances, including components of the 
extracellular matrix and components of the necrotic plaque core, which induce platelet activation 
and thrombus formation. In summary, platelets are implicated in all aspects of atherosclerosis; 
hence the development of multiple anti-platelet agents, such as aspirin (COX-1 inhibitor), αIIbβ3 
inhibitors (abciximab, eptifibatide, and tirofiban), P2Y12 inhibitors (clopidogrel and ticlopidine), 
and thrombin inhibitors (heparin), in order to dampen or limit platelet activation.240 
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Figure 1.11: Model of the role of platelets in atherosclerotic plaque formation. Platelets adhere to the activated 
endothelium by a two step mechanisms, the first is mediated by the weak interactions of platelet GPIb/IX/V or 
PSGL-1 with endothelial P-selectin, then followed by the firm adhesion mediated by αIIbβ3. Activated adherent 
platelets then secrete pro-inflammatory compounds that trigger an inflammatory reaction in the endothelium. 
Moreover, adherent platelets favour recruitment and transmigration of leukocytes at the lesion site. Gawaz M. et al. 
The Journal of Clinical Investigation. 2005; 115:3378-3384. 
 
1.5.2 Thrombosis 
One of the major complications in the circulatory system is thrombosis, which is the formation of 
a blood clot (thrombus) within the blood vessel. Partial or complete occlusion of a blood vessel 
due to a thrombus leads to reduction or blockage of the blood flow, which ultimately causes 
ischemia or infarction of the irrigated organ because of lack of nutrients to meet its metabolic 
needs. Thrombosis is divided into two categories, depending on the location where the thrombus 
is formed, giving rise to arterial or venous thrombosis. Despite similarities between arterial and 
venous thrombosis, in that they both contain a fibrin mesh (the end product of the coagulation 
cascade) and platelet aggregates, there are differences in the initiating cause and the composition 
of the two thrombus types. For instance, there is a body of evidence suggesting that venous 
thrombosis is caused by a disturbance in blood flow, such as stagnation, while in arterial 
thrombosis disturbance in blood flow has a role in initiating thrombus formation but 
atherosclerotic plaque rupture is of more significance.241, 242 In addition, venous thrombi are also 
designated as "red clots" because they contain more fibrin and trapped red blood cells, as well as 
less platelets than arterial thrombi, which are referred to as "white clots".243 This section will 
focus on the mechanisms underlying arterial thrombosis, specifically atherothrombosis, and the 
platelet contribution to the disease. 
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 Atherothrombotic diseases are the leading cause of mortality, and account for more than 
25% of deaths worldwide.244 Development of a clot, following atherosclerotic plaque rupture or 
erosion, in the coronary or cerebral circulation (causing acute myocardial infarction or ischemic 
stroke, respectively) is now the single most common cause of morbidity and mortality globally, 
and involves both aggravated platelet and coagulation cascade activation. Although the 
endothelium actively secretes a range of molecules that inhibit platelet activation (PGI2, NO, 
NTPDase-1) and thrombin generation (thrombomodulin), plaque rupture in combination with a 
severe pre-existing arterial stenosis (abnormal narrowing of blood vessel) leads to an 
exaggerated platelet aggregation response.245, 246 Exposure of the sub-endothelial matrix as well 
as the highly thrombogenic necrotic core to the circulation, following plaque rupture, leads to 
platelet adhesion and activation onto the components of the sub-endothelial matrix (vWF and 
collagen), and the subsequent recruitment and activation of circulating platelets by secreted 
secondary mediators (ADP and TxA2). In addition, at the surface of the growing thrombus, blood 
flow is accelerated, thereby subjecting platelets and immobilized ligands, such as vWF, to 
extensional drag forces.247 Thus platelet recruitment onto the thrombus surface becomes 
extensively dependent on vWF and platelet GPIbα interactions, which is then followed by the 
stable platelet-platelet aggregates mediated by the αIIbβ3 integrin interactions with its ligands, 
such as vWF, fibrinogen, fibrin, and/or fibronectin, and P-selectin interactions with its cognate 
ligands on platelets (see section 1.4.4).87 
 Another important function of activated platelets in thrombus formation is their ability to 
support the assembly of coagulation complexes on their plasma membrane, either through the 
direct recruitment of TF to phosphatidylserine (PS) expressed on the membrane or through the 
indirect binding of TF bearing microparticles (derived from activated or apoptotic 
monocytes/macrophages and T lymphocytes) and leukocytes mediated by P-selectin/PSGL-1 
interactions.153, 248 TF on its turn favours formation of thrombin, which is not only the most 
potent platelet activator, but also converts fibrinogen to fibrin during the coagulation process, 
both of which are important for thrombus growth and stability.164 Moreover, disturbance in blood 
flow, which is an important but yet incompletely understood aspect of thrombogenesis, has an 
impact on platelet adhesiveness and the blood clotting process. Specific alterations in blood flow, 
including flow acceleration at the apex of the stenosis (narrowing caused by growing thrombus) 
followed by flow deceleration, promote platelet deposition onto the thrombogenic surfaces.247 
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The flow deceleration downstream from the site of plaque injury also induces recirculation and 
stagnation of the blood, which favours blood coagulation, leading to the propagation of a fibrin 
and red blood cell rich thrombus that is known as the "fibrin tail".249 Figure 1.12 schematizes 
thrombosis following atherosclerotic plaque rupture. 
 Thrombosis is of a more threat for individuals with hyperactive platelets, such as diabetic 
patients, which are also resistant to regular anti-platelet therapy and therefore require more 
intensive anti-platelet regimens, and in thrombosis-prone groups, including individuals with 
hypertension, hypercholesterolemia, and cigarette smokers and the elderly.250-256 In addition, 
platelet deposition onto reactive surfaces induced by shear gradients is not prevented by 
antiplatelet therapy, such as aspirin, clopidogrel or thrombin inhibitors.247 Therefore, a more 
comprehensive understanding of the role and the possible inhibition avenues of the platelet 
involvement in thrombus formation could be of benefit for atherothrombotic disease 
management. 
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Figure 1.12: Cartoon representation of thrombosis. A) Representation of the ruptured atherosclerotic plaque covered 
by a "white thrombus" formed by platelet aggregates, followed by a "fibrin tail" formed by a fibrin mesh entrapping 
red blood cells. B) Representation of the differences between haemostatic plug formation and thrombosis. Jackson 
S. P. Nature Medicine. 2011; 17:1423-1436. 
 
1.5.3 Inflammation and immunity 
The platelets' role was thought to be restricted to haemostasis, but it is now clear that platelets 
actively participate in inflammation and the host's defence against foreign pathogens. The active 
contribution of platelets to the initiation, development and progression of the atherosclerotic 
plaque (see section 1.5.1), was among the first signs showing their pathological pro-
inflammatory functions.257 Now a plethora of evidence shows that platelets actively interact with 
bacteria, viruses and fungi, and help modulate the immune system. 
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 Toll-like receptors (TLR), which are probably the most important receptors of the innate 
immune system, are pattern recognition receptors that recognize broadly shared molecules by 
pathogens, such as lipopoplysaccharide (LPS), lipoproteins, and other bacterial wall 
constituents.258 Platelets contain TLR1, 2, 4, 6, and 9, which enable platelets to bind bacteria, 
thereby favouring either platelet mediated killing of the bacteria through secretion of 
thrombocidins (antibacterial proteins within platelet α-granules, including thombocidin 1 and 2) 
or by aggregating around the bacteria and "trapping" them for elimination by professional 
phagocytes.259-263 Interestingly, platelet derived thrombocidins have also been shown to kill 
fungi, such as Cryptococcus neoformans. Moreover, LPS activated platelets via TLR4, such as in 
severe sepsis, induce neutrophil activation and their subsequent release of inflammatory 
compounds, including tumour necrosis factor-α (TNF-α) and IL-6 as well as the formation of 
neutrophil extracellular traps consisting of extracellular DNA and nuclear proteins that trap and 
kill free bacteria.261, 264, 265 Platelets have also been shown to drive pathological events during 
infection with Plasmodium spp. parasites (the causative agents of malaria) by promoting 
sequestration and killing of infected red blood cells.262, 266 Platelets also actively aid in combating 
viruses, through phagocytosis of viral particles, which is mediated by either the indirect 
internalization of virus/IgG complexes by the FcγRIIA or through the direct capture of viruses by 
platelet receptors, such as the capture of HIV-1 by platelet DC-SIGN (dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin, CD209) and CLEC-2 (C-type lectin 
receptor) receptors.267, 268 
 An abundant amount of evidence now points to the role of platelets in modulating both 
the innate and adaptive arms of the immune system. Besides their above mentioned participation 
in killing foreign pathogens, platelets and platelet derived microparticles focus the complement 
system (consisting of a series of proteases and inhibitors that are activated in a cascade-like 
fashion during host defence) to sites of vascular injury and inflammation.269 In addition, secreted 
chemokines and cytokines (RANTES, IL-1β and MCP-1), as well as P-selectin expression by 
platelets, favour recruitment, adhesion and transmigration of leukocytes at sites of vascular 
injury. On the other hand, platelets promote cytotoxic T lymphocyte (CTL) mediated antiviral 
immune response during infection with the hepatitis B virus, where platelet activation has been 
shown to be necessary for the accumulation of virus-specific CTLs at the site of hepatic 
inflammation.270 Moreover, CD40L expressed on activated platelets not only induces an 
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inflammatory response in the endothelium, but also mediates activation of antigen presenting 
cells (dendritic cells [DC] and macrophages), leading to enhanced antigen presentation to T 
lymphocytes. CD40L on activated platelets can also mediate B cell differentiation and Ig class-
switching as demonstrated in virus infected CD40L deficient mice.5, 6 Furthermore, patients with 
immune thrombocytopenia have deficiencies in regulatory T (TReg) cells, and therapeutical 
increase in platelet counts restores TReg cell numbers and functions in these individuals.271-274 
Whether this is due to TGFβ secreted by platelets is still unclear, but given that TReg cell 
differentiation requires TGFβ, it is possible that platelets contribute to TReg formation. 
 Finally, platelets also have important inflammatory functions. This is not only reflected 
by their contribution to the local inflammatory environment during atherosclerotic lesion 
formation, but also to the development of different pathological diseases, such as rheumatoid 
arthritis. Platelet derived microparticles have been shown to be present in joint fluid from 
patients with rheumatoid arthritis.275 This was demonstrated to be dependent on the interaction of 
platelet GPVI with fibroblast-like synoviocytes in the joint, leading to platelet shedding of 
microparticles. In turn, activated platelets as well as platelet derived microparticles induce an IL-
1 dependent inflammatory response in fibroblast-like synoviocytes that is characterized by the 
release of pro-inflammatory cytokines and chemokines, such as IL-8, which promote neutrophil 
recruitment and activation within the joint.275 
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Chapter 2 
The CD40/CD40L Axis 
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2.1 The CD40/CD40L dyad 
Since its initial discovery more than two decades ago, the CD40/CD40L dyad has gained much 
attention in the scientific community. The pivotal role of CD40/CD40L dyad in immunity was 
initially evidenced by the finding that patients suffering from the X-linked hyper-IgM syndrome 
(HIGM) are characterized by mutations in their CD40L gene, resulting in loss of function in the 
CD40L protein. The resulting inactive CD40L protein is unable to induce T cell dependent B cell 
responses, which are characterized by severe defects in humoral immunity, as well as the 
absence of IgG, IgA, and IgE antibodies due to a lack of B cell Ig isotype switching.276 Now it is 
clear that aside from its importance for appropriate immune responses, the CD40/CD40L dyad 
has a much broader cell expression pattern and it is associated with diverse physiological and 
pathological processes. 
   
2.1.1 Structure of CD40 
Human CD40 is a type I transmembrane protein of 48 kDa belonging to the TNF receptor 
superfamily.277, 278 It was initially identified on B lymphocytes by antibody binding, then cloned 
in the Burkitt lymphoma Raji cell line, revealing a cDNA encoding for a 1.5 kb mRNA.279, 280 
The gene encoding CD40 was then localized to region q12-13.2 of human chromosome 20, 
which includes 9 exons.281, 282 Transcription of the human CD40 gene results in a 277 amino acid 
membrane-bound protein that consists of a 22 amino acid leader sequence, a 171 amino acid 
extracellular domain, a single 22 amino acid transmembrane domain, and a 62 amino acid 
cytoplasmic tail.1 A homology exists between CD40 and other members of the TNF receptor 
family, in which the C-terminal domain of CD40 is intracellular, while its N-terminal domain is 
extracellular. In addition, the extracellular domain of CD40 is characterized by a cysteine-rich 
repetitive pattern consisting of 20 cysteines, which form four subdomains composed of a 
combination of two cysteine modules (A1, A2, B1, and B2) (Figure 2.1).278, 283 
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Figure 2.1: Human CD40 gene and protein structure. A) Structure of the CD40 on the human chromosome 20, 
region q12-q13.2, including the 9 exons, which encode for the leader sequence (exon I), the extracellular domain 
(exons II - VI), transmembrane domain (TMD; exon VII), and cytoplasmic domain (exons VIII - IX). Schonbeck U. 
et al. Cellular and Molecular Life Sciences. 2001; 58:4-43. B) Schematic representation of the extracellular domain 
of CD40 containing the 20 cysteine residues (horizontal lines) forming four cystein-rich subdomains composed of a 
combination of two cysteine modules (A1, A2, B1, and B2). The N-terminal region of CD40 is extracellular, while 
the C-terminal region is intracellular. Van Kooten C. et al. Journal of Leukocyte Biology. 2000; 67:2-17. 
 
 It remains unclear whether CD40 molecules are arranged as monomers or multimers on 
the surface of the cell membrane. Certain reports indicate the formation of CD40 dimers on the 
cell surface, while others point to the constitutive trimer composition of the receptor, which 
probably favours its interaction with its trimeric ligand, CD40L.284-286 It seems that the 
monomeric form of CD40 on the cell surface, which then forms trimers following ligation with 
CD40L is probably the most credible arrangement, given that trimeric CD40L molecules exhibit 
a higher potency than the monomeric or dimeric forms (discussed in more detail in section 
2.1.3).287, 288 
 
2.1.2 Structure of CD40L 
Human CD40L (also known as CD154, gp39, TBAM, and TRAP) is a type II transmembrane 
protein belonging to the TNF superfamily.289 The human CD40L cDNA was initially identified 
by screening activated human peripheral blood T lymphocytes with the murine CD40L probe, 
which revealed a 13 kb DNA sequence that was later mapped to the region q26.3-q27.1 of 
chromosome X.289-291 This DNA sequence contains five exons, of which exons II - V mainly 
encode the extracellular domain, while exon I encodes the transmembrane and the cytoplasmic 
domains of CD40L (Figure 2.2).287, 292 Transcription of the human CD40L gene results in a 261 
amino acid membrane-bound protein that consists of a 215 amino acid extracellular domain, a 
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single 24 amino acid transmembrane domain, and a 22 amino acid cytoplasmic tail. Unlike 
CD40, the N-terminal of the CD40L protein is intracellular, while its C-terminal is extracellular. 
On the other hand, the amino acid backbone of CD40L predicts a protein of 29 kDa; however, 
CD40L is identified as a 39 kDa protein, which suggests that posttranslational modifications 
convey its actual molecular mass.278 In addition to the 39 kDa membrane bound full-length form 
of CD40L, soluble forms of the ligand have been described with molecular weights of 31, 18, 
and 14 kDa, of which the 18 kDa form is mainly derived from enzymatic cleavage of CD40L 
expressed on activated platelets.7, 293-295 
 
      
Figure 2.2: Human CD40L gene and protein structure. A) Structure of the CD40L on the human chromosome X, 
region q26.3-q27.1, including the 5 exons, which encode the extracellular domain (exons II - V), transmembrane 
domain (TMD; exon I), and cytoplasmic domain (exon I). Schonbeck U. et al. Cellular and Molecular Life Sciences. 
2001; 58:4-43. B) Schematic representation of CD40L with its extracellular C-terminal region and intracellular N-
terminal region. Van Kooten C. et al. Journal of Leukocyte Biology. 2000; 67:2-17. 
 
 Despite being a type II transmembrane protein, CD40L is expressed on the cell surface as 
a trimeric complex.296 This multimeric conformation of CD40L is of crucial importance for its 
effective interaction with CD40 and the subsequent intracellular signalling induced by the 
latter.286 Moreover, the soluble forms of CD40L also retain their ability to form trimers, which 
could bind CD40 and deliver biological signals.293, 294, 297 
 
2.1.3 CD40/CD40L interactions 
The X-ray crystal structure of CD40L, as well as mutagenesis analysis of both CD40 and 
CD40L, allowed the identification of the residues implicated in stabilizing the interaction 
between these two molecules. The polar interaction between the charged residues, with CD40L 
presenting the basic chains K143, R203, and R207, while CD40 presenting the acidic side chains 
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D84, E114, and E117, favour ligation of the receptor/ligand dyad. In addition, the CD40/CD40L 
complex is further stabilized by a wall of hydrophobic residues surrounding the interacting 
groups.298-300 
 As mentioned above, there is a discrepancy regarding the arrangement of CD40 on the 
cell surface. Whether CD40 is present as a monomer or trimer on the cell surface gave rise to 
two hypothetical models of CD40/CD40L interactions. The first model, in which trimers of 
CD40L interact with constitutive CD40 trimers that form the pre-ligand-binding assembly 
domains (PLAD) (Figure 2.3B), gained much attention within the scientific community. Given 
that CD40 is a member of the TNF receptor family, which are pre-assembled in a trimeric 
composition on the cell membrane, supports this model of interaction.285 On the other hand, a 
second school of thought favours the ligand-induced receptor trimerization model, in which 
trimeric molecules of CD40L induce oligomerization of the CD40 receptor (Figure 2.3A). This 
model is probably the most logical scenario of CD40/CD40L interactions, since the CD40 
intracellular adapter proteins have been shown to form homotrimers or heterodimers and to 
associate with the receptor following its oligomerization, which is due to their increased avidity 
for the cytoplasmic domain of the trimeric receptor.301-303 Moreover, different degrees of 
antibody-induced cross-linking of CD40 have been shown to result in different cellular 
responses, which are probably due to different levels of affinity of the CD40 intracellular adapter 
proteins to the receptor.288, 304 Finally, it has been shown that trimeric molecules of CD40L exert 
a more potent biological response than their monomeric or dimeric counter parts, which is 
probably due to different degrees of ligand-induced receptor oligomerization.288 Thus, there is 
ample amount of evidence supporting the ligand-induced receptor trimerization model of 
CD40/CD40L interactions. 
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Figure 2.3: Models of CD40/CD40L interaction. A) Timeric CD40L-induced CD40 trimerization interaction model. 
(CRAF: CD40 associated factors. They signify the old nomenclature for the CD40 intracellular adapter proteins). B) 
Model of trimeric CD40L interaction with the pre-assembled CD40 trimer. (PLAD: pre-ligand-binding assembly 
domain). Anand S. X. et al. Thrombosis and Haemostasis. 2003; 90:377-384. 
 
2.1.4 Alternative CD40L receptors 
Besides CD40, the dedicated receptor, CD40L has been shown to bind three other receptors, 
namely the αIIbβ3, α5β1, and Mac-1 (αMβ2) integrins (Figure 2.4). Interaction of CD40L with the 
αIIbβ3 integrin was first identified in platelets. Although the αIIbβ3 integrin mainly binds ligands 
(such as fibrinogen) with a RGD motif, the discovery of a snake venom that is capable of binding 
the integrin via a KGD motif, shed light into the possibility that the KGD motif within CD40L 
could favour its interaction with αIIbβ3 on platelets.305, 306 Indeed, CD40L was shown to stabilize 
in vivo thrombus formation by promoting platelet activation through an interaction with the αIIbβ3 
integrin.4 This interaction was later shown to induce tyrosine phosphorylation within the 
cytoplasmic tail of the β3 subunit of the integrin, which ultimately mediates "outside-in" signals 
by the latter (see section 1.4.4 of chapter 1).307 However, the CD40L/αIIbβ3 interaction requires 
an active conformation of the integrin, because αIIbβ3 is unable to bind its ligands in its inactive 
conformation. 
 
42 
 
 
Figure 2.4: CD40L and its receptors. Binding of CD40L to CD40, αIIbβ3, α5β1, or Mac-1 (αMβ2) induces different 
biological responses. Gaxiola E. (2012). Atherothrombosis. INTECH. p. 82. 
 
 The fibronectin receptor, α5β1, has recently been shown to be one of the CD40L 
receptors. This was demonstrated in the U937 human monocytic cell line, which lacks both 
CD40 and αIIbβ3 expression, where inhibition of either CD40L or α5β1 abolished sCD40L 
binding to the cell surface, as well as sCD40L-induced cell activation.308 Interestingly, sCD40L 
was also shown to only interact with the α5β1 integrin in its inactive conformation, and activation 
of the integrin prevents this interaction. Moreover, point mutations of residues within CD40L, 
which are involved in its interaction with either CD40 or αIIbβ3, revealed that CD40L is capable 
of binding α5β1 independently of its interaction with either CD40 or αIIbβ3.309 Therefore, it seems 
that CD40L is capable of simultaneously binding multiple receptors. Whether this is the case in 
cells that express more than one CD40L receptor, such as platelets (CD40, αIIbβ3, and α5β1), 
remains to be explored.4, 308, 310, 311   
 Finally, Mac-1, also known as αMβ2, is a highly promiscuous receptor capable of binding 
multiple ligands, including GPIbα, fibrinogen, and vitronectin. It is also an important mediator of 
neutrophil and monocyte adhesion to the activated endothelium during inflammation.  Recently, 
it has been demonstrated that Mac-1 is another receptor for CD40L, which is involved in 
mediating CD40L/Mac-1-dependent monocyte and neutrophil adhesion and transmigration at the 
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atherosclerotic lesion site, as well as neointimal formation during atherogenesis.312, 313 
Furthermore, binding of CD40L to Mac-1 requires an active conformation of the integrin. 
 
2.2 Cellular expression and function of the CD40/CD40L dyad 
As mentioned earlier, the CD40/CD40L dyad was initially identified on cells of the immune 
system, specifically on B and T lymphocytes. Now, it is well known that these two molecules 
have a much broader cell expression pattern, encompassing not only cells of the immune system, 
but also cells of the circulatory and vascular systems (Table 2.1). The intricate role of this dyad 
in these systems highlights its crucial function in inflammation and immunity (Table 2.2). 
 
Table 2.1: Cell types expressing the CD40/CD40L dyad. (N/A: no documentation available, - : no expression, + :  
weak expression, ++ : average expression, +++ : strong expression). Modified from Lievens D. et al. Thrombosis 
and Haemostasis. 2009; 102:206-214. 
 
Cell Type 
CD40 CD40L 
Forms of CD40L 
Resting Activated Resting Activated 
CD4+ T lymphocytes - +++ - +++ Membrane, soluble 
B lymphocytes +++ +++ ++ +++ Membrane 
Macrophages + +++ + +++ Membrane 
Platelets ++ +++ - +++ Membrane, soluble 
Dendritic cells (DCs) - +++ ++ +++ Membrane 
Neutrophils + +++ + + Membrane 
Endothelial cells + +++ + + Membrane 
SMCs +++ N/A + N/A Membrane 
 
2.2.1 B lymphocytes 
The CD40/CD40L dyad has a crucial role in B lymphocytes-mediated humoral immunity. B 
lymphocytes constitutively express CD40, and ligation of this receptor with CD40L expressed on 
activated T lymphocytes, in addition to secreted cytokines by the latter, induces proliferation, 
differentiation, and Ig production of B lymphocyte. CD40 activation guides B lymphocytes 
throughout their differentiation program, initiated by pre-B lymphocytes activation and 
differentiation into naive B lymphocytes, which in turn undergo a maturation process, thereby 
forming germinal center cells. Further engagement of CD40L on activated T lymphocyte with 
CD40 on germinal center cells induces their proliferation and differentiation into plasma cells 
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(antibody producing cells) and memory B lymphocytes (Figure 2.5).278, 314 However, the 
presence of the IL-2 and IL-10 cytokines is also required for the differentiation of germinal 
center cells into memory B lymphocytes. In addition, ligation of CD40 on germinal center and 
memory B lymphocytes induces re-expression of telomerase activity, thereby contributing to the 
expanded life-span of these cells.315 On the other hand, activation of CD40 on memory B 
lymphocytes induces Fas expression, which increases their susceptibility for Fas-mediated 
apoptosis (process of bystander B lymphocyte elimination), an effect that is prevented by 
engagement of the B cell antigen receptor (BCR) in the presence of IL-4.316, 317 Interestingly, 
activated B lymphocytes have been shown to express CD40L, which is capable of inducing 
CD40 activation on adjacent B lymphocytes in a similar way as CD40L expressed on activated T 
lymphocytes.318 
 CD40 activation favours B lymphocytes proliferation and differentiation by increasing 
their expression of co-stimulatory molecules (VCAM-1, ICAM-1, lymphocyte function-
associated angtigen-1 [LFA-1], CD23 [FcεRII], CD80 [B7.1], and CD86 [B7.2]) and their 
release of cytokines (IL-6, IL-10, TNF-α, TGF-β, and lymphotoxin-α [LT-α]).1, 319-325 CD40 
engagement also increases surface expression of the major histocompatibility complexes-I and -
II (MHC-I and MHC-II) on B lymphocytes, thereby improving their antigen presenting 
function.326 
 Finally, CD40 activation is responsible for B lymphocyte Ig isotype class switching, a 
process absent in patient suffering from HIGM, in whom there is accumulation of circulating 
IgM antibodies.276 Although activation of CD40 on B lymphocytes is sufficient to induce the 
switch to IgA and IgG, the switch to IgE and IgG4 requires the IL-4 and IL-13 cytokines.1, 278, 327 
Additional cytokines, namely IL-7, IL-2, IL-10, and TGF-β, fine-tune and enhance Ig isotype 
switching and production.327-329 
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Figure 2.5: Effects of CD40 activation on different stages of B lymphocyte differentiation. CD40L-expressing T 
lymphocytes interact and modulate all stage of B lymphocyte differentiation. Activation of CD40 on memory B 
lymphocytes can either lead to a new round of germinal center reaction and/or an accelerated differentiation into 
plasma cells. (act-T: activated T lymphocyte; pre-B: pre-B lymphocyte; GC: germinal center cell). van Kooten C. et 
al. Journal of Leukocyte Biology. 2000; 67:2-17. 
 
2.2.2 T lymphocytes 
Efficient T lymphocyte activation requires two signals. The first antigen-specific signal is 
provided by the T-cell receptor (TCR), which interacts with a specific antigen presented on 
MHC molecules of APCs, such as dendritic cells, B lymphocytes, and macrophages. This first 
signal induces the expression of the co-stimulatory molecules CD28 and CD40L on T 
lymphocytes, which in turn interact with B7.1 or B7.2 and CD40 on APCs, respectively. This 
provides the second antigen non-specific signal that is required for effective T lymphocyte 
activation and maturation into effector T lymphocytes.1, 330 This second co-stimulatory signal is 
necessary for T lymphocyte proliferation, differentiation, and survival, since its absence leads to 
T lymphocyte anergy, T lymphocyte deletion or the development of immune tolerance.331-334 
Moreover, interaction of CD40L on T lymphocytes with CD40 on APCs induces proliferation, 
differentiation, and activation of the APCs, as well as their up-regulation of the MHC-I and 
MHC-II, and the co-stimulatory molecules B7.1 and B7.2 (see section 2.2.3). Therefore, the 
CD40/CD40L dyad provides a bidirectional signalling mechanism that not only activates, but 
also amplifies the activation of both T lymphocytes and APCs. Furthermore, T lymphocyte 
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membrane-bound CD40L is cleaved by a disintegrin and metalloproteinase domain-containing 
protein-10 (ADAM-10), generating sCD40L, which accounts for a minor proportion of 
circulating sCD40L, given that platelets generate most of the sCD40L within the circulation.7, 335 
 Interestingly, T lymphocytes also express CD40 upon activation; however, its exact role 
remains unclear.336 It seems that, like B lymphocytes, engagement of CD40 on CD8+ T 
lymphocytes with CD40L on CD4+ lymphocytes favours CD8+ memory T lymphocytes 
generation.337 
 
2.2.3 Dendritic cells 
Dendritic cells are APCs by profession, which have a central role in linking innate and adaptive 
immunity. They are sentinels of the innate immune system that immediately react to potential 
pathogens and modulate the adaptive immune system by capturing, processing, and presenting 
antigens on MHCs to antigen-specific T lymphocytes. Immature DCs are capable of efficiently 
up-taking antigens, but they express low levels of MHC and co-stimulatory molecules, such as 
CD40, B7.1 and B7.2. However, upon microbial challenge-induced maturation, DCs up-regulate 
their expression of the MHC/antigen complexes, as well as the co-stimulatory molecules CD40, 
B7.1, and B7.2, thereby increasing their ability to stimulate naive T lymphocytes.330, 338, 339 
Ligation of CD40L on activated T lymphocytes with CD40 on mature DCs provides a 
bidirectional signalling mechanism that stimulates efficient T lymphocyte activation, 
proliferation, and differentiation, and amplifies DC function by increasing their surface 
expression of co-stimulatory and MHC molecules.338, 340 Moreover, continuous stimulation of 
CD40 on DCs induces their release of IL-12, which in combination with CD40L stimulation on 
T lymphocytes drives a potent T helper 1 (Th1) immune response.341-343 
 DCs also express CD40L at levels comparable to those on activated T lymphocytes. In 
addition, ligation of CD40 on DCs further increases their surface expression of CD40L.344 
Although the function of CD40L on DCs is not as well characterized as that of CD40, it seems to 
be involved in mediating activation of CD40 on B lymphocytes and adjacent DCs. This 
activation favours B lymphocyte activation and differentiation, as well as IL-12 production by 
DCs.345, 346 
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2.2.4 Monocytes/macrophages 
Monocytes constitutively express CD40, and given their APC nature, they modulate T 
lymphocyte activation through a CD40/CD40L interaction. Ligation of CD40L on activated T 
lymphocytes with CD40 on monocytes provides a bidirectional signalling mechanism that 
stimulates efficient T lymphocyte activation and proliferation, as well as monocyte 
differentiation into macrophages. CD40 ligation on monocytes/macrophages also induces their 
up-regulation of co-stimulatory molecules (ICAM-1, LFA-3, B7.1 and B7.2), and their release of 
cytokines (IL-1β, IL-6, IL-8, IL-12, and TNF-α), MMPs (MMP-1, MMP-2, MMP-3, and MMP-
9), and TF.347-353 All of which are main mediators involved in the inflammatory, immune, and 
angiogenic functions of monocytes/macrophages.  
 Aside from CD40, monocytes also express Mac-1 and α5β1, which are also CD40L 
receptors. Recruitment and transmigration of monocytes at the site of vascular lesion has been 
shown to be dependent on Mac-1/CD40L interactions, which also induce myeloperoxidase 
secretion by monocytes.313 On the other hand, α5β1/CD40L interactions induce monocyte 
activation and their subsequent IL-8 production.308 Finally, upon activation, monocytes not only 
up-regulate CD40 expression, but also that of CD40L.354 Although the exact function of CD40L 
expressed on monocytes is still unclear, it seems to be involved in the up-regulation of B7.2 
expression on B lymphocytes, as well as atherosclerotic plaque progression and allograft 
rejection.354, 355 
 
2.2.5 Neutrophils 
Neutrophils are the most abundant leukocytes within the circulation, and they are among the first 
immune cells to be recruited to the site of inflammation, where they occupy an indispensable role 
in host defence.356, 357 CD40 was initially identified on neutrophils through assessment of 
neutrophil priming by sCD40L within stored blood pools.358 Neutrophil CD40 was later shown 
to mediate platelet/neutrophil interactions by interacting with platelet CD40L. This 
CD40/CD40L interaction influences both cell types, where activated platelets release sCD40L, 
which binds CD40 on neutrophils and induces their production of ROS. In its turn, ROS 
mediates stimulation of additional platelets, thereby creating a positive feedback loop.359 Platelet 
sCD40L also enhances Mac-1 expression on neutrophils, and elevated levels of sCD40L (mainly 
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platelet derived) have been shown to promote platelet/neutrophil aggregates and neointima 
formation following arterial injury.312 
 
2.2.6 Platelets 
As mentioned in the previous chapter, platelets are not only recognized for their physiological 
haemostatic role, but also for their contribution in inflammation, as well as their modulation of 
both the innate and adaptive branches of the immune system. Since the discovery of the 
CD40/CD40L dyad in platelets, platelet CD40L has gained significant attention within the 
scientific community, given the platelet origin of 95% of circulating sCD40L. However, the 
amount of information regarding the role of platelet CD40 is scarce. Chapter three is dedicated to 
describe the role of the CD40/CD40L dyad in platelet function; therefore, this section will 
provide a brief overview. 
 In resting platelets CD40 is constitutively expressed on the cell surface, while CD40L is 
translocated to the surface following activation.2 CD40L expressed on activated platelets has 
been shown to interact with CD40 on endothelial cells and monocyte, and to mediate an 
inflammatory reaction in these cells, which is characterized by the up-regulation of adhesion 
molecules (E-selectin, ICAM-1, and VCAM-1), and the secretion of chemokines (MCP-1), 
cytokines (IL-6, and IL-8), and MMP-9.2, 3 Platelet CD40L has also been shown to stabilize in 
vivo thrombus formation by promoting platelet activation through an interaction with the αIIbβ3 
integrin.4, 307 On the other hand, ligation of CD40 on platelets leads to the generation and 
secretion of ROS and RANTES, in addition to being a requirement for CD40L cleavage and 
release to its soluble form.3, 360, 361 
 
2.2.7 Endothelial cells 
The CD40/CD40L dyad plays an important role in the inflammatory, angiogenic, and pro-
coagulant functions of endothelial cells. Although both CD40 and CD40L are expressed on 
endothelial cells, the biological repercussions of this dyad on these cells predominantly stem 
from CD40 activation following leukocyte (monocyte, lymphocyte, and neutrophil) and platelet 
adhesion to the activated endothelium. CD40 activation mediates an inflammatory phenotype in 
endothelial cells by inducing the expression of adhesion molecules (E-selectin, VCAM-1, and 
ICAM-1), and the secretion of chemokines and cytokines (IL-1, IL-6, IL-8, MCP-1, MIP-1α, and 
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RANTES), all of which promote monocytes and lymphocytes recruitment at the site of lesion. 2, 
354, 362-367 
 Endothelial cells actively participate in the angiogenic process, which is greatly 
influenced by the CD40/CD40L dyad. Interaction of CD40L with CD40 on endothelial cells 
induces the synthesis and release of extracellular matrix degrading enzymes (MMP-1, MMP-3, 
and MMP-9), which are essential for the infiltration of endothelial cells through the extracellular 
matrix during angiogenesis.368 Moreover, CD40 activation on endothelial cells has been shown 
to favour their proliferation by inducing the secretion of endothelial growth factors, including 
VEGF, FGF, and PAF, which are potent angiogenic agents.369-371 
 Finally, activation of CD40 on endothelial cells favours their pro-coagulant activity, 
which is manifested by TF generation and secretion.372, 373 TF on its turn promotes activation of 
the coagulation cascade, and the subsequent platelet activation. 
   
2.2.8 Smooth muscle cells 
Vascular smooth muscle cells express both CD40 and CD40L; however, little information is 
available regarding the role of this dyad in the function of these cells.354 Ligation of CD40 on 
vascular SMCs has been shown to mediate their release of the IL-8 and MCP-1 chemokines 
through the activation of mitogenic signalling pathways, namely the Src family-kinase pathway, 
which lead to the activation of p38 mitogen-activated protein kinase (MAPK), and the 
extracellular signal-regulated protein kinases (Erk) 1 and 2.374 In addition, ligation of CD40 on 
vascular SMCs activates the IL-1β converting enzyme (caspase-1), and induces IL-6 release.354, 
375 Finally, CD40 activation promotes SMC proliferation, migration and neointimal formation, as 
well as the pro-atherogenic and pro-thrombotic functions of vascular SMCs by favouring the 
release of matrix degrading enzymes (MMP-1, MMP-3, and MMP-9), and TF.376-380 
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Table 2.2: Cell type specific CD40/CD40L-induced signalling. 
 
Receptor Induced by Cell type Effect 
CD40 CD40L 
B lymphocyte 
- Isotype switching 
- Expression of MHC-I, MHC-II, VCAM-1, 
ICAM-1, LFA-1, FcεRII, B7.1, B7.2, and Fas 
- Cytokine production (IL-6, IL-10, TNF-α, TGF-
β, and LT-α) 
Monocyte/ 
Macrophage 
- Up-regulation of co-stimulory activity (ICAM-1, 
LFA-3, B7.1, and B7.2) 
- Myeloperoxidase secretion 
- Cytokine secretion (IL-1β, IL-6, IL-8, IL-12, and 
TNF-α) 
- MMP secretion (MMP-1, MMP-2, MMP-3, and 
MMP-9) 
- TF secretion 
Platelet - Platelet activation 
- RANTES and ROS secretion 
Neutrophil - ROS production 
- Enhanced Mac-1 expression 
DC 
- Cytokine secretion (IL-10 and IL-12) 
- Up-regulation of co-stimulory activity (CD40, 
CD40L, MHC-I, MHC-II, B7.1, and B7.2) 
Endothelial 
cell 
- Up-regulation of adhesion molecules (E-selectin, 
VCAM-1, and ICAM-1) 
- Chemokines and cytokines secretion (IL-1, IL-6, 
IL-8, MCP-1, MIP-1α, and RANTES) 
- ROS production 
- MMP secretion (MMP-1, MMP-3, and MMP-9) 
- Growth factor secretion (VEGF, FGF, and PAF) 
- TF secretion 
- Up-regulation of COX-2 
SMC 
- Chemokines and cytokines secretion (IL-1β, IL-
6, IL-8, and MCP-1) 
- MMP secretion (MMP-1, MMP-3, and MMP-9) 
- TF secretion 
- Up-regulation of COX-2 
T lymphocyte - CD8+ memory T lymphocyte generation 
CD40L CD40 T lymphocyte - Activation of T lymphocyte 
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2.3 CD40 intracellular signalling 
The CD40/CD40L dyad exerts its biological function on the above mentioned different cell types 
by activating specific intracellular signalling pathways. Although both members of the dyad are 
capable of inducing intracellular signals, CD40 has been regarded as the main signalling receptor 
following its interaction with CD40L. Despite the extensive amount of work performed on 
understanding the signalling mechanisms downstream of CD40, there is much controversy and 
the generated information is still incomplete. The discrepancies result from differences in CD40 
mediated signal transduction among different cell types, as well as between the different stages 
of differentiation within the same cell type. Nonetheless, culmination of the knowledge regarding 
CD40 mediated signals lead to the identification of TNF receptor associated factor (TRAF)-
dependent and -independent signalling mechanisms. The cytoplasmic domain of CD40 lacks 
intrinsic kinase activity, and therefore utilizes members of the TRAF family as adaptor proteins 
to mediate signalling events, which account for the majority of the signals generated by CD40 
activation. Following their recruitment to the cytoplasmic domain of CD40, TRAFs thereafter 
induce activation of multiple signalling pathways, including the canonical and non-canonical 
nuclear factor-κB (NF-κB) (see section 2.3.2), the MAPKs (p38 MAPK, Erk1/2, Akt, and c-jun 
N-terminal kinases [JNKs]), the PI3K, and the PLCγ pathways.381 On the other hand, the TRAF-
independent signalling pathway induces activation of the signal transducer and activator of 
transcription 5 (STAT5) through the direct interaction of the janus kinase 3 (JAK3) with the 
cytoplasmic tail of CD40 following its ligation.382, 383 Figure 2.6 summarizes the main CD40-
mediated signalling pathways induced by the different TRAF members, as well as JAK3. 
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Figure 2.6: The different CD40-mediated signalling pathways. Following CD40 activation, TRAF members are 
recruited to its cytoplasmic tail. Each TRAF member then induces activation of a distinct signalling pathway; 
however, some signalling pathways are activated by multiple TRAF members. JAK3 interacts with the cytoplasmic 
tail of CD40, and induces activation of the TRAF-independent pathway. These signals regulate different cellular 
processes. Modified from Elgueta R. et al. Immunological Reviews. 2009; 229:152-172. 
 
2.3.1 Structure and function of TRAFs 
Up to date seven members of the TRAF family have been identified, including TRAF1 to 
TRAF7. These TRAF members have similar structures, which are formed by a TRAF-C domain 
(WD40 domain repeats in TRAF7) at the C-terminal, followed by a leucine rich coiled-coil 
domain, one or multiple zing-finger domains, and a RING domain (except TRAF1) at their N-
terminal (Figure 2.7).381, 384 The TRAF-C domain of TRAFs 1 to 6 is involved in their 
oligomerization, as well as their interaction with members of the TNF receptor family, including 
CD40, while the WD40 domain repeats of TRAF7 are involved in its interaction with MAPK 
kinase kinase 3 (MEKK3). The coiled-coil domain (a.k.a. TRAF-N) is involved in the homo- or 
heterotrimerization of TRAF proteins, such as TRAF3/TRAF5 heterotrimerization.385 The zinc-
finger and RING domains are involved in the ubiquitination of TRAF proteins and their 
subsequent interactions with downstream signalling molecules, such as transcription factors and 
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kinases. Moreover, as mentioned above, following CD40 ligation, TRAFs are recruited to the 
cytoplasmic tail of the receptor. This is done either directly or indirectly through the aid of 
additional TRAF members, as is the case for TRAF5 recruitment, which requires its 
heteroligomerization with TRAF3. Although each TRAF member has a distinct interaction site 
on the cytoplasmic tail of CD40, it seems that the interaction site for TRAF1, TRAF2, and 
TRAF3 overlap.385 
 
  
Figure 2.7: Structure of TRAF proteins. Image is produced by Hachem A. 
 
2.3.1.1 TRAF1 
TRAF1 was initially identified as a molecule interacting with CD120b (TNF receptor 2).386 
Unlike the other TRAFs, TRAF1 does not have zinc-finger and RING domains; therefore it has 
an important role in regulating other TRAF proteins, specifically TRAF2. Indeed, absence of 
TRAF1 in dendritic cells and B lymphocytes results in a reduced recruitment of TRAF2 to the 
cytoplasmic domain of CD40, as well as an increased TRAF2 degradation.387, 388 This, suggests 
that TRAF1 may promote TRAF2-mediated CD40 signals by prolonging membrane localization 
of TRAF2. On the other hand, absence of TRAF2 results in a weak binding of TRAF1 to the 
cytoplasmic domain of CD40.385 Moreover, TRAF1 deficiency in B lymphocytes results in a 
decrease of CD40-mediated IgM production, whereas TRAF1 and TRAF2 deficient B 
lymphocytes exhibit reduced canonical NF-κB pathway and JNK activation, and reduced IgM 
production as compared to cells deficient in either TRAF alone.388 Interestingly, CD40 activation 
leads to the up-regulation of TRAF1 protein level, which probably plays a role in the feedback 
regulation of receptor signalling.389 
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2.3.1.2 TRAF2 
TRAF2 was initially identified through its association with the TNF receptor 2.386 Actually, 
TRAF2 is known to be responsible for the activation of the p38, Erk1/2, Akt, and JNK MAPKs, 
as well as the canonical and non-canonical NF-κB pathways following CD40 ligation. These 
signalling pathways were evidenced in B lymphocytes and embryonic fibroblasts deficient in 
TRAF2, which showed reduced activation of these pathways upon CD40 engagement.390-394 
Activation of the p38, Erk1/2, and JNK MAPKs does not occur directly by TRAF2, but rather 
through the indirect recruitment of the protein kinase MEKK1 by TRAF2 to the cytoplasmic tail 
of CD40. MEKK1 is an essential protein kinase involved in CD40-induced activation of the 
aforementioned MAPKs following CD40 engagement.395 
 Activation of the canonical NF-κB pathway by TRAF2 was put into evidence in TRAF2 
deficient B lymphocytes. However, TRAF2 deficiency does not completely abolish activation of 
the canonical NF-κB pathway, given that TRAF6 can also activate it (Figure 2.8).391, 393 Indeed, 
activation of the canonical NF-κB pathway following CD40 engagement has been shown to be 
completely abolished in B lymphocytes lacking both TRAF2 and TRAF6 binding to CD40.391 
On the other hand, the exact mechanism by which TRAF2 activates the canonical NF-κB 
pathway is still unclear. It was initially thought that the nuclear factor-κB-inducing kinase (NIK) 
was responsible for activating the IκB kinase (IKK), which ultimately mediates canonical NF-κB 
pathway activation. However, NIK deficiency does not result in a defective CD40 response.396, 
397 Therefore, TRAF2 probably activates IKK through its association with MEKK1, which has 
already been shown to activate IKK.398, 399 
 Despite its above mentioned activating roles, TRAF2 negatively regulates the non-
canonical NF-κB pathway. In the absence of CD40 ligation, TRAF2 interacts with the cellular 
inhibitor of apoptosis (cIAP) 1 and 2, TRAF3, and NIK.400, 401 Under these conditions, cIAP1/2 
antagonizes the non-canonical NF-κB pathway by inducing degradation of NIK.402, 403 Indeed, 
deficiency in either TRAF2 or cIAP results in NIK accumulation in mouse embryonic fibroblasts 
(MEF).404 Furthermore, CD40 ligation destabilizes the TRAF2/TRAF3/NIK/cIAP1/2 complex, 
thereby favouring TRAF2 and TRAF3 recruitment to the cytoplasmic tail of CD40.381 Once 
recruited, TRAF2 undergoes auto-degradation, whereas TRAF3 is degraded by cIAP1/2.403, 405 
Degradation of both TRAF2 and TRAF3 induces accumulation of NIK, which, in turn, mediates 
activation of the non-canonical NF-κB pathway.381 
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 In summary, in the absence of CD40/CD40L interactions, TRAF2 acts as a negative 
regulator of the non-canonical NF-κB pathway activation, whereas TRAF2 mediates activation 
of both the canonical and non-canonical NF-κB pathways following CD40 ligation. Activation of 
the canonical and non-canonical NF-κB pathways is responsible for B lymphocyte activation and 
differentiation into plasma cells.398, 400 
 
     
Figure 2.8: Activation of the canonical and non-canonical NF-κB pathways by CD40. TRAF2 interactions with the 
cytoplasmic domain of CD40 induce activation of both NF-κB pathways, whereas TRAF6 induces activation of the 
canonical NF-κB pathways. CD40-induced activation of the canonical NF-κB pathway results in nuclear 
translocation of NF-κB complexes, including the Rel-A/p50 NF-κB complex. Whereas the non-canonical NF-κB 
pathway results in nuclear translocation of predominantly the Rel-B/p52 NF-κB complex. Modified from Bishop G. 
A. Nature Reviews Immunology. 2004; 4:775-786. 
 
2.3.1.3 TRAF3 
TRAF3 was initially identified by its interaction with CD40 and the Epstein-Barr virus 
transforming protein LMP1.406, 407 A controversy exists as to the role of TRAF3 in CD40-
induced NF-κB pathway activation; given that TRAF3 has opposing effects in different cell 
types. As mentioned above, TRAF3 negatively regulates CD40 signalling in B lymphocytes in 
the absence of CD40/CD40L interactions. In fact, in B lymphocytes, expression of a TRAF3-
dominant negative protein or deficiency in TRAF3 leads to the activation of the canonical NF-κB 
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and JNK signalling pathways, as well as the accumulation of NIK and an enhancement in 
TRAF2 recruitment to the cytoplasmic domain of CD40.402, 403, 408, 409 In the presence of 
CD40/CD40L interactions, TRAF3 relieves its negative regulation of the CD40-induced signals 
through its degradation by cIAP1/2. In contrast, in epithelial cells, over-expression of TRAF3 
induces activation of the canonical NF-κB pathway upon CD40 ligation.410, 411 Therefore, 
additional investigations are required in order to better understand the different functions of 
TRAF3 in CD40 signalling. 
 
2.3.1.4 TRAF4 
The TRAF4 gene was initially discovered by screening of cDNA libraries for genes expressed in 
malignant breast cancers.412 Its biological significance was later put into evidence in TRAF4 
deficient mice, which exhibited tracheal malformations.413 TRAF4 is mainly expressed in 
neuronal and epithelial cells, and plays a significant role in embryonic development.413-415 
Although TRAF4 does not interact with CD40, it has been shown to interact with other members 
of the TNF receptor family, namely the lymphotoxin-β receptor (LTβR) and the p75 nerve 
growth factor receptor.414 
 
2.3.1.5 TRAF5 
There is much discrepancy regarding the role of TRAF5 in CD40 signalling. Whether TRAF5 is 
capable of directly or indirectly binding CD40 remains a matter of controversy, given that early 
studies showed direct binding of TRAF5 to the cytoplasmic domain of CD40, whereas later 
studies showed that TRAF5 requires heterotrimerization with TRAF3 for interaction with 
CD40.385, 416 Furthermore, it has been shown that B lymphocytes treated with small interfering 
RNAs (siRNAs) specific for TRAF5 and B lymphocytes of TRAF5 deficient mice exhibit a 
reduction in the canonical and non-canonical NF-κB pathways activation, which is manifested by 
a decrease in antibody production, proliferation, and co-stimulatory molecules expression.417, 418  
Therefore, the roles of TRAF5 and TRAF2 in activating CD40-mediated downstream signals 
seems to be redundant.398 Further investigations are required for elucidating the exact role of 
TRAF5 in CD40 signalling. 
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2.3.1.6 TRAF6 
TRAF6 was initially identified through its interaction with CD40 in a yeast two-hybrid system. 
Now TRAF6 is known to mediate CD40-induced activation of the canonical NF-κB pathway, as 
well as the p38, JNK, and Akt MAPK pathways, which were evidenced in TRAF6 deficient 
MEF and epithelial cells.381 Interestingly, although TRAF6 has a dedicated binding site on the 
cytoplasmic domain of CD40, excision of this site in B lymphocytes does not affect TRAF6 
induced JNK activation and enhanced B7.1 expression following CD40 engagement, as 
compared to TRAF6 deficiency in B lymphocytes.381, 419 This is due to the interaction of TRAF6 
with TRAF2, which subsequently mediates TRAF6 signals independently of its recruitment to its 
binding site on the cytoplasmic domain of CD40.419, 420 
 As mentioned above, TRAF6 induces activation of Akt, a process independent of NF-κB 
activation following CD40 ligation.421 Akt activation occurs in a PI3K dependent manner, in 
which PI3K forms a complex with TRAF6, the Casitas B-lineage lymphoma b (Cbl-b), and the 
Casitas B-lineage lymphoma (c-Cbl) following CD40 engagement.421 In turn Cbl-b induces 
phosphorylation of Akt through PI3K.422 Activation of PI3K/Akt has a crucial role on cell 
survival following CD40 ligation, by mediating inhibition of the pro-apoptotic proteins, caspase 
9 and B-cell leukemia (Bcl); in addition to inducing up-regulation of the anti-apoptotic proteins, 
caspase 8 and the cellular homolog of viral Fas-associated via death domain-like IL-1β 
converting-enzyme inhibitory protein p43 (cFLIPp43).422-425 
 
2.3.1.7 TRAF7 
TRAF7 is the most recent member of the TRAF family to be identified. It was first discovered as 
a protein associated with MEKK3, which is required for TNF-α-induced activation of NF-κB.426 
TRAF7 was later identified through the screening for protein-protein interactions around known 
and candidate components of the TNF-α/NF-κB pathway.427 Up to date, there is still no evidence 
linking TRAF7 to any members of the TNF receptor family; however, it seems to be involved in 
the TLR-2 signalling pathway.428 Moreover, TRAF7 seems to be involved in the activation of the 
JNK and p38 MAPKs, as well as the activation or inhibition of NF-κB, depending on the cellular 
model and biological setting.384 
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2.3.1.8 JAK3 
Although most of the work has focused on the involvement of TRAFs as CD40 adaptor proteins, 
it has been shown in B lymphocytes that the cytoplasmic domain of CD40 contains a binding 
region for JAK3.429 However, JAK3 activation following CD40 ligation is cell type dependent. 
For instance, in B lymphocytes, CD40 stimulation does not induce JAK3 phosphorylation, 
whereas in monocytes and APCs it does.382, 383, 430 JAK3 induces activation of STAT5, thereby 
leading to gene expression of inflammatory cytokines, including TNF-α, interferon (INF)-γ, and 
IL-6, as well as maturation of DCs.431 
 
2.3.2 Structure and function of NF-κB 
NF-κB is a important transcription factor involved in the expression of a wide range of genes 
implicated in different biological processes, including immune responses, cell survival, stress 
responses, and maturation of various cell types (Table 2.3). In mammals, the NF-κB complexes 
are formed by homo- or heterodimerization of five transcription factors: Rel-A (p65), Rel-B 
(p68), c-Rel, and the precursors p105 (NF-κB1) and p100 (NF-κB2), which are processed into 
p50 and p52, respectively. These transcription factors contain an N-terminal DNA-
binding/dimerization domain known as the Rel homology domain, which allows their 
dimerization, as well as their DNA binding (as dimers) at target sequences termed κB sites. The 
Rel-A, Rel-B, and c-rel transcription factors also contain C-terminal transcription activation 
domains (TADs), which favour co-activator recruitment and the subsequent expression of target 
genes. The p50 and p52 transcription factors lack TADs, and therefore activate transcription by 
forming heterodimers with Rel-A, Rel-B, or c-Rel. In contrast, p50 and p52 can inhibit 
transcription if they bind DNA as homodimers, given that they lack TADs.432  
 In the absence of receptor stimulation, the NF-κB complexes are maintained in the 
cytoplasm in an inactive state complexed with the inhibitory inhibitor κB (IκB) proteins (IκBα, 
IκBβ, IκBε, IκBζ, p100, p105, Bcl3, and IκBns), which sequester NF-κB complexes in a latent 
state through their ankyrin-repeat domains.433 Upon receptor activation, and the subsequent 
TRAF recruitment, activation of the NF-κB signalling pathway leads to proteasomal degradation 
of the IκB proteins and the consequential release and nuclear translocation of the NF-κB 
complexes. Activation of the canonical NF-κB pathway leads to nuclear translocation of four 
transcriptional activator complexes (Rel-A/Rel-A, Rel-A/p50, c-Rel/c-Rel, and c-Rel/p50), 
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whereas activation of the non-canonical NF-κB pathway leads to nuclear translocation of 
predominantly Rel-B/p52 complexes.432, 433 Figure 2.9 schematizes the NF-κB and IκB family 
members, in addition to the IκB kinase (IKK) members (discussed below). 
 
Table 2.3: Genes induced by the NF-κB signalling pathway activation.434, 435 
 
Cytokines and growth factors - IL-1β 
- IL-2 
- IL-6 
- IL-8 
- TNF-α 
- Lymphotoxin (TNF-β) 
- IP-10 
- MIP-1α 
- MCP-1 
- RANTES 
- INF-β 
- Macrophage colony-stimulating factor (M-CSF) 
- Granulocyte/macrophage colony-stimulating factor (GM-CSF) 
- Granulocyte colony-stimulating factor (G-CSF) 
- Melanoma growth stimulating activity (Gro-α, -β and -γ/MGSA) 
- Proenkephalin 
Immunoreceptors - Ig-κ light chain 
- TCR 
- MHC-I 
- MHC-II 
- MHC-II invariant chain 
- β2-microglobulin 
- Tissue factor-1 
- IL-2 receptor α chain 
Adhesion molecules - ICAM-1 
- VCAM-1 
- Endothelial-leukocyte adhesion molecule-1 (ELAM-1) 
Acute phase proteins - Angiotensinogen 
- Serum amyloid A precursor 
- Complement factor B 
- Complement factor C4 
Transcription factors and regulators - c-Rel 
- p105 
- IκBα 
- c-myc 
- Interferon regulatory factor 1 (IRF-1) 
Others - iNOS 
- Vimentin 
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Figure 2.9: Schematic representation of the mammalian NF-κB, IκB and IKK family members. Alternative 
nomenclatures are in parenthesis. The precursors p100 and p105 act as IκB; however, following receptor activation 
and their subsequent proteasomal degradation into p52 and p50, respectively, they function as NF-κB family 
members. (ANK: ankyrin-repeat domain; DD: death domain; RHD: REL homology domain; TAD: transcription 
activation domain; LZ: leucine-zipper domain; GRR: glycin-rich region; HLH: helix-loop-helix domain; Z: zinc-
finger domain; CC: coiled-coil domain; NBD: NEMO-binding domain; MOD/UBD: minimal oligomerization 
domain/ubiquitin-binding domain; PEST: proline, glutamic acid, serine, and threonine rich.) Modified from Hayden 
M. S. et al. Cell Research. 2011; 21:223-244. 
 
2.3.2.1 Canonical pathway 
As mentioned above, in the absence of receptor activation, the NF-κB complexes are sequestered 
in the cytoplasm in a latent state through their association with IκBs. In the canonical pathway, 
the classical IκB (IκBα, IκBβ, and IκBε) sequester the canonical NF-κB complexes (Rel-A/Rel-
A, Rel-A/p50, c-Rel/c-Rel, and c-Rel/p50) in the cytoplasm, and the release of these complexes 
requires phosphorylation and proteasomal degradation of the IκBs following receptor 
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engagement.433 Phosphorylation of IκBs in the canonical pathway is dependent on the activation 
of the IKK complex, which is formed by the two catalytic subunits IKKα (a.k.a IKK1) and IKKβ 
(a.k.a IKK2), and the regulatory subunit NF-κB essential modulator (NEMO; a.k.a. IKKγ). 
Activation of the IKK complex, specifically phosphorylation of IKKβ on serines 177 and 181, 
leads to IκBα phosphorylation at serines 32 and 36.436, 437 Once phosphorylated, IκBα is targeted 
for degradation by the 26S proteasome, thereby releasing the canonical NF-κB complexes, which 
then translocate into the nucleus and initiate transcription of target genes (Figure 2.8). The IκBβ 
and IκBε are also phosphorylated by the IKK complex, and thereafter targeted for proteasomal 
degradation, and the consequential release and nuclear translocation of canonical NF-κB 
complexes.433 
 Since the canonical NF-κB pathway induces expression of genes involved in the 
inflammatory and immune response, its activation must be tightly controlled, given that improper 
regulation of NF-κB activation has been shown to be implicated in pathological conditions, such 
as chronic inflammation and cancer.433, 438, 439 Indeed, IκBα and IκBε have been shown to be 
important negative regulators of the canonical NF-κB pathway activation, as their absence results 
in lethality due to hyperinflammation and increased cytokine expression.439, 440 Additionally, NF-
κB has been shown to induce transcription of the IκBα gene, thereby forming a negative 
feedback loop that limits activation of the canonical NF-κB pathway.441 
 
2.3.2.2 Non-canonical pathway 
In contrast to the canonical pathway, activation of the non-canonical NF-κB pathway is 
dependent on NIK and IKKα. As mentioned in section 2.3.1.2, following degradation of TRAF3, 
there is an accumulation of cytoplasmic NIK. In turn, NIK activates IKKα, which then 
phosphorylates the precursor p100.442 Phosphorylation of p100 targets it for degradation by the 
26S proteasome. However, unlike IκBα, proteasomal degradation of p100 results in degradation 
of only its C-terminal containing ankyrin-repeat domains.443 Removal of these domains generates 
the p52 transcription factor containing the Rel homology domain, which, in turn, preferentially 
associates with Rel-B (Figure 2.8). The formed heterodimer subsequently translocates to the 
nucleus and mediates transcription of the non-canonical NF-κB pathway target genes, which are 
involved in the development and maintenance of secondary lymphoid organs.443, 444 
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 Unlike the canonical pathway, there is limited information regarding the negative 
regulation of the non-canonical pathway. It has been reported that IKKα induces phosphorylation 
and the subsequent destabilization of NIK, which probably provides a mean to down-regulate 
activation of the non-canonical NF-κB pathway.445 
 
2.3.3 Other CD40 intracellular signalling molecules 
Members of the NF-κB family have been the main focus of most of the work on CD40/TRAFs-
induced transcriptional activity. However, NF-κB family members are not the only transcription 
factors downstream of TRAFs. Activation of CD40 in B lymphocytes stimulates activation of a 
wide array of immuno-regulatory proteins, including cytokines, chemokines, Ig, and adhesion 
molecules; however, inhibition of CD40-induced activation of the NF-κB pathways ablates most, 
but not all CD40-mediated gene expression.446, 447 For instance, IL-6 gene expression following 
CD40 activation does not require NF-κB nuclear translocation. The transcription factors activator 
protein 1 (AP1) and nuclear factor of IL-6 (NF-IL-6; a.k.a C/EBPβ) have been shown to mediate 
CD40-induced transcriptional activity alongside NF-κB family members in a TRAF6 dependent 
manner.448 NF-IL-6 and AP1 have an important role in CD40-mediated IL-6 production, as well 
as the subsequent IgM production by B lymphocytes. 
 
2.4 Physiological role of the CD40/CD40L axis 
Section 2.2 covered the biological function of the CD40/CD40L dyad in a cell type specific 
manner, while section 2.3 described the signalling pathways ensued by CD40 following its 
interaction with CD40L. The role of this dyad in the interactions among the different cell types 
in a physiological setting, such as in humoral immunity, cell-mediated immunity and apoptosis, 
will be the main focus of this section. 
 
2.4.1 Humoral immunity 
Humoral immunity, which is also known as thymus-dependent humoral immune response, is a 
branch of immunity that is mediated through antibody production by B lymphocytes. The 
intricate cell-cell contact interactions between APCs (specifically DCs), T and B lymphocytes, as 
well as the crucial role of the CD40/CD40L dyad in these interactions culminate in B 
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lymphocyte activation and differentiation into antibody producing cells, also known as 
plasmocytes. 
 The importance of the CD40/CD40L dyad in the development of humoral immunity was 
initially evidenced in individuals with HIGM, who have a mutation in the gene encoding CD40L 
resulting in a non-functional protein.276 The importance of this dyad was later confirmed by 
genetic deletion of either the CD40 or CD40L gene, and by antibody blockade of the CD40L 
protein.449, 450 Under such conditions, there is a severe impairment in the humoral immune 
response, which is manifested by the lack of germinal center formation and progression, 
antibody isotype switching and affinity maturation, and memory B cells and plasma cells 
formation.276, 449, 450 
 The intricate interactions between DCs, T and B lymphocytes in mounting an effective 
humoral immune response are initiated by the interaction of DCs with pathogens. Upon a 
pathogenic challenge, DCs acquire and present pathogenic antigens to naive CD4+ T 
lymphocytes, which recognize the antigens through the TCR and become fully activated 
following engagement of CD40L and CD28 with their cognate receptors (CD40 and B7.1 or 
B7.2, respectively) on DCs.1, 330 On the other hand, ligation of CD40 on DCs induces their up-
regulation of co-stimulatory (CD40 and B7.2 or B7.1) and MHC molecules (MHC-I and MHC-
II), in addition to inducing secretion of the IL-12, IL-10 and IL-6 cytokines.330, 338, 339, 341, 451, 452 
In turn, IL-12, IL-10 and IL-6 favour T lymphocytes differentiation into effector Th1, TReg and 
Th17 lymphocytes, respectively.343, 452, 453 This bidirectional crosstalk favours clonal 
differentiation of antigen-specific T lymphocytes, as well as maturation and survival of DCs.400 
Activated T lymphocytes then home toward B lymphocyte follicles and position themselves at 
the border of the T lymphocyte zone and B lymphocyte follicles, where they encounter activated 
B lymphocytes expressing the cognate antigen.454, 455 Activation of naive B lymphocytes prior to 
their interaction with activated T lymphocytes occurs through their direct uptake of pathogenic 
antigens or by their interaction with tissue-resident DCs that are activated by the pathogen and 
subsequently home toward the B lymphocyte zone in secondary lymphoid organs.456, 457 
Interaction of T and B lymphocytes at the border zone induces B lymphocyte differentiation into 
either plasmablasts or germinal center cells.458, 459 Interestingly, the extent of CD40/CD40L 
interactions depicts the fate of B lymphocyte differentiation, where extensive CD40/CD40L 
interactions favour plasmablast differentiation.400, 458 Further engagement of T lymphocyte 
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CD40L with CD40 on B lymphocytes stimulates B lymphocyte proliferation, isotype switching, 
and differentiation into plasma cells.278, 314 In summary, pathogen-activated DCs induce 
activation of T lymphocytes, which in turn induce B lymphocyte proliferation, isotype switching, 
and differentiation, where CD40/CD40L interactions play a major role at each interaction step. 
 In contrast, DCs are capable of inducing T lymphocyte-independent B lymphocyte 
antibody production. CD40 activation on DCs by CD40L on activated T or B lymphocytes 
induces expression of the B lymphocyte stimulator protein (BLys or BAFF) and a proliferation 
induced ligand (APRIL) on DCs.460 In turn, BAFF interacts with the BAFF receptor and the B 
cell maturation antigen (BCMA) on B lymphocytes, while ARPIL interacts with the 
transmembrane activator and calcium modulator and cyclophylin ligand interactor (TACI). 
These interactions in the presence of IL-2 and IL-4 secreted by T lymphocytes, favour B 
lymphocytes survival, isotype switching, and IgG and IgA secretion.460-462 
 
2.4.2 Cell-mediated immunity 
It was initially thought that the function of CD40/CD40L dyad was limited to humoral immunity; 
however, substantial amount of evidence now supports its role in cell-mediated immunity. This 
branch of immunity does not involve antibody production or activation of the complement 
system, but is rather mediated by a plethora of agents secreted and expressed by immuno-
competent cells, including T and B lymphocytes, macrophages, natural killer cells, endothelial 
cells, SMCs, platelets, and fibroblasts.1, 463 Ligation of CD40 induces a pro-inflammatory 
response in these cells, which is characterized by the up-regulated expression of adhesion 
molecules, as well as the induced secretion of pro-inflammatory mediators, namely cytokines, 
chemokines, extracellular degrading enzymes (MMPs), growth factors, and coagulation factors 
(TF). All of which are important mediators for both inflammation and immunity as they favour 
recruitment and activation of additional immuno-competent cells at the lesion/infection site. In 
addition, the various secreted growth factors and MMPs influence the wound repair process after 
the resolution of infection and inflammation.1, 368, 463 Tables 2.2 and 2.3 summarize the 
aforementioned mediators influenced by the CD40/CD40L dyad in cell-mediated immunity. 
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2.4.3 Apoptosis 
Aside from its role in immunity, the CD40/CD40L dyad has a role in modulating cell survival. 
Signals induced by CD40 following its ligation either induce or prevent apoptosis depending on 
the cell type in which they occur. For instance, CD40 signals rescue B lymphocytes from 
apoptosis, whereas in certain B lymphoma cell lines they induce apoptosis.464-469 
 CD40-induced inhibition of apoptosis is mediated through its modulation of mediators of 
the intrinsic and extrinsic apoptotic pathways. The intrinsic apoptotic pathway is triggered by 
mitochondrial stress resulting in cytochrome c and Smac/DIABLO release from the 
mitochondria. Association of cytochrome c with Apaf-1 and caspase 9 leads to caspase 3 
activation and the subsequent cellular death by apoptosis.470 Inhibition of the intrinsic apoptotic 
pathway by CD40 is mediated through the up-regulation of the anti-apoptotic Bcl-2 family 
members (Bcl-XL, Mcl-1 and Bfl-1) and survivin that prevent cytochrome c release from the 
mitochondria and block caspase 3 activation, respectively.464, 465, 470-475 On the other hand, the 
extrinsic apoptotic pathway is mediated by activation of Fas and TNF receptor 1, which lead to 
caspase 8 activation and the subsequent caspase 3 activation.470 CD40 inhibits the extrinsic 
apoptotic pathway by up-regulating A20 and cFLIP expression, which respectively inhibit Fas 
and TNF receptor 1 mediated caspase 8 activation.476, 477 Therefore, CD40 signals induce 
expression of anti-apoptotic proteins, which rescue B lymphocytes from apoptosis induced by 
either extrinsic factors (IgM, Fas ligand [FasL] and TNF) or intrinsic factors that induce 
mitochondrial damage. 
 In contrast, activation of CD40 on certain malignant and B lymphoma cell lines results in 
growth arrest and induced apoptosis.470, 478, 479 The pro-apoptotic effect of CD40 activation in 
these cells is mediated through the up-regulation of the pro-apoptotic Bcl-2 family members 
(Bik, Bax and Bak), which favour cytochrome c release from the mitochondria, and the 
subsequent caspase 3 activation.480, 481 CD40 also drives the extrinsic apoptotic pathway by 
inducing the up-regulation of FasL and TNF, thereby leading to caspase 8 activation following 
Fas/FasL and TNF/TNF receptor interactions.482, 483 
 
2.5 Pathological role of the CD40/CD40L axis 
In the previous sections, the physiological function of the CD40/CD40L dyad was discussed. 
The interactions between CD40 and CD40L were shown to be central for mounting an effective 
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inflammatory and immune response. However, these interactions must be tightly regulated, given 
that the improper expression of CD40 and CD40L or the unsuitable interactions between them 
are associated with the pathogenesis of multiple diseases, including autoimmune diseases, cancer 
and atherosclerosis.484-486 This section will focus on the CD40/CD40L contribution to the 
development and progression of these pathologies. 
 
2.5.1 Autoimmune diseases 
An autoimmune disease arises when the body mounts an immune response against substances 
and tissues normally present in the body. In other words, the body attacks its own cells, thereby 
damaging a specific organ or tissue that is present in multiple parts of the body. Given its central 
role in modulating the immune response, the CD40/CD40L dyad significantly contributes to the 
development and progression of multiple autoimmune diseases, such as inflammatory bowel 
disease, type I diabetes, thyroiditis, multiple sclerosis, systemic lupus erythematosus, and 
rheumatoid arthritis. This section will cover the general contribution of the CD40/CD40L dyad 
in the development of autoimmune diseases, as well as its implication in the aforementioned 
diseases. 
 
2.5.1.1 Mechanism of action 
Up to date, there are three proposed mechanisms for the contribution of the CD40/CD40L dyad 
to T lymphocyte-dependent autoimmune diseases. The first proposed mechanism is mediated 
through improper T lymphocyte selection in the thymus. Under normal circumstances, 
expression of tissue-restricted antigens by medullary thymic epithelial cells results in negative 
selection (deletion) of potentially auto-reactive T lymphocytes and the subsequent induction of 
self-tolerance. As CD40 has been shown to cooperate with the receptor activator of NF-κB 
(RANK) in promoting medullary thymic epithelial cells development, a disruption in CD40 
activation in these cells could probably result in their inadequate development.486, 487 Therefore, 
the disturbed development of medullary thymic epithelial cells potentially permits auto-reactive 
T lymphocyte clones to escape negative selection, leading to failure of central tolerance and the 
subsequent potential development of auto-immune diseases. 
 The second proposed mechanism of CD40/CD40L contribution to autoimmune diseases 
occurs in secondary lymphoid organs, where T lymphocytes are primed by APCs (B 
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lymphocytes or DCs) over-expressing CD40 either constitutively or transiently.486 The over-
expression of CD40 leads to increased interactions between CD40L on T lymphocytes and CD40 
on APCs, which favour the activation of auto-reactive T lymphocytes, as well as the production 
of pro-inflammatory cytokines by APCs and auto-antibodies by B lymphocytes.452 Among the 
secreted pro-inflammatory cytokines, IL-6 has been shown to drive T lymphocytes 
differentiation into Th17 cells.452 In turn, Th17 cells induce cell-mediated tissue damage by 
secreting IL-17.488 Therefore, the increase in CD40 expression and the subsequent exaggerated 
CD40/CD40L interactions potentially lead to the development of autoimmune diseases. 
 The third proposed mechanism results from abnormal expression of CD40 in tissues 
where it is normally undetectable. Under such conditions, the tissues themselves contribute to the 
initiation of the autoimmune disease. Indeed, elevated expression levels of CD40 in target tissues 
(thyroid and pancreatic islet cells) have been associated with the initiation of thyroiditis, and the 
production of inflammatory cytokines resulting in the failure of pancreatic islet cell 
transplants.489, 490 
 
2.5.1.2 Inflammatory bowel disease 
The two major subtypes of inflammatory bowel disease are Crohn's disease and ulcerative 
colitis. They are characterized by recurring inflammation of the small and large intestine. 
Infiltration of macrophages, T and B lymphocytes into the intestinal epithelium disrupts its 
barrier function, resulting in diarrhea, abdominal pain, rectal bleeding, and malnutrition in 
attained individuals.491 
 The initial evidences pointing at the contribution of CD40/CD40L to the autoimmune 
inflammatory bowel disease came from studies in mice. The results from these studies 
demonstrated that the CD40/CD40L interactions were crucial for the initiation of the disease, but 
were not necessary for the progression of the inflammatory responses. In fact, administration of a 
blocking CD40L antibody at the onset of colitis initiation inhibits lymphocytic infiltration into 
the intestinal epithelium, and disease occurrence, whereas blocking CD40L four weeks following 
colitis initiation only improves the disease symptoms.492, 493 Additionally, in mice, over-
expression of CD40L in T lymphocytes results in T lymphocyte infiltration in multiple organs 
and death caused by inflammatory bowel disease by 3-6 weeks of age.494 
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 In patients with Crohn's disease, CD40 is over-expressed on microvascular endothelial 
cells in the inflamed mucosa, and there is an increase in CD40+ DCs found within the intestinal 
mucosa.495, 496 In contrast, genomic association studies did not show an association between the 
CD40 gene and inflammatory bowel disease incidences.497 Nonetheless, in a small study, 77% of 
the patients with Crohn's disease that where treated with a chimeric antagonistic CD40 antibody 
showed a beneficial response to treatment, while the remaining 22% of the patients entered into 
remission.498 
 
2.5.1.3 Type I diabetes 
Type I diabetes, also known as insulin-dependent diabetes, is an autoimmune disease 
characterized by the complete absence of insulin production resulting from the destruction of the 
beta cells in the islets of Langerhans in the pancreas.499 Much of the knowledge regarding type I 
diabetes development came from studies in animal models of this human disease, specifically 
non-obese diabetic (NOD) mice, which spontaneously develop diabetes following insulitis 
(inflammation of the islets of Langerhans), and leukocytic infiltration and destruction of the 
islets. In NOD mice, CD8+ and CD4+ T lymphocytes specific for beta cell antigens, as well as B 
lymphocytes, have been shown to be essential for the pathogenesis of the disease. Transfer of 
CD8+ or CD4+ T lymphocytes specific for beta cell antigens from NOD mice into normal mice 
induces diabetes in the latter, whereas depletion of these cells in NOD mice prevents the 
disease.499 In addition, diabetes in NOD mice is prevented by B lymphocyte depletion.500 
Although B lymphocytes do produce auto-antibodies directed against beta cell antigens (insulin 
and glutamic acid decarboxylase), their role as APCs in promoting diabetogenic T lymphocytes 
activation and proliferation might be of more significance, given that the role of the produced 
auto-antibodies in the pathogenesis of the disease is still unclear.499, 501 Given the central role of 
the CD40/CD40L dyad in the cross-talk between B and T lymphocytes, blocking this interaction 
with an antagonistic CD40L antibody has been shown to delay or prevent diabetes in NOD mice 
and bio-breeding diabetes-prone rats.502, 503 
 The role of CD40+ T lymphocytes in diabetes has recently been examined. Triggering of 
the TCR and CD40 in T lymphocytes from NOD mice up-regulates the level of expression of 
CD40 on these cells. Additionally, the use of an antibody to block CD40 on diabetogenic T 
lymphocytes from NOD mice prevents diabetes induction in NOD SCID (severe combined 
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immunodeficiency) following T lymphocyte transfer.504 In humans, the levels of CD40+ T 
lymphocytes have been shown to be elevated in type I diabetes patients as compared to type II 
diabetes patients and controls.505 
 Finally, the CD40/CD40L dyad also contributes to the inflammatory environment within 
the islets of Langerhans. Pancreatic beta cells from human and mice constitutively express 
CD40, and activation of this receptor in these cells leads to the production of pro-inflammatory  
cytokines (IL-6, IL-8, MIP-1α, and MCP-1β); hence, promoting leukocyte recruitment and 
inflammation.490, 506 Therefore, the CD40/CD40L dyad is a major component in diabetes 
development. 
 
2.5.1.4 Thyroiditis 
Autoimmune thyroid disease affects approximately 5% of humans, and includes Graves' disease 
and Hashimoto's thyroiditis. Graves' disease is characterized by thyrotoxicosis (excess 
circulating thyroid hormones due to an overactive thyroid), infiltration of lymphocytes into the 
thyroid gland, goiter, and presence of auto-antibodies directed against the thyroid stimulating 
hormone receptor. Hashimoto's thyroiditis differs from Graves' disease by a more intense 
infiltration of lymphocytes into the thyroid gland, a loss of thyroid function, and auto-antibodies 
directed against thyroglobulin and thyroid peroxidase.507 
 In Graves' disease patients, analysis of thyroid epithelial cells demonstrated an up-
regulation of MHC-II and co-stimulatory (CD40 and B7.1) molecules, suggesting that these cells 
probably contribute to disease development by enhancing presentation of thyroid auto-antigens, 
as well as co-stimulatory molecules to T lymphocytes.486, 508 Moreover, a single nucleotide 
polymorphism in the Kozak sequence (a consensus sequence in 5'-UTR of an mRNA) of the 
CD40 gene, which gives rise to an allele with a C polymorphism, has been associated with an 
increased risk for Graves' disease.507 This increased risk is probably due to an augmented level of 
CD40 expression on resting B lymphocytes and thyrocytes, when both alleles of the CD40 gene 
harbour this C polymorphism.486, 509 
 In contrast, there are no polymorphisms in the CD40 gene that have been linked to 
Hashimoto's thyroiditis.486 Nonetheless, the CD40/CD40L dyad seems to play a role in the 
development of this disease, since the use of a blocking antibody against CD40L averts 
experimental autoimmune thyroiditis induced in animal models through thyroglobulin 
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injection.510 Additionally, B and T lymphocytes from experimental autoimmune thyroiditis mice 
treated with a CD40L blocking antibody are unable to induce the disease following their transfer 
into immuno-deficient mice, thus, confirming the involvement of the CD40/CD40L dyad in 
autoimmune thyroid disease development..511  
 
2.5.1.5 Multiple sclerosis 
Multiple sclerosis is an autoimmune disease characterized by demyelination of the brain and 
spinal cord due to an infiltration of T lymphocytes (CD4+ and CD8+), B lymphocytes, 
macrophages, and microglia (central nervous system  resident macrophages) into the CNS and 
the subsequent destruction of myelin on nerve fibers, leading  to motor and sensory 
dysfunction.512 Most of the knowledge regarding multiple sclerosis pathogenesis came from 
analyzing human post-mortem brain lesions and experimental autoimmune encephalomyelitis 
(EAE) animal models that are featured by central nervous system infiltration by immune cells 
following immunization with myelin components.512 Analysis of post-mortem brain lesions from 
patients with multiple sclerosis demonstrated that the majority of the cells within the lesion that 
express CD40L were CD4+ T lymphocytes, whereas those expressing CD40 were B 
lymphocytes, macrophages, and microglia.513 In addition, analysis of EAE mice demonstrated 
the expression of CD40 in the spinal cord during the acute and relapse phases of the disease, 
whereas CD40L expression only peaked during the relapse phase.514 
 The contribution of the CD40/CD40L dyad to multiple sclerosis development was 
evidenced in mice deficient in CD40L or mice treated with a CD40L blocking antibody on the 
onset of EAE induction, which prevented disease development probably by favouring a non-
pathogenic Th2 immune response rather than a Th1 one.513, 515, 516 Indeed, CD40L blocking 
antibody treatment in mice at the peak of the acute phase of the disease decreased the level of 
infiltration of inflammatory cells into the central nervous system, as well as Th1 cell 
differentiation.517 Moreover, CD40 is expressed by microglia and it is up-regulated by INF-γ 
treatment.518 Activation of CD40 in these cells induces their activation and secretion of IL-12 
and TNF, which induce Th1 differentiation and the subsequent neuronal cell death.518-520 CD40 
expressed on microglia has also been shown to be an important contributor for EAE 
development, given that CD40 deficiency in microglia results in a less severe EAE due to a 
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decrease in T lymphocyte infiltration into the central nervous system, in addition to a reduction 
in demyelination.520, 521 
 Finally, there is accumulating evidence pointing toward a genetic background for 
multiple sclerosis; however, no correlation was found between the CD40 gene and incidence of 
the disease.497, 512, 522 
 
2.5.1.6 Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that affects multiple 
organs of the body, including skin, joints, lungs, kidneys, brain, and heart. It is due to circulating 
auto-antibodies directed against dsDNA (double stranded DNA) and other nuclear components, 
which form immune complexes (antibody and antigen) that deposit on small blood vessels and 
subsequently favour recruitment and assembly of the complement system, thereby causing 
vasculitis (inflammatory destruction of blood vessels).523 
   Patients with an active SLE disease have T lymphocytes (CD4+ and CD8+) that over-
express CD40L, in addition to B lymphocytes and monocytes that abnormally express 
CD40L.523-526 The implication of CD40L expressed on B lymphocytes in SLE pathogenesis was 
put into evidence by two approaches. The first approach showed that B lymphocytes from SLE 
patients produced antibodies in a CD40L-dependent manner, whereas the second approach 
demonstrated a lupus-like disease development in transgenic mice that harbour CD40L+ B 
lymphocytes. 524, 527 Interestingly, in patients with SLE, there is a correlation between circulating 
levels of CD40L and disease severity.528 Moreover, in these patients, there is a decrease in the 
number of CD34+ haematopoietic progenitor cells in the bone marrow, which was shown to be 
due to CD40 activation and the subsequent Fas-mediated apoptosis of these cells.529 The 
decrease in the number of CD34+ haematopoietic progenitor cells in SLE patients probably 
correlates with the frequent pancytopenic (reduced number of circulating white and red blood 
cells, and platelets) phenotype in these patients. 
 In a mouse model of SLE, treatment with an anti-CD40L blocking antibody before any 
apparent SLE symptoms prevents complications associated with the disease, such as proteinuria 
(high urine protein levels), kidney disease, in addition to prolonging survival and decreasing the 
levels of circulating antibodies against dsDNA.530-532 Interestingly, a long-term positive outcome 
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on kidney function, levels of anti-dsDNA antibodies and survival is observed albeit a short 
treatment period with an anti-CD40L antibody.533 
 Finally, SLE incidence has been shown to be associated with multiple genomic loci.497, 523 
The region q11.2-13.1 on chromosome 20, which harbours the CD40 gene, has been recognized 
as a site potentially linked to SLE occurrence.523, 534 Moreover, a missense single nucleotide 
polymorphism within the CD40 gene, which gives rise to a CD40 protein with a higher 
signalling capacity, aggravates SLE symptoms in patients with a pre-established disease. 
However, there is no correlation between this polymorphism and SLE incidence.535, 536 
 
2.5.1.7 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is an autoimmune disease affecting approximately 1% of humans and 
it is characterized by chronic inflammation within the joint due to the infiltration of immune cells 
and activation of fibroblast-like synoviocytes, which create a local inflammatory environment 
through the secretion of pro-inflammatory compounds, such as cytokines, chemokines and 
MMPs.537, 538 In addition, joints of RA patients are characterized by thickening of the synovium 
and destruction of the cartilage and bone, which are mainly caused by fibroblast-like synoviocyte 
activation and proliferation.537 
 Fibroblast-like synoviocytes from RA patients have been shown to express CD40 that is 
additionally up-regulated following INF-γ and TNF-α treatment.539 Activation of CD40 on these 
cells contributes to joint destruction by inducing the up-regulation of adhesion molecules 
(ICMA-1 and VCAM-1), as well as the secretion of pro-inflammatory cytokines (IL-6, IL-8, IL-
15, IL-17 and TNF), chemokines (MIP-1α and MCP-1), and growth factors (GM-CSF).537-542 
Additionally, osteoclast-mediated bone resorption is stimulated by the RANK ligand, which is 
expressed by fibroblast-like synoviocytes following CD40 activation.543 On the other hand, 
activation of CD40 expressed on DCs within the synovial tissue induces secretion of TNF, which 
has been shown to contribute to collagen degradation in ex vivo cultures.544 
 T lymphocytes from RA patients highly express CD40L as compared to healthy 
individuals and this level of expression correlates with higher disease severity and increased Ig 
production by B lymphocytes in these patients.545-547 Moreover, T lymphocytes form these 
patients have been shown to induce IL-12 secretion by synovial DCs and macrophage, in a 
CD40L-dependent manner.548 In a mouse model of arthritis, treatment with a CD40L blocking 
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antibody prevents the disease if given prior to disease induction; however, it does not reverse the 
disease if given once the disease has established.549, 550 On the other hand, treatment with an 
agonistic CD40 antibody at the onset of arthritis induction aggravates the disease.551 Therefore, it 
seems that the CD40/CD40L dyad has a main role only at the initial stages of arthritis. 
 Finally, as for most autoimmune diseases, RA has a strong genetic component. Multiple 
genomic loci have been associated with RA incidence, including the CD40 locus which has been 
associated with juvenile RA.497, 552 Furthermore, a single nucleotide polymorphism in the CD40 
gene, as well as single nucleotide polymorphisms in signalling molecules downstream of CD40, 
including A20 and TRAF1 have been associated with RA occurrence in the European 
population.553 
  
2.5.2 Cancer 
As mentioned earlier in this chapter, CD40 was initially cloned in Burkitt's lymphoma. It was 
later identified on multiple tumour cell types, including epithelial neoplasia, non-Hodgkin's 
lymphoma, melanoma, bladder carcinoma, and osteosarcoma.279, 280, 554-558 Therefore, cancer is 
probably the first human disease to be associated with the CD40/CD40L dyad. Given the 
widespread expression of CD40 on multiple tumours, it is suggested to play a role in tumour 
pathogenesis. Indeed, accumulating evidence demonstrates that a constitutive low-level of CD40 
engagement favours neoplastic cell growth by promoting tumour cell proliferation and protection 
against apoptotic cell death in an NF-κB dependent manner.559-561 The constitutive low-level of 
CD40 activation is due to the low level of CD40L co-expression on tumour cells, including non-
Hodgkin lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia, and breast carcinoma, 
which mediates CD40 ligation in an autocrine manner. Disruption of this low-level of 
CD40/CD40L interactions by a CD40L blocking antibody has been shown to reduce tumour cell 
proliferation and favour tumour cell death.559-562 
 In contrast, the CD40/CD40L dyad has been shown to have a rather negative impact on 
tumour pathogenesis. Patients with HIGM syndrome, who lack a functional CD40L protein, have 
a severely compromised immune system, and are therefore presented with higher incidences of 
multiple leukemia and carcinoma.563 Additionally, patients with chronic lymphocytic leukemia, 
who display a lack of CD40L on activated CD4+ T lymphocytes, show characteristics 
comparable to those of HIGM patients, including immunodeficiency and increased tumour 
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incidences.564 In mice, CD40L deficiency results in a lack of a protective anti-tumour immune 
response against fibrosarcoma, melanoma, bladder carcinoma, and adenocarcinoma, as compared 
to wild-type mice.565, 566 Moreover, treatment of tumour-bearing mice with an agonistic CD40 
antibody results in a reduction of tumour growth and metastasis due to an increase in tumour 
specific CTLs and natural killer (NK) cell activation.567, 568 
 The CD40/CD40L dyad exerts its anti-tumour function through indirect and direct 
mechanisms. The indirect mechanism involves activation of NK cells and tumour-specific CTLs 
that mediate tumour eradication.569 The direct mechanism is mediated through the activation of 
CD40 on tumour cells, which induces their up-regulation of pro-apoptotic mediators, thereby 
driving apoptotic cell death. The direct mechanism also involves the up-regulation of adhesion 
and MHC molecules on tumour cells following CD40 activation, which favours their recognition 
by anti-tumour immune cells.569 
 
2.5.3 Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease of the arterial wall, and it is the major 
pathology at the root of cardiovascular diseases, including myocardial infarction, stroke and 
peripheral arterial disease.215 The atherosclerotic plaque is characterized by the accumulation of 
lipids, cells, cellular debris, calcium and extra-cellular matrix within the arterial wall.570 
Development and progression of an atherosclerotic lesion involve the contribution of immune (T 
lymphocytes, B lymphocytes, monocytes/macrophages, neutrophils, and mast cells) and non-
immune cells (vascular SMCs, endothelial cells, and platelets). Both CD40 and CD40L are 
expressed on these different cell types in the atherosclerotic lesion.463, 571 Interestingly, CD40 and 
CD40L are detected in the atherosclerotic lesions in the early stages of atherosclerosis, and their 
expression levels increase with plaque progression reaching highest expression levels in 
advanced, rupture-prone and ruptured plaques.571 
 The involvement of the CD40/CD40L dyad in atherosclerotic plaque development is 
supported by a substantial amount of evidence. For instance, treatment of hyperlipidemic low-
density lipoprotein (LDL) receptor deficient mice with an anti-CD40L blocking antibody has 
been shown to considerably decrease the size and lipid content of the atherosclerotic lesions.572, 
573 Moreover, CD40L deficiency or inhibition with a blocking antibody in ApoE-/- mice results in 
a 5.5 fold decrease in atherosclerotic plaque area, as well as an increase in the level of collagen 
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and SMCs, and a decrease in the lipid levels and the number of inflammatory cells within the 
atherosclerotic plaque.573, 574 Moreover, treatment of ApoE-/- mice with an anti-CD40L blocking 
antibody at the onset of atherosclerosis or after atherosclerosis establishment results in the 
formation of lipid-poor and collagen rich plaques, thereby demonstrating the involvement of 
CD40L in the initiation and progression of atherosclerotic plaques.575 Therefore, it seems that 
lack of CD40L favours the development of stable atherosclerotic plaques by removing its 
influence on the initiation, progression, and stability of the plaques. 
 
2.5.3.1 Plaque initiation 
Initiation of the atherosclerotic plaque is characterized by the retention and modification of 
LDLs in the arterial wall, which is subsequently followed by chemokines and adhesion 
molecules expression. Expression of these molecules favours monocytes, neutrophils and T 
lymphocytes recruitment at the lesion site and their consequential trans-endothelial migration.576 
The CD40/CD40L dyad plays a substantial role in mediating this process. However, the initial 
factors involved in the expression of members of this dyad on macrophages, endothelial cells, 
SMCs and T lymphocytes in the developing atherosclerotic lesion are still unclear. Oxidized 
LDLs (oxLDLs), pathogens (e.g. Chlamydia pneumonia), disturbed mechanical forces within the 
arterial lumen, and heat shock proteins (HSPs) are among the candidates driving CD40 and 
CD40L expression on these cell types at the onset of atherosclerotic plaque formation.463, 577 
Ligation of CD40 on endothelial cells by CD40L expressed on activated T lymphocytes or 
platelets induces pro-inflammatory and pro-atherogenic phenotypes of endothelial cells, which 
are characterized by the expression of adhesion molecules (P-selectin, E-selectin, ICAM-1, 
VCAM-1, and LFA-1) and secretion of cytokines and chemokines (MCP-1, MCP-3, MIP-1α, 
MIP-1β, MIP-3α, RANTES, IL-6, IL-8, and IL-15).367, 463, 578, 579 Thereby, favouring additional 
leukocyte recruitment, adhesion, and trans-endothelial migration at the lesion site. 
 
2.5.3.2 Plaque progression 
Progression of an atherosclerotic plaque into a complex lesion is distinguished by the formation 
of foam cells in the sub-endothelial space, which derive from phagocytosis of oxLDL particles 
by monocyte-derived macrophages. This is accompanied by the migration and proliferation of 
SMCs into the intima, ultimately forming a fibrous cap overlying a lipid-rich necrotic core, as 
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well as the formation of neovessels that sustain lesion growth. In the sub-endothelial space, 
interaction of CD40 on monocyte-derived macrophages with CD40L on infiltrating T 
lymphocytes induces the secretion of cytokines (IL-1β, IL-6, IL-12, and TNFα), and matrix 
degrading enzymes (MMP-1 and MMP-3) by macrophages, which favour SMCs proliferation 
and migration from the medial layer to the intima.485, 571 Additionally, ligation of CD40 on 
migrating SMCs induces the secretion of MCP-1, IL-1β, IL-6, and IL-8, all of which contribute 
to the progression of the atherosclerotic lesion.374, 571 Fibroblasts migrating from the adventitial 
layer into the atherosclerotic lesion also contribute to the progression of the atherosclerotic lesion 
by secreting chemoattractant cytokines, such as IL-6 and IL-8, following CD40 ligation.580 
 Irrigation of a developing atherosclerotic plaque is favoured by the formation of 
neovessels, which is greatly influenced by the CD40/CD40L dyad. Ligation of CD40 on 
endothelial cells and macrophages induces secretion of pro-angiogenic factors, namely growth 
factors (VEGF, FGF, and PAF) and MMPs (MMP-1, MMP-2, MMP-3, and MMP-9).368-371 
MMPs degrade the extracellular matrix, therefore allowing endothelial cells to infiltrate and to 
proliferate within the matrix, a process favoured by growth factors. 
 Accumulation of these events leads to the formation of a fibro-fatty plaque consisting of 
infiltrated leukocytes, foam cells, proliferating SMCs, extracellular matrix proteins, and lipid-
rich particles.581 
 
2.5.3.3 Plaque instability 
A stable atherosclerotic plaque is characterized by a thick fibrous cap containing a considerable 
amount of intact fibrillar collagen overlying a small necrotic core. On the other hand, a 
vulnerable or unstable rupture-prone atherosclerotic plaque is characterized by a thin fibrous cap 
containing scarce amounts of collagen overlying a large necrotic core.463 Rupture of a vulnerable 
atherosclerotic plaque exposes its thrombogenic necrotic core, as well as components of sub-
endothelial matrix, to the circulation leading to thrombus formation and the subsequent partial or 
complete occlusion of the affected vessel. The CD40/CD40L dyad promotes plaque instability 
by favouring thinning of the fibrous cap and contributing to the thrombogenicity of the necrotic 
core. 
 Thinning of the fibrous cap of an atherosclerotic plaque is due to a disturbance in the 
balance between extra-cellular matrix production and MMP secretion.582, 583 Activation of CD40 
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on SMCs, endothelial cells, and macrophages increases the production of MMP-1, MMP-2, 
MMP-3, and MMP-9.350, 351, 368, 376, 378 In addition, MMP-1, MMP-8, MMP-13 have been shown 
to co-localize with CD40 within human and experimental atherosclerotic lesions.584, 585 
Therefore, MMP accumulation within the atherosclerotic plaque favours degradation of the 
extracellular matrix, specifically interstitial collagen, which leads to fibrous cap thinning and 
plaque instability. 
 The CD40/CD40L dyad enhances the thrombogenic property of the atherosclerotic 
plaque by increasing its TF content. Indeed, CD40 activation on SMCs, endothelial cells, and 
macrophages increases TF expression, which is a potent stimulator of the coagulation process 
and platelet activation.350, 372, 377 Furthermore, CD40 ligation on endothelial cells decreases the 
expression of thrombomodulin, which is an anticoagulant factor that inactivates thrombin.586 
Finally, CD40L stimulates platelet activation and stabilizes thrombus formation through its 
interaction with the αIIbβ3 integrin, thereby enhancing thrombosis following plaque rupture.4, 307 
Figure 2.10 summarizes the role of the CD40L in atherothrombosis. 
 
         
Figure 2.10: Role of CD40L in atherosclerotic plaque initiation, progression and stability. Gaxiola E. (2012). 
Atherothrombosis. INTECH. p. 84. 
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2.5.4 sCD40L as a marker of cardiovascular diseases 
Given the significant contribution of the CD40/CD40L dyad to the initiation, development and 
instability of atherosclerotic lesions, in addition to the platelet origin of 95% of circulating 
sCD40L, the sCD40L has gained much attention in the scientific community as a probable 
predictor of cardiovascular diseases. Indeed, multiple clinical studies have assessed the 
correlation between the levels of circulating sCD40L and cardiovascular diseases, specifically in 
stable and acute coronary artery disease, stable and unstable angina and myocardial infarction 
(Table 2.4). Data from these studies showed increases in the level of circulating sCD40L in 
patients with acute myocardial infarction, unstable angina, or stable angina, as compared to 
healthy individuals.8, 10, 587-593 In addition, the levels of circulating sCD40L were shown to 
correlate with the severity of ACS.8, 591 Interestingly, the increase in the levels of sCD40L in 
these patients is independent of other important inflammatory markers, such as IL-6, soluble 
VCAM-1, soluble ICAM-1, C reactive protein, and troponin.588, 594 Therefore, the levels sCD40L 
could be used as a better diagnostic marker of cardiovascular events. 
 Multiple clinical studies have assessed the correlation between the levels of plasma 
sCD40L and complications related to cardiovascular diseases. For instance, the CAPTURE 
(c7E3 Fab anti-platelet therapy in unstable refractory angina) trial showed a 3 fold higher risk for 
cardiovascular death and acute myocardial infarction in patients with higher levels of sCD40L.595 
Additionally, the MIRACL (myocardial ischemia reduction with aggressive cholesterol 
lowering) study showed that elevated levels of sCD40L are an independent risk factor for 
reoccurring cardiovascular events.596 Moreover, individuals with a 3459A>G single nucleotide 
polymorphism within the CD40L gene have a higher risk of acute myocardial infarction 
incidence.590 Finally, a small study demonstrated that high plasma levels of sCD40L could 
predict increased restenosis following coronary angioplasty.597  
 Whether the elevated levels of circulating sCD40L is a cause or a consequence of the 
underlying cardiovascular disease is still inconclusive. Elevated sCD40L levels could either be 
the consequence of a higher degree of platelet activation in these patients, or the cause of disease 
development and the associated complications related to the disease. Therefore, further 
investigations are required to clarify the role of the CD40/CD40L dyad in cardiovascular disease. 
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Table 2.4: CD40L in stable and unstable coronary syndrome. (UA: unstable angina; SA: stable angina; AMI: acute 
myocardial infarction; CAD: coronary artery disease) 
Population Syndromes sCD40L levels 
 vs. control 
Reference 
26 patients with UA 
29 patients with SA 
19 controls  
UA 
SA 
↑ 
- 
 
Aukrust P. et al.8 
20 patients with UA 
10 patients with SA 
10 controls 
UA 
SA 
↑ 
↑ 
 
Wang Y. et al.593 
20 patients with UA 
24 patients with SA 
12 patients with AMI 
16 controls 
UA 
SA 
AMI 
↑ 
↑ 
↑ 
 
Yan J. et al.589 
15 patients with AMI 
12 patients with UA 
23 patients with SA 
30 controls 
AMI 
UA 
SA 
↑ 
↑ 
- 
 
Peng D. Q. et al.591 
15 patients with AMI 
25 patients with UA 
15 patients with SA 
12 controls 
AMI 
UA 
SA 
↑ 
↑ 
- 
 
Garlichs C. D. et al.10 
109 patients with AMI 
201 patients with stable CAD 
286 controls  
AMI 
Stable CAD 
↑ 
↑ 
 
Tousoulis D. et al.588 
204 patients with stable CAD 
189 controls 
CAD ↑ Tayebjee M. H. et al.592 
219 patients with AMI 
389 controls 
AMI ↑ Antoniades C. et al.587 
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Chapter 3 
The CD40/CD40L Axis in Platelets 
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3.1 Differential expression of the CD40/CD40L dyad in platelets 
As mentioned in the previous chapter, both members of the CD40/CD40L dyad are present in 
platelets. CD40 is constitutively expressed on the surface of resting or activated platelets, and its 
expression levels have been shown to slightly increase following platelet activation.2, 330 On the 
other hand, as for other cell types expressing CD40, it remains unclear whether CD40 is arranged 
as monomers or multimers on the platelet surface (see section 2.1.3 of chapter 2). 
 Unlike CD40, CD40L is not expressed on resting platelets, but upon activation by 
thrombin, collagen, or ADP, CD40L is translocated to the platelet surface. The expression of 
CD40L on platelets seems to coincide with α-granule secretion, which is characterized by P-
selectin expression and the release of granule contents (PF4, TGFβ, and PDGF), suggesting that 
CD40L is present within α-granules; however, further investigations are required to clarify this 
issue.330 Once on the platelet surface, CD40L is cleaved into its soluble 18 kDa form within 1 to 
2 hours of platelet activation, which accounts for approximately 95% of circulating plasmatic 
sCD40L levels. However, the mechanisms by which CD40L is cleaved on the platelet surface 
remain poorly characterized. MMP-9 has been shown to be involved in platelet CD40L cleavage, 
as its inhibition in Crohn disease patients significantly reduces CD40L shedding.598 In addition, 
it has been demonstrated that shedding of sCD40L from the platelet surface requires engagement 
of CD40.3 On the other hand, MMP-2 and its association with the αIIbβ3 integrin have been 
shown to be required for effective sCD40L release by activated platelets, given that the 
enzymatic activity of platelet MMP-2 depends on activation of the αIIbβ3 integrin.599-601 
Moreover, as for CD40L expressed and shed by T lymphocytes, CD40L is also expressed and 
shed as a trimer by platelets.3 
 Although the presence of the CD40L/CD40 dyad in platelets is now well established, the 
amount of information regarding its involvement in platelet function is scarce. Soluble CD40L 
has been shown to induce platelet activation, and secretion of ROS and the chemokine RANTES 
through binding of CD40.310, 360, 361 In contrast, sCD40L has been shown to activate platelets and 
stabilize thrombus formation in an αIIbβ3-dependent manner.4, 307 Moreover, platelet CD40L 
induces an inflammatory response in endothelial cells, which is characterized by chemokine and 
cytokine secretion and the expression of adhesion molecules.2 
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3.2 Platelet response following CD40 activation 
In 2001, the first hint for a functional role of CD40 in platelets was put into evidence, where its 
ligation was shown to be required for platelet release of sCD40L.3 In 2003, stimulation of resting 
platelets with sCD40L was shown to induce responses characteristic of platelet activation, such 
as P-selectin expression, platelet shape change, and formation of platelet/leukocyte aggregates.310 
These responses were shown dependent on CD40L/CD40 but not CD40L/αIIbβ3 interactions, as 
blockade of αIIbβ3 with epitifibatide does not affect them. Moreover, the formed 
platelet/leukocyte aggregates are due to the CD40L-induced expression of P-selectin on platelets 
and its interaction whit PSGL-1 on leukocytes, although CD40L expressed on T lymphocytes has 
been shown to bind platelet CD40.361 Activation of CD40 on resting platelets by sCD40L was 
later shown to induce the secretion of the chemokine RANTES and the production of ROS.360, 361 
These studies also show activation of the p38 MAPK in platelets following sCD40L stimulation; 
however, the involvement of TRAFs and the NF-κB signalling pathway in sCD40L-induced 
platelet responses were not evaluated. 
 
3.3 Platelet CD40L in thrombus formation 
As mentioned in the previous chapter, CD40L harbours a KGD motif, which allows its 
recognition by the αIIbβ3 integrin on platelets.4, 307 Mice deficient in CD40L (CD40L-/-) are 
presented with an in vivo defect in arterial thrombus stability and a delay in arterial occlusion 
time, despite not having a defect in initial adhesion of single platelets or the time required for 
first thrombus growth.4 Infusion of sCD40L into these mice corrects thrombus instability and 
reduces the arterial occlusion time, suggesting that CD40L is involved in the formation of stable 
and irreversible platelet aggregates. Furthermore, the effects of sCD40L on thrombus stability 
depend on its interaction with the αIIbβ3 integrin and not CD40; since injection of a mutated form 
of sCD40L that lacks αIIbβ3 binding dose not correct the haemostatic defects in CD40L-/- mice, as 
compared to its non-mutated form. Moreover, CD40 deficient mice do not exhibit a haemostatic 
defect, which further confirms the role of the CD40L/αIIbβ3 but not the CD40L/CD40 interactions 
in platelet aggregate stability. This CD40L/αIIbβ3 interaction was later shown to induce tyrosine 
phosphorylation within the cytoplasmic tail of the β3 subunit of the integrin, which ultimately 
mediates "outside-in" signals by the latter.307 In light of these studies, the CD40L/αIIbβ3 
interaction probably favours thrombus stability by inducing "outside-in" signals through αIIbβ3 
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that mediate Bcl-3 synthesis in platelets, which is involved in fibrin clot retraction, given that 
platelets from Bcl-3 deficient mice exhibit a defect in fibrin retraction and stabilization.602, 603 
 
3.4 Platelet CD40L in endothelial cell activation 
In 1998, a functional role for platelet CD40L was put into evidence for the first time.2 Ligation 
of CD40 on endothelial cells with CD40L on activated platelets was shown to induce 
inflammatory and pro-thrombotic responses in endothelial cells, which are characterized by the 
expression of adhesion molecules (E-selectin, VCAM-1, and ICAM-1) and TF, as well as the 
secretion of cytokines (MCP-1, IL-6, and IL-8) and MMP-9.2, 3 These cellular response induced 
by platelet CD40L on endothelial cells are of great importance in the development of 
atherosclerotic lesions. Indeed, as mentioned in the first chapter, platelets are among the first (if 
not the first) cells to be recruited to the atherosclerotic-prone sites and their interaction with the 
activated endothelium is essential for plaque development. This highlights the importance of the 
platelet CD40L and endothelial CD40 interaction in inflammation and atherosclerosis. 
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Hypothesis and Objectives 
Multiple lines of evidence now support the existence of a plethora of inflammatory mediators 
potentially involved in the pathogenesis of vascular disease. Among these, the CD40L/CD40 
dyad has gained much attention and circulating levels of sCD40L are now considered as reliable 
predictors of cardiovascular events. Although the presence of the CD40L/CD40 dyad in platelets 
is well defined, its exact involvement in platelet function remains elusive. Soluble CD40L has 
been shown to activate platelets and stabilize thrombus formation in an αIIbβ3-dependent manner. 
In contrast, sCD40L has been shown to induce platelet activation, and secretion of ROS and the 
chemokine RANTES through binding of CD40. Nonetheless, the physiological impact, and the 
cellular and molecular mechanisms involved in CD40L-induced platelet activation are still 
undefined. 
Hypothesis: Platelets play a central role in the development of cardiovascular diseases, and since 
platelets constitutively express CD40, elevated levels of circulating sCD40L, as seen in ACS 
patients, may activate quiescent platelets through CD40 and subsequently contribute to disease 
progression and complications. 
Objectives: 
1 -  To evaluate the in vitro effects of sCD40L on platelet activation and aggregation 
2 -  To determine the receptor on platelets on which sCD40L mediates its effects 
3 -  To elucidate the intracellular signalling pathways induced by sCD40L 
4 -  To evaluate the in vivo effects of elevated levels of circulating sCD40L on thrombus 
formation in a mouse model 
Expected results: 
1 -  sCD40L activates resting platelets and enhances platelet function 
2 -  sCD40L mediates its effects on platelet function via CD40 and the subsequent TRAF 
association   
3 -  Increased levels of circulating sCD40L exacerbate thrombus formation in response to 
vascular injury 
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Chapter 4 
Scientific Contribution 
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Background for the first article 
 
Since its discovery, the CD40/CD40L dyad has gained much attention within the scientific 
community. It has been shown to be involved in immune and inflammatory responses, and to 
have a broad expression pattern encompassing not only cells of the immune system, but also 
cells of the circulatory and vascular systems. Elevated levels of circulating sCD40L are tightly 
linked to incidence of cardiovascular diseases, which makes them potential diagnostic and 
preventative tools for future cardiovascular disease treatments. 
 Given that platelets express CD40 and account for 95% of circulating sCD40L, multiple 
studies have focused on the impact of the CD40/CD40L dyad on platelet function. However, the 
underlying cellular and molecular mechanisms by which this dyad affects platelet function, 
including platelet activation, aggregation, and in vivo thrombus formation remain poorly 
characterized; hence the objective of this study. 
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Abstract 
Objective—CD40 ligand (CD40L) is a thrombo-inflammatory molecule that predicts 
cardiovascular events. Platelets constitute the major source of soluble CD40L (sCD40L), which 
has been shown to influence platelet activation, although its exact functional impact on platelets 
and the underlying mechanisms remain undefined. We aimed to determine the impact and the 
signaling mechanisms of sCD40L on platelets.  
Methods and Results—sCD40L strongly enhances platelet activation and aggregation.  Human 
platelets treated with a mutated form of sCD40L that does not bind CD40, and CD40-/- mouse 
platelets failed to elicit such responses. Furthermore, sCD40L stimulation induces the association 
of the tumor necrosis factor receptor-associated factor-2 with platelet CD40. Noticeably, 
sCD40L primes platelets through activation of the small GTPase Rac1 and its downstream target 
p38 mitogen-activated protein kinase, which leads to platelet shape change and actin 
polymerization. Moreover, sCD40L exacerbates thrombus formation and leukocyte infiltration in 
wild type mice but not in CD40-/- mice. 
Conclusion—sCD40L enhances agonist-induced platelet activation and aggregation through a 
CD40-dependant tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated 
protein kinase signaling pathway. Thus, sCD40L is an important platelet primer predisposing 
platelets to enhanced thrombus formation in response to vascular injury. This may explain the 
link between circulating levels of sCD40L and cardiovascular diseases. (Aretioscler Thromb 
Vasc Biol. 2010; 30:2424-2433) 
   
Key Words: platelets ■ signal transduction ■ thrombosis ■ CD40L 
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Multiple lines of evidence now support a plethora of inflammatory mediators potentially 
involved in the pathogenesis of vascular disease. Among these, the CD40 ligand (CD40L)/CD40 
dyad has been the focus of much attention and circulating levels of soluble CD40L (sCD40L) are 
now considered as reliable predictors of cardiovascular events.1-4 
 CD40L is a 48-kDa trimeric transmembrane protein belonging to the tumor necrosis 
factor superfamily originally identified on cells of the immune system.5, 6 Interaction of CD40L 
with its respective receptor on B cells, CD40, a 39-kDa glycoprotein from the tumor necrosis 
factor receptor family, is of critical importance for immunoglobulin isotype switching during the 
immune response.7 Today, we know that these two molecules are also present on cells of the 
vascular system, including endothelial cells, monocytes/macrophages, smooth muscle cells and 
platelets,8, 9 and have important implications in inflammatory reactions, through up-regulation of 
cell adhesion molecules and production of pro-inflammatory cytokines, chemokines, growth 
factors, matrix metalloproteinases and pro-coagulants.8, 10-12 The involvement of the 
CD40L/CD40 dyad in thrombo-inflammation has been highlighted in all pathogenic phases of 
atherosclerosis, including endothelial dysfunction, platelet activation, thrombosis, and neointima 
formation.13-20 
 Platelets are highly specialized blood cells of paramount importance in normal 
hemostasis and thrombo-inflammatory complications. The pioneering work of Heen et al. 
showed that both CD40L and its receptor CD40 are found in platelets.8 Whereas CD40 is 
constitutively expressed on platelets, CD40L rapidly appears on the platelet surface following 
activation, on which it is subsequently cleaved, generating a soluble fragment of 18-kDa, termed 
sCD40L, accounting for >95% of its plasmatic concentration.21 Circulating levels of sCD40L in 
patients have now emerged as strong indicators of cardiovascular risk, as there appears to be a 
significant correlation between levels of sCD40L and vascular complications such as 
atherosclerosis and acute coronary syndromes (ACS).2-4  
 Although the presence of the CD40L/CD40 dyad in platelets is well defined, its exact 
involvement in platelet function remains elusive. Andre and al. have shown that CD40L binds to 
αIIbβ3 and stabilizes arterial thrombi in mice,13 whereas others have shown that CD40L can 
induce platelet activation and secretion of reactive oxygen species and the chemokine RANTES 
through binding of CD40.14, 17, 22 Nevertheless, the physiological impact and the mechanisms 
involved in CD40L-induced platelet activation are poorly characterized. Here we show that 
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sCD40L primes and enhances agonist-induced activation and aggregation of human platelets 
through a CD40-mediated tumor necrosis factor receptor-associated factor (TRAF)-2/Rac1/p38 
mitogen-activated protein kinase (MAPK)-dependant pathway, which ultimately leads to platelet 
shape change and actin polymerization. Moreover, we show that enhanced levels of sCD40L 
exacerbate thrombus formation and leukocyte infiltration in response to vascular injury, in a 
CD40-dependant manner. 
 
Materials and Methods 
Reagents and antibodies 
Recombinant human soluble CD40L (sCD40L) was obtained from R&D systems           
(Minneapolis, MN), while recombinant mouse soluble CD40L (msCD40L) came from Alexis 
Biochemicals (San Diego, CA). Recombinant human mutant sCD40LR/Y (Arginin (R) 203 for 
Alanin and Tyrosin (Y) 145 for Alanin) and its wild type counterpart sCD40LWT were generated 
as previously described.23 Antibodies against TRAF-1, -2, -3, and -6 were all purchased from 
Cell Signaling Technology (Beverly, MA). Anti-CD40 antibody used for immunoprecipitation of 
human CD40 was also from R&D systems, while anti-CD40 antibody used for detection of 
CD40 by immunoblotting came from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
phospho-VASP (Ser157), anti-phospho-p38 (Thr180/Tyr182), anti-VASP (total) and anti-p38 (total), 
as well as the antibody against Rac1 were all procured from Cell Signaling Technology (Beverly, 
MA). Antibodies against P-selectin (AK4) and the active form of αIIbβ3 (PAC-1) were obtained 
from BD Biosciences (Mississauga, ON). The specific Rac1 NSC23766 inhibitor, the p38 
SB203580 inhibitor and the actin polymerization Latrunculin B inhibitor were purchased from 
Calbiochem (San Diego, CA). Alexa Fluor 555-phalloidin came from Invitrogen (Carisbad, CA). 
Protein A agarose beads were obtained from Upstate Biotechnology, Inc. (Lake Placid, NY) and 
p21-activated kinase-protein binding domain (PAK1-PBD) beads were from Cytoskeleton, Inc 
(Denver, CO). Native type I collagen and adenosine diphosphate (ADP) were from Chronolog 
Corp. (Havertown, PA), while human thrombin was purchased from Sigma-Aldrich (Oaskville, 
ON). 
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Animals 
Age- and sex-matched wild type (WT) and CD40-/- mice, both on C57BLK/J6 background, were 
purchased from the Jackson Laboratory (Bar Harbor, ME) and housed under pathogen free 
conditions. Handling and care of animals were in compliance with guidelines established by the 
animal care and ethical committee of the Montreal Heart Institute.      
 
Isolation of human and mouse platelets 
Venous blood was drawn from healthy volunteers, free from medication known to interfere with 
platelet function for at least 10 days before the experiment, in accordance with the guidelines of 
the human ethical committee of the Montreal Heart Institute. Platelet-rich plasma (PRP) was 
obtained by centrifugation of acid citrate dextrose (ratio of 1:5) anticoagulated blood at 200g for 
15 minutes. Platelets were then pelleted from PRP, to which 1 g/mL of PGE1 was added, 
washed with HBSS-Hank’s sodium citrate buffer (138 mM NaCl, 5 mM KCl, 0.34 mM 
Na2HPO4, 0.4 mM KH2PO4, 4.2 mM Na2HCO3, 5.6 mM Glucose, 10 mM HEPES, 12.9 mM 
sodium citrate, pH 7.4), also containing PGE1 (0.5 g/mL), and finally resuspended in HBSS-
Hank’s buffer containing 2 mM MgCl2 and 2 mM CaCl2. 
 Murine washed platelets were prepared from mice anesthetized with a mixture of 75 
mg/kg of Ketamine (Vetalar, Belleville, QC) and 0.5 mg/kg of medetomidine (Domitor, Pfizer, 
Kirkland, QC). Blood was drawn by cardiac puncture in 1-cc syringes containing 50 L of 
heparin (1000 iU/mL) and diluted (1:1) with modified Tyrode’s buffer (150 mM NaCl, 2.5 mM 
KCl, 12 mM NaHCO3, 2 mM MgCl2, 2 mM CaCl2, 1 mg/mL BSA, 1 mg/mL dextrose, pH 7.4), 
containing prostacyclin (0.2 g/mL). PRP was obtained by centrifugation of blood at 164g for 8 
minutes, to which prostacylin (0.1 g/mL) was added, and platelets were pelleted by 
centrifugation at 1000g for 5 minutes. Platelets were finally resuspended in modified Tyrode’s 
buffer. 
 Human and mouse platelets were adjusted to 250 x 106 platelets/mL, unless otherwise 
specified, and allowed to rest at 37ºC for 30 minutes before further manipulation.  
 
Flow cytometry analysis of platelet activation 
Translocation of platelet P-selectin and activation of αIIbβ3 were measured by flow cytometry, as 
previously described.24 Platelets were preincubated with sCD40L prior to cell stimulation with 
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agonists, fixed with 1% paraformaldehyde, washed and stained with saturating concentrations of 
anti-P-selectin antibody (AK4-PE conjugated) for 30 minutes or its isotype-matched control IgG. 
For measurement of αIIbβ3 activation, PAC-1 antibody (FITC-conjugated) was incubated with 
platelet suspensions prior to activation with sCD40L and agonists. Samples were analyzed 
(20,000 events) on an Altra flow cytometer (Beckman Coulter, Mississauga, ON) and platelets 
were gated by their characteristic forward and side scatter properties.         
 
Measurement of platelet aggregation 
Aggregation of human and mouse washed platelets was monitored on a four-channel optical 
aggregometer (Chronolog Corp., Havertown, PA) under shear (1000 rpm) at 37ºC. sCD40L 
(human, mouse and the mutated R/Y and WT forms) was pre-incubated with platelet suspensions 
under static conditions at 37ºC, 30 minutes prior to addition of agonists, and traces were recorded 
until stabilization of platelet aggregation was reached.       
 
Immunoprecipatation of CD40  
Platelets (500 x 106/mL) were stimulated as indicated, pelleted, then lysed into ice-cold RIPA 
lysis buffer (1% NP-40, 0.25% deoxycholic acid, 150 mM NaCl, 50 mM Tris-HCl pH 7.4, 1 mM 
EDTA, 1 mM PMSF, 1 mM sodium-orthovanadate, 1 mM sodium fluoride, 1 μg/mL aprotinin, 1 
μg/mL leupeptin, and 2 μg/mL benzamidin) for 1 hour at 4ºC. Lysates were sonicated on ice and 
pre-cleared with 100 L of protein A agarose beads for 15 minutes at 4ºC. Beads were then 
pelleted and the supernatant was incubated with 5 g/mL of anti-CD40 antibody overnight at 
4ºC. Samples were treated with 100 L of protein A agarose beads for 1 hour at 4ºC and 
precipitated by centrifugation, washed three time with ice-cold RIPA lysis buffer, resuspended in 
2X Laemmli buffer, and boiled for 5 minutes. Supernatants were analyzed by immunoblot for the 
presence of TRAF-1, -2, -3, and -6, as well as CD40. 
 
SDS-PAGE and immunoblotting 
Proteins were resolved in 8% or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) gels and transferred to nitrocellulose membranes. The membranes were blocked 
with 5% non-fat dry milk for 1 hour, washed three times with TBS/T (150 mM NaCl, 20 mM 
Tris, pH 7.4, 0.1 % Tween-20) and incubated with appropriate primary antibody overnight at 
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4ºC. Following washing steps, membranes were labeled with horseradish peroxidase-conjugated 
secondary antibody for 1 hour, washed and bound peroxidase activity was detected by enhanced 
chemiluminescence (PerkinElmer Life Sciences, Waltham, MA). 
 
Rac1 activation assay 
Platelets (1 x 109/mL) were treated with sCD40L and reactions were terminated by addition of an 
equi-volume of ice-cold 2X lysis buffer (50 mM HEPES, 300 mM NaCl, 2% Igepal, 20% 
glycerol, 20 mM MgCl2, 50 mM sodium fluoride, 2 mM EDTA, 2 mM sodium orthovanadate, 20 
g/mL leupeptin, and 20 μg/mL aprotinin). Lysates were then clarified by centrifugation at 
14,000g for 5 minutes at 4ºC and supernatants were treated with 10 μg of PAK1-PBD beads for 
1 hour at 4ºC. Beads were centrifuged and washed three times with ice-cold lysis buffer. They 
were then resuspended in 2X Laemmli sample buffer, boiled for 5 minutes, and supernatants 
were analyzed by immunoblotting for the presence of Rac1.  
 GDP and GTPγS were used as negative and positive controls, respectively. Supernatants 
from lysates were treated with either GDP (1 mM) or GTPγS (100 μM) for 15 minutes at room 
temperature, and reactions were terminated by placing samples on ice and adding MgCl2 (60 
mM). Samples were then clarified by centrifugation, incubated with PAK1-PBD beads, and 
treated with the same procedure as described above.        
 
Scanning electron microscopy 
Platelets treated or not with sCD40L were allowed to immobilize on 2% bovine serum albumin 
(BSA)-treated glass cover slips for 30 minutes at 37ºC. Samples were then fixed in 2% 
paraformaldehyde overnight at 4ºC. Dehydration of surfaces was achieved by placing samples in 
ethanol/water followed by amyl acetate/ethanol baths for 15 minutes each, increasing the 
ethanol/water proportion from 30% to 100% and the amyl acetate/ethanol proportion from 25% 
to 100%. Slides were subsequently coated with gold palladium particles and analyzed on a 
Hitachi S-4700 Field Emission Gun Scanning Electron Microscope (FEG-SEM).       
 
Actin polymerization assay 
Platelets treated or not with sCD40L in the presence or absence of Latrunculin B were allowed to 
immobilize on 2% BSA-treated glass cover slips for 30 minutes at 37ºC. Samples were then 
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fixed in 2% paraformaldehyde for 20 minutes at room temperature. Platelets were permeabilized 
with 0.05% Triton X-100 in 2% BSA and stained with Alexa555-phalloidin in 1% BSA for F-
actin detection. Series of fluorescent confocal images (Z stacks) were acquired with a LSM 510 
confocal microscope (Zeiss. Oberkochen, Germany). Alexa555-phalloidin was visualized using a 
543-nm helium-neon laser line and a 63/1.4 plan-apochromat objective (Zeiss) was used for 
magnification (voxel size is 28 nm X 28 nm X 250 nm (X,Y,Z)). Final images were produced 
using the Zeiss LSM 510 software and saved as LSM files.  
 
Thrombosis model 
The effect of sCD40L on thrombus formation was determined in a FeCl3 mouse carotid injury 
model, as previously described.25, 26  Briefly, anesthetized C57BL6 WT and CD40-/- mice were 
injected with sCD40L (0.25 mg/Kg) through the jugular vein, 5 minutes prior to FeCl3 (4%) 
injury of the right carotid artery, and blood flow and time to thrombotic occlusion (blood flow of 
0 mL/minute) were measured with the aid of a miniature ultrasound flow probe (0.5 VB 552, 
Transonic Systems Ithaca, NY) interfaced with a flow meter (T206, Transonic Systems) and a 
computer-based data acquisition program (Iox 2.2.17.19, Emka, Falls Church, VA). Mouse 
plasmatic sCD40L was measured by ELISA (Bender MedSystems, San Diego, CA), according to 
the manufacturer’s instructions.    
 
Histology and Immunostaining   
Following in vivo thrombosis measurements in mice, injured and contralateral non-injured 
carotid arteries were excised, fixed in 10% buffered formalin and analyzed by hematoxylin and 
eosin staining or CD45 immunostaining for leukocytes infiltration within the thrombus mass, as 
previously described.25 Briefly, sections were embedded in paraffin, sectioned at 6 microns, and 
stained with hematoxylin and eosin, or an anti-CD45 antibody (Santa Cruz, Santa Cruz, CA). 
Samples were visualized using an Olympus BX60 microscope (Olympus imaging America Inc, 
Center Valley, PA) and images were captured with a Retiga 2000R camera (QImaging 
Corporation, Surrey, BC) and visualized through the Image Pro Plus 6.2 software (Media 
Cybernetics, Bethesda, MD). 
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Measurement of intracellular calcium flux 
Platelets in HBSS-Hank’s sodium citrate buffer were incubated with 5 μg/ml Fluo-4 AM for 30 
minutes at 37°C. Platelets were then removed from excess Fluo-4 AM by centrifugation and 
resuspended in final HBSS-Hank’s buffer containing 2 mM MgCl2 and 2 mM CaCl2. Platelets 
were then placed onto a FluoroDish and mounted on a LSM 510 confocal microscope (Zeiss. 
Oberkochen, Germany). sCD40L (1 μg/ml) or thrombin (0.1 U/ml) was added to the platelet 
suspension and series of fluorescent confocal images were acquired in real-time at a rate of 30 
images/second (excitation wavelength selected was 488 nm). 
 
Dense granule release 
ATP release was measured by a Lumi-Aggregometer according to the manufacturer’s 
instructions (Chrono-log Corp. Havertwon, PA). Briefly, 25 μl Luciferin-Luciferase (Chrono-
Lume) reagent was added to a 475 μl platelet suspension 2 minutes before addition of sCD40L (1 
μg/ml) or thrombin (0.1 U/ml). 
 Dense granule release was measured by mepacrine uptake into platelets.27 Platelets in 
HBSS-Hank’s sodium citrate buffer were incubated with 5 μM mepacrine (Quinacrine 
dihydrochloride, Sigma-Aldrich) for 30 minutes at 37°C. Platelets were then removed from 
excess mepacrine by centrifugation and resuspended in final HBSS-Hank’s buffer containing 2 
mM MgCl2 and 2 mM CaCl2. Secretion of dense body constituents was evaluated by flow 
cytometry as the fluorescence remaining in platelets upon stimulation with sCD40L or thrombin; 
in comparison to resting platelets.  
 
Statistical analysis 
Results are presented as mean ± SEM of at least 3 independent experiments. Statistical 
comparisons were done using a one-way ANOVA, followed by a Dunnetts-t-test for comparison 
against a single group. Data with P<0.05 were considered statistically significant. 
 
 
 
 
 
97 
 
Results 
sCD40L Enhances Platelet Activation and Aggregation Through Interaction With CD40 
We first evaluated the functional effects of sCD40L on platelet activation and aggregation, as it 
remains poorly characterized. Incubation of platelets with sCD40L alone had no effect on 
platelet aggregation (Figure 1A, upper panel) but led to a significant and dose-dependent 
increase of platelet aggregation induced by a subthreshold or priming concentration of collagen, 
thrombin or ADP (Figure 1A), indicating that this is a broad platelet phenomena and not agonist-
specific. As sCD40L showed a significant impact on platelet aggregation, we sought to 
determine its effect on platelet activation. As expected, sCD40L was unable to trigger activation 
of αIIbβ3 on resting platelets, whereas it caused a significant increase in P-selectin expression 
(Figure 1B). However, αIIbβ3 activation and P-selectin expression were both significantly 
enhanced in the presence of subthreshold concentrations of collagen, thrombin and ADP.  
 Because it has been shown that αIIbβ3, in addition to CD40, can constitute a CD40L 
receptor on the platelet surface,13, 28 it was imperative to investigate through which receptor 
sCD40L acts. To address this issue, we first generated a mutant recombinant sCD40L 
(sCD40LR/Y), that does not bind CD40 while retaining αIIbβ3 binding (Supplemental Figure I) and 
showed that this molecule failed to enhance platelet aggregation induced by a priming 
concentration of collagen compared to its WT counterpart (sCD40LWT) (Figure 1C). Second, 
unlike platelets from WT mice, platelets from CD40-/- mice were insensitive to mouse sCD40L 
in response to a subthreshold concentration of collagen (Figure 1D). These data clearly show that 
sCD40L enhances platelet function through interaction with its counterreceptor CD40. 
 
sCD40L Triggers TRAF-2 Association With CD40 
It is well established that the TRAF family is tightly linked to CD40 signaling in immune cells. 
The TRAF family comprises six known members, among which TRAF-1, -2, -3 and -6 have 
been the most studied, although their expression in platelets is yet to be determined. We 
therefore investigated the expression of the major TRAF members and their association with 
CD40 on sCD40L stimulation. Interestingly, we found that in addition to CD40, platelets express 
TRAF-1, -2, and -6, and traces of TRAF-3 were detected (Figure 2A). Most importantly, only 
TRAF-2 associates with CD40 after stimulation of resting platelets with sCD40L, whereas none 
of these members were shown to be associated with CD40 at baseline conditions (Figure 2A and 
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2B). In addition, sCD40LWT, but not sCD40LR/Y, caused association of TRAF-2, further 
supporting the contribution of CD40 in response to sCD40L. 
 
sCD40L Induces Platelet Shape Change and Actin Polymerization 
In search of the underlying cellular and molecular events involved in the effects of sCD40L on 
platelet function, we first found that stimulation of resting platelets with sCD40L caused a 
significant morphological shape change characterized by an increase in lamellipodia and 
filopodia formation (Figure 3A).  Second, sCD40L induced actin polymerization, as noted by the 
increase in F-actin staining in treated platelets (Figure 3B). To determine the implication of these 
cytoskeletal and morphological changes in sCD40L-induced potentiation of platelet aggregation, 
we pretreated platelets with latrunculin B, a specific inhibitor of actin polymerization, and found 
that it completely reversed sCD40L’s capacity to increase platelet aggregation (Figure 3C and 
3D). 
 
The Small GTPase Rac1 and p38 MAPK Are Required for sCD40L Signaling  
The Rho family GTPase member Rac1 and the VASP represent key signaling components 
required for cytoskeletal reorganization and shape change in platelets. Phosphorylation of VASP, 
particularly at Ser157, regulates its anticapping activity and thereby promotes platelet filopodia 
formation.29 As shown in Figure 4A, stimulation of resting platelets with sCD40L, but not with 
sCD40LR/Y, induced phosphorylation of VASP on Ser157 and activation of Rac1. To assess the 
implication of the small GTPase Rac1, we used a specific Rac1 inhibitor, NSC23766. 
Pretreatment of platelets with NSC23766 significantly reversed sCD40L’s ability to enhance 
platelet aggregation (Figure 4B) and P-selectin expression (Figure 4C) in resting platelets.  
 Activation of p38 MAPK is of significant importance in CD40 signaling, and in platelets 
it could therefore act as a downstream target of Rac1 in response to sCD40L. In fact, sCD40L 
induced a time-dependent activation of p38 MAPK and inhibition of Rac1 with NSC23766 
significantly reduced its activation, indicating that p38 MAPK does indeed act as a downstream 
target of Rac1 (Figure 5A). Furthermore, specific blockade of p38 MAPK with SB203580, 
which prevented its phosphorylation (Supplemental Figure II), impaired the effects of sCD40L 
on platelet P-selectin expression (Figure 5B) and aggregation (Figure 5C), thus highlighting its 
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implication in these responses. These data establish Rac1 and its downstream effector p38 
MAPK as key components involved in sCD40L signaling in platelets. 
 
sCD40L Exacerbates Thrombus Formation and Leukocyte Infiltration  
To date, no direct correlation between circulating levels of sCD40L and thrombosis has been 
established, and this could be of important clinical and physiopathological relevance. In order to 
explore this aspect, we injected sCD40L (0.25 mg/kg or approximately 5 µg/mouse) into WT 
and CD40-/- mice before vascular injury, thereby enhancing its plasma circulating levels to 47.5 ± 
3.7 ng/mL (n=4), and assessed thrombus formation. Infusion of sCD40L into WT mice 
significantly exacerbated thrombus formation, in comparison to vehicle-treated mice, in which 
occlusion was only partial (Figure 6). Interestingly, CD40-/- mice were protected from increased 
levels of circulating sCD40L, as no significant difference in thrombosis between treated and non-
treated groups was observed (Figure 6A and 6B), confirming the in vivo contribution of the 
CD40 receptor in sCD40L-induced thrombus formation. Because sCD40L induces surface 
expression of P-selectin on platelets (Figure 1B), we sought to determine the extent of leukocyte 
infiltration within the thrombus because of its involvement in platelet/leukocyte interactions, a 
well-established aspect of hemostasis known to potentiate thrombus formation.30 Leukocyte 
infiltration, as measured by CD45 immunostaining (Figure 6C) and optical quantification of 
histological sections post-thrombosis (Figure 6D), was significantly increased in WT but not in 
CD40-/- mice that received sCD40L. These results establish a direct in vivo correlation between 
circulating levels of sCD40L and arterial thrombosis, while highlighting the requirement of the 
CD40 receptor in this process.  
 
Discussion 
CD40L has gained much attention over the years for its involvement in the pathogenesis of 
atherosclerosis and today, numerous clinical studies show a tight association between levels of 
sCD40L and vascular diseases.1-4 The majority of sCD40L found in plasma is believed to 
originate from activated platelets, and this in turn has been shown to influence platelet activation. 
Here, we provide novel insights into the regulation of platelet function by CD40L, as we show 
that sCD40L primes platelets and enhances aggregation through a CD40-mediated TRAF-
2/Rac1/p38 MAPK-dependant pathway. This ultimately leads to shape change and actin 
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polymerization. Furthermore, we establish a direct correlation between circulating levels of 
sCD40L and thrombus formation. 
 To get insights into the cellular and molecular impact of sCD40L on platelet function, it 
was important that we first investigate its effect on platelet aggregation and activation. sCD40L 
was unable to trigger aggregation of resting platelets or to induce activation of the integrin αIIbβ3, 
whereas it significantly increased the expression of P-selectin, in accordance with previous 
studies.14, 17, 22 This may attributed to the fact that sCD40L alone does not affect intraplatelet 
calcium influx (Supplemental Figure III) or dense granule secretion, as assessed by ATP release 
and mepacrine uptake (Supplemental Figure IV), which are necessary for integrin activation and 
platelet aggregation.  However, we found that sCD40L strongly enhanced platelet aggregation, 
P-selectin expression and αIIbβ3 activation in response to subthreshold concentrations of platelet 
agonists, indicating that it rather acts as a broad and potent primer of platelets, such as matrix 
metalloproteinase-2, plasma protein growth arrest-specific 6 and stromal derived factor-1α.31-33 
Moreover, this priming phenomenon holds true for B cell proliferation, as sCD40L requires 
costimulation with interleukin-4 for immunoglobulin E secretion.34, 35 Taken together, this would 
indicate that CD40L acts as an accessory, but important, element in platelet function. 
 One important aspect of controversy regards the identification of the platelet receptor for 
sCD40L. In our study, we were able to show by molecular and genetic approaches that sCD40L 
enhances platelet function by interacting with CD40. These results are in agreement with 
previously published data showing that sCD40L can induce platelet activation and secretion of 
reactive oxygen species and the chemokine RANTES through binding to CD40.14, 17, 22 In 
addition to CD40, its constitutively expressed receptor on platelets, it has been reported that 
sCD40L binds to αIIbβ3.13, 28 However, this occurs in the presence of 40 µg/mL of rsCD40L on 
preactivated platelets (αIIbβ3 already in its active form), which is 40 times higher than the 
concentration used in the present study. This may suggest that CD40 and αIIbβ3 constitute the 
high- and low-affinity receptors for sCD40L, respectively. However, additional studies are 
necessary to specifically address this issue. Thus, it appears that increased levels of circulating 
sCD40L, as seen in ACS patients, prime platelets via CD40, whereas its interaction with αIIbβ3 at 
the site of vascular injury, where higher levels of sCD40L may be generated, stabilizes platelet 
aggregates. 
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 CD40 signaling in immune and endothelial cells requires its association to TRAF 
proteins. To our knowledge, the expression of TRAF members in platelets and their association 
with platelet CD40 following sCD40L stimulation are still unknown. Here, we found that only 
TRAF-2 associates with CD40 upon ligation, indicating that it may be responsible for 
sCD40L/CD40-induced signaling in platelets. Although present in platelets, neither TRAF-1 nor 
TRAF-6 associate with CD40, indicating that they may rather play a role in tumor necrosis factor 
signaling. Even though CD40 contains binding sites for both TRAF-2 and TRAF-6, binding of 
either one is sufficient to induce activation of nuclear factor-B in B cells.36 This would also hold 
true for platelets, as binding of TRAF-2 alone appears sufficient to trigger downstream signaling.  
 In platelets, Rac1 and VASP govern shape change, cytoskeletal reorganization and 
spreading, through lamellipodia and filopodia formation, respectively. VASP is typically 
phosphorylated on two main residues, Ser239 and Ser157. Platelet inhibitors induce 
phosphorylation of both residues, whereas agonists that cause platelet activation trigger 
phosphorylation of VASP on Ser157, thereby promoting anticapping activity and favoring actin 
polymerization and filopodia formation.37, 38 Our finding that sCD40L promotes phosphorylation 
of VASP on Ser157 provides evidence for its role as an inducer of shape change in platelets. As 
further support for the role of sCD40L in these processes, we highlight its capacity to induce 
activation of the small GTPase Rac1. Rac1 activation in response to sCD40L was shown to be of 
physiological importance, given that its specific inhibition significantly reduced sCD40L’s 
ability to potentiate platelet aggregation and P-selectin expression. Interestingly, in accordance 
with our results, it has recently been shown that in endothelial and WEHI 231 B cells, CD40 
signaling-induced reactive oxygen species generation requires activation of Rac1.19, 39 Moreover, 
in immune cells, CD40L is classically known to induce activation of MAPKs, such as p38. Here, 
we were able to confirm that sCD40L induces activation of p38 MAPK in resting platelets, 17, 22 
and further highlight its involvement in platelet activation and aggregation as a downstream 
effector of Rac1 in response to sCD40L. Consistent with its role in sCD40L-induced shape 
change and platelet priming, p38 MAPK has been shown to be an important regulator of actin 
polymerization and platelet spreading.40 
 Whether enhanced levels of sCD40L seen in patients with ACS are a consequence of 
increased platelet activation or a predetermining cause of these complications (or perhaps both) 
is still unknown. Here, we provide novel evidence demonstrating a direct correlation between 
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enhanced levels of sCD40L and thrombosis. Mice that received sCD40L prior to vascular injury 
showed increased thrombus formation, indicating that they were predisposed to thrombotic 
stimulus. Our study adds new insights to a previous work showing that CD40L-/- mice develop 
unstable thrombi and that this deficiency can be overcome by infusion of 1.6 mg/kg sCD40L in a 
αIIbβ3-dependent manner.13 Here, a different approach was employed, as we increased circulating 
levels of sCD40L in mice by injecting 0.25 mg/kg to reach approximately 50 ng/mL of plasma 
sCD40L, to mimic conditions similar to those seen in patients with ACS. In this experimental 
setting, sCD40L was shown to exacerbate thrombosis in WT mice but not in CD40-/- mice, 
indicating that enhanced levels of sCD40L prime resting platelets in a CD40-dependent manner, 
predisposing them to enhanced thrombus formation. Because CD40-/- mice do not show a defect 
in thrombus formation, it is likely that CD40 is not essential for platelet hemostasis in the 
absence of significant levels of sCD40L but rather has a pathological importance in 
atherothrombosis in the presence of elevated levels of circulating sCD40L as seen in patients 
with ACS. Given that sCD40L induces platelet P-selectin expression, which is involved in 
platelet/leukocyte interactions14, 17, 20  and stabilization of thrombus mass,30 we measured the 
extent of leukocyte infiltration within the thrombus. We found significantly more leukocytes 
within the thrombus of sCD40L-treated mice, presumably accounting for the increase in 
thrombus formation seen in these animals, concomitantly with enhanced platelet predisposition 
to activation and aggregation in response to vascular injury.  
 Elevated levels of sCD40L are associated with increased cardiovascular risk, as seen in 
patients with ACS, such as unstable angina41 and acute myocardial infarction.3 However, the 
relative importance of the soluble form versus the membrane-bound form in thrombus formation 
is still unknown. It is likely that both forms are involved in primary hemostasis, whereas under 
pathological conditions, thrombosis is exacerbated by increased levels of the soluble form. 
Nevertheless, the involvement of CD40L in atherogenesis, thrombus formation, platelet-
mediated inflammation, and plaque destabilization makes it a potential therapeutic target in 
atherothrombosis. Accordingly, it would be pertinent for future clinical studies to evaluate the 
degree of platelet priming in ACS patients, specifically through sCD40L-induced TRAF-2 
association with CD40, for instance. Hence, a direct clinical link between sCD40L and platelet 
function could be established for pharmacological targeting.  
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 In summary, aside from this newly identified TRAF-2/Rac1/p38 MAPK pathway 
involved in  platelet priming in response to sCD40L, we highlight the relevance of sCD40L in a 
physiopathological setting of platelet function and thrombus formation. Indeed, enhanced levels 
of sCD40L potentiate platelet aggregation and exacerbate thrombus formation and leukocyte 
infiltration in response to vascular injury, in a CD40-dependant manner. This study provides 
novel evidence for the regulation of platelet function by sCD40L and may partly explain the link 
between levels of circulating sCD40L and the occurrence of cardiovascular complications. The 
CD40L/CD40 axis may ultimately represent a therapeutic target in the treatment of thrombo-
inflammatory diseases. 
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Figure legends 
Figure 1: sCD40L enhances platelet activation and aggregation through interaction with 
CD40. A, Dose-dependent effect of sCD40L on platelet aggregation. Platelets were preincubated 
with the indicated concentrations of sCD40L for 30 minutes at 37ºC, and aggregation was 
induced by a priming dose of collagen (0.25 μg/mL). Upper aggregation traces show the effect of 
sCD40L alone (1 μg/mL). Histogram represents the mean of data of platelet aggregation in 
response to sCD40L alone (no agonist) or in the presence of a priming (low) dose of collagen 
(0.25 μg/mL), thrombin (0.02 U/mL), or ADP (5 μM). High doses of agonists (5 μg/mL 
collagen, 0.5 U/mL thrombin, or 20 µmol/L ADP) were used as positive controls (n=5; *P<0.05 
versus low dose). B, Effect of sCD40L on P-selectin (CD62P) expression and αIIbβ3 activation, as 
assessed by flow cytometry. Left plots represent resting platelets (- collagen: gray for baseline, 
black for sCD40L). Right plots represent platelets in the presence of a priming concentration of 
collagen (+ collagen: gray for priming dose of collagen, black for priming dose + sCD40L, and 
white for high-dose collagen alone, as positive control). Histograms represent the mean of data 
of plots for CD62P expression and αIIbβ3 activation in response to sCD40L alone (no agonist) or 
in the presence of a priming (low) dose of collagen (1 μg/mL), thrombin (0.02 U/mL), or ADP (5 
μM). High doses of agonists (collagen 5 μg/mL, thrombin 0.5 U/mL or ADP 20 μM) were 
employed as positive controls (n=5; †P<0.05 versus baseline and *P<0.05 versus low dose). C, 
Effect of recombinant mutant sCD40LR/Y and sCD40LWT on human platelet aggregation. 
Platelets were incubated with 1 μg/mL of sCD40LR/Y or sCD40LWT for 30 minutes at 37ºC, and 
aggregation was induced by a priming dose of collagen (0.25 μg/mL). sCD40L was employed as 
a positive control. D, Effect of mouse (m) sCD40L on WT and CD40-/- mouse platelet 
aggregation. Platelets were incubated with msCD40L (1 μg/mL) for 30 minutes at 37ºC, and 
aggregation was induced by a priming concentration of collagen (1 μg/mL). Data in parentheses 
shown in C and D represent the mean ± SEM of n=4. 
 
Figure 2:  sCD40L induces TRAF-2 association with CD40. A, Representative blots of lysates 
from resting (baseline) or sCD40L (1 μg/mL)-stimulated platelets immunoprecipitated using an 
anti-CD40 monoclonal antibody and analyzed by SDS-PAGE for TRAF-1, -2, -3, and -6. B, 
Histogram represents the mean of data of blots in A, expressed as arbitrary units of optical 
density (n=5; *P<0.05 versus baseline). C, CD40 was immunoprecipitated from lysates of 
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resting (baseline), or 1 μg/mL of sCD40LR/Y or sCD40LWT stimulated platelets. 
Immunoprecipitates were then analyzed by SDS-PAGE for TRAF-2. Blot shown is 
representative of 4 independent experiments. 
 
Figure 3:  sCD40L induces platelet shape change and actin polymerization. A, Scanning 
electron micrographs of resting (baseline), sCD40L, sCD40LWT, and sCD40LR/Y (all at 1 
μg/mL)-stimulated platelets at low (top: 2,500) and high (bottom: 30,000) magnifications. 
Images are representative of 4 independent experiments. B, Actin polymerization in resting 
(baseline) and in sCD40L (1 μg/mL)-treated platelets, with or without 10 μmol/L latrunculin B 
(Lat), as assessed by confocal microscopy. Images are representative of 3 independent 
experiments. C, Platelets were preincubated with latrunculin B (10 μmol/L) or vehicle dimethyl 
sulfoxide for 15 minutes at 37ºC. Cells were then left unstimulated (control) or incubated with 
sCD40L (1 μg/mL) and aggregation was triggered by a priming dose of collagen (0.25 μg/mL). 
D, Represents the mean of data of traces in C (n=3; *P<0.05).  
 
Figure 4:  The Rho-GTPase Rac1 is required for sCD40L signaling. A, VASP 
phosphorylation and Rac1 activation were detected from platelets left untreated (baseline) or 
incubated with sCD40L (1 μg/mL) for the indicated time. Control experiments were performed 
in parallel with 1 µg/mL of sCD40LR/Y and sCD40LWT after 30 minutes stimulation. Blots are 
representative of 4 independent experiments. B, Effect of Rac1 inhibition on sCD40L-induced 
potentiation of platelet aggregation. Platelets were preincubated with the Rac1 inhibitor 
NSC23766 (50 mol/L) or vehicle demethyl sulfoxide for 15 minutes at 37 ºC. Cells were then 
left unstimulated (control) or incubated with sCD40L (1 μg/mL). Aggregation was then monitor 
in the presence of a priming dose of collagen (0.25 μg/mL).  Histogram represents the mean of 
data of aggregation traces (n=4; *P<0.05 versus sCD40L). C, Platelets were left untreated 
(baseline) or incubated with sCD40L (1 μg/mL) with or without NSC23766 (50 mol/L) and 
assessed by flow cytometry for CD62P expression. Histogram shows the mean data of overlay 
plot (n=3; *P<0.05 versus sCD40L). 
 
Figure 5:  The p38 MAPK is an important Rac1 downstream target in response to sCD40L. 
A, Platelets were left untreated (time 0) or stimulated with sCD40L (1 μg/mL), with or without 
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NSC23766 (50 mol/L), for the indicated time and assessed for p38 MAPK phosphorylation by 
SDS-PAGE. Results are expressed as fold increase in optical density (O.D.) over time 0 (n=4; 
*P<0.05). B, Platelets were left unstimulated (baseline) or incubated with sCD40L (1 μg/mL), 
with or without the p38 MAPK inhibitor SB203580 (5 mol/L) and assessed for CD62P by flow 
cytometry. Histogram represents the mean of data of overlay plot (n=5; *P<0.05 versus 
sCD40L). C, Platelets were preincubated with SB203580 (5 mol/L) or vehicle demethyl 
sulfoxide for 15 minutes at 37ºC. Cells were then left unstimulated (control) or incubated with 
sCD40L (1 μg/mL), and aggregation was then induced by a priming dose of collagen (0.25 
μg/mL). Histogram represents the mean of data of aggregation traces (n=4; *P<0.05 versus 
sCD40L). p-p38 indicates phosphorylated p38 
 
Figure 6:  sCD40L exacerbates thrombus formation and leukocyte infiltration. A, WT and 
CD40-/- mice were injected with sCD40L (0.25 mg/kg) or vehicle (control) prior to FeCl3-
induced injury of the right carotid artery, and thrombus formation was monitored by residual 
blood flow measurements. Traces are representative of 6 mice/group (*P<0.05 versus control). 
B, Representative histological sections stained with hematoxylin–eosin and observed by optical 
microscopy (magnification, 20). C, CD45-positive cells, observed by immunostaining of the 
injured carotid arteries, were mainly detectable in sCD40L-treated WT mice (arrows), indicative 
of leukocyte incorporation within the thrombus mass (magnification, 40). D, Histogram shows 
quantitative measurements of leukocytes/thrombus section (n=6, *P<0.05 versus WT).   
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
 
 
  
117 
 
Supplemental Figure I 
 
 
 
Supplemental Figure I: Specific binding of CD40 ligand to CD40- or αIIbβ3-coated well plates. Plates were 
coated with 4 μg of soluble hCD40 or αIIbβ3 overnight at room temperature. After extensive washing, plates were 
blocked with 1% BSA, then recombinant soluble hsCD40L wild type (WT) or hsCD40L R/Y was added overnight 
at a concentration of 100 ng/mL. A polyclonal anti-hCD40L-biotinylated antibody was used followed by addition of 
striptavidin-HRP. The signal was detected by addition of TMB substrate. The reaction was halted by the addition of 
1N H2SO4. Optical density (O.D.) was then measured by spectrophotometry. 
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Supplemental Figure II 
 
 
 
Supplemental Figure II: Effect of SB203580 (0.1 μM -10 μM) on sCD40L-induced p38 MAPK 
phosphorylation. Resting platelets were preincubated with the indicated concentration of SB203580 for 15 minutes 
at 37ºC or left untreated, and then stimulated with sCD40L (1 μg/mL). Total platelet lysates were analyzed by SDS-
PAGE for phospho-p38 MAPK. Blot shown is representative of 3 independent experiments. 
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Supplemental Figure III 
 
 
 
Supplemental Figure III: Effect of sCD40L on intracellular calcium flux. Intracellular calcium was measured by 
Fluo-4 AM fluorescence by real-time confocal microscopy following stimulation of platelets with either sCD40L (1 
μg/mL) or thrombin (0.5 U/mL), as described in materials and methods. Tracings are representative of 3 
experiments. 
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Supplemental Figure IV 
 
 
 
Supplemental Figure IV: Effect of sCD40L on platelet dense granule secretion. A, ATP secretion as measured 
by Luciferase assay (Chrono-Lume, Chrono-log). Results are expressed as a measure of increase in luminescence. 
Blot is representative of 3 independent experiments. B, Dense granule secretion was evaluated by measuring the loss 
of mepacrine fluorescence following activation by sCD40L (1 μg/mL) or thrombin (0.5 U/mL); in comparison to 
untreated cells which was set as 100% fluorescence (n=3; *P< 0.05 vs. baseline). 
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Supplemental Figure V 
 
 
 
Supplemental Figure V: Effect of sCD40L on high dose collagen. Washed platelets were incubated with sCD40L 
(1 μg/mL) or left untreated for 30 minutes at 37°C, then stimulated with collagen (aggregation: 2 μg/mL; flow 
cytometry: 5 μg/mL), and assessed by optical aggregometry and flow cytometry for CD62P expression and αIIbβ3 
activation, as described in materials and methods. 
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Background for the second article 
 
In our first study we demonstrated that sCD40L enhances platelet activation and aggregation in 
response to subthreshold concentrations of platelet agonists, including thrombin, collagen and 
ADP, through a CD40-dependent TRAF2/Rac1/p38 MAPK signalling pathway. We also showed 
that increased levels of circulating sCD40L, as seen in ACS patients, exacerbates thrombus 
formation and leukocyte infiltration within the thrombus mass in a CD40-dependent manner. 
 In B lymphocytes, it is well documented that CD40 induces activation of the NF-κB 
signalling pathway through either TRAF2 or TRAF6. In platelets, the members of the NF-κB 
family have recently been identified and shown to be involved in platelet activation and 
aggregation. However, their role in platelet CD40 signalling remains unknown; hence the 
objective of this study. 
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Abstract 
CD40 ligand (CD40L) is a thrombo-inflammatory molecule that predicts cardiovascular events. 
Platelets constitute the major source of soluble CD40L (sCD40L), which has been shown to 
potentiate platelet activation and aggregation, in a CD40-dependent manner, via p38 mitogen-
activated protein kinase (MAPK) and Rac1 signaling. In many cells, the CD40L/CD40 dyad also 
induces activation of nuclear factor kappa B (NF-κB). Given that platelets contain NF-κB, we 
hypothesized that it may be involved in platelet CD40 signaling and function. In human platelets, 
sCD40L induces association of CD40 with its adaptor protein the tumor necrosis factor receptor 
associated factor 2 and triggers phosphorylation of IκBα, which are abolished by CD40L 
blockade. Inhibition of IκBα phosphorylation reverses sCD40L-induced IκBα phosphorylation 
without affecting p38 MAPK phosphorylation. On the other hand, inhibition of p38 MAPK 
phosphorylation has no effect on IκBα phosphorylation, indicating a divergence in the signaling 
pathway originating from CD40 upon its ligation. In functional studies, inhibition of IκBα 
phosphorylation reverses sCD40L-induced platelet activation and potentiation of platelet 
aggregation in response to a sub-threshold concentration of collagen. This study demonstrates 
that the sCD40L/CD40 axis triggers NF-κB activation in platelets. This signaling pathway plays 
a critical role in platelet activation and aggregation upon sCD40L stimulation and may represent 
an important target against thrombo-inflammatory disorders. (Biochem Biophys Res Commun. 
2012; 425:58-63) 
 
Keywords: Platelet, CD40L, TRAF, NF-κB, p38 MAPK 
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1. Introduction  
 CD40 is a 48 kDa membrane glycoprotein belonging to the tumor necrosis factor (TNF) 
receptor family. It was first discovered on human bladder carcinoma cells [1], but is now known 
to be present on a plethora of cell lines including B lymphocytes, endothelial cells, monocytes, 
dendritic cells and platelets [2,3,4,5]. Interaction of CD40 with its CD40 ligand (CD40L), a 
member of the TNF superfamily, plays a pivotal role in the immune response. The cytoplasmic 
domain of CD40 lacks direct kinase activity and therefore utilizes members of the TNF receptor-
associated factors (TRAFs) as adapter proteins to mediate signaling events. TRAF1, 2, 3, 5 and 6 
have been shown to interact with the cytoplasmic domain of CD40 and regulate downstream 
signaling pathways upon its ligation [6,7,8]. TRAF6 and TRAF2 mediate the activation of the 
canonical and non-canonical NF-κB pathways in response to CD40 engagement. 
 Nuclear factor κB (NF-κB) proteins are formed by hetero- or homo-dimerization of the 
five Rel/NF-κB DNA-binding subunits, which include RelA (p65), RelB (p68), c-Rel, p50 (NF-
κB1) and p52 (NF-κB2). These NF-κB complexes are maintained in the cytoplasm in an inactive 
state through the inhibitor κB (IκBα or IκBβ). In response to stimuli, the NF-κB dimers in 
association with the inhibitory IκB subunit are regulated by the IκB kinase (IKK), which consists 
of two kinase subunits, IKKα and IKKβ, and a regulatory subunit, IKKγ/NEMO. Upon 
phosphorylation by IKK, the IκB subunit is targeted for proteosomal degradation, thereby 
releasing an active form of NF-κB that translocates into the nucleus. Nuclear translocation of 
p50/RelA and p52/RelB is responsible for the canonical and non-canonical NF-κB pathways, 
respectively [9]. Liu et al. [10] has demonstrated the presence of NF-κB and IκBα in platelets, as 
well as the induction of the NF-κB signaling pathway following platelet activation. Thereafter, 
Malaver et al. [11] has shown that IκBα is phosphorylated in thrombin-activated platelets and 
pharmacological inhibition of this factor leads to impairment of platelet function, thereby 
attributing non-genomic functions to NF-κB in anucleated platelets. In contrast, Gambaryan et 
al. [12] showed that NF-κB negatively regulates platelet activation by thrombin and collagen via 
PKAc activation.  
 Platelets are pivotal contributors to thrombosis and homeostasis, but also participate in 
inflammation and immunity [13]. The work by Henn et al. [5,14] demonstrated the presence of 
the CD40L/CD40 dyad in platelets; they showed that CD40 is constitutively expressed on the 
platelet surface, while CD40L rapidly appears on the platelet surface following activation.  
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Surface expressed CD40L is subsequently cleaved into an 18 kDa fragment, which accounts for 
>95% of plasmatic soluble CD40L (sCD40L) concentrations [15]. Circulating levels of sCD40L 
in patients have now emerged as strong indicators of cardiovascular risk, as there appears to be a 
significant correlation between elevated levels of sCD40L and vascular complications such as 
atherosclerosis and acute coronary syndromes [16,17,18]. 
 We have previously shown that sCD40L enhances agonist-induced platelet activation and 
aggregation through a CD40-dependent TRAF2/Rac1/p38 mitogen-activated protein kinase 
signaling (MAPK) pathway [19]. Although the presence of both the CD40L/CD40 dyad and NF-
κB/IκBα in platelets is recognized, the involvement of NF-κB/IκBα in platelet CD40 signaling 
and function remains unknown. This study was therefore designed to test the hypothesis that NF-
κB is involved in platelet CD40 signaling and function. 
 
2. Materials and methods 
2.1 Reagents and Antibodies 
 Recombinant human sCD40L was obtained from R&D systems. Antibodies against 
TRAF2 (rabbit polyclonal), phospho-IκBα (mouse monoclonal, Ser32/36), phospho-p38 MAPK 
(rabbit polyclonal, Thr180/Tyr182) and β-actin (rabbit polyclonal) were purchased from Cell 
Signaling Technology. The mouse monoclonal anti-CD40 antibody used for 
immunoprecipitation of human CD40 was also from R&D systems, while the rabbit polyclonal 
anti-CD40 antibody used for detection of CD40 by immunoblotting came from Santa Cruz 
Biotechnology. Antibody against CD62P (mouse monoclonal, AK4-PE conjugated) was 
obtained from BD Biosciences. The specific IKK inhibitor VII and the p38 MAPK inhibitor 
SB203580 were purchased from Calbiochem, while the IκBα phosphorylation inhibitor BAY 11-
7082 was purchased from Sigma-Aldrich. Protein A agarose beads were obtained from Upstate 
Biotechnology, Inc. Native type I collagen was from Chronolog Corp. 
 
2.2 Platelet isolation 
 Venous blood was drawn from healthy volunteers, free from medication known to 
interfere with platelet function for at least 10 days before the experiment. The protocol was 
approved by the human ethical committee of the Montreal Heart in accordance with the 
declaration of Helsinki for experiments involving humans. Washed platelets were prepared as 
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previously described [19], adjusted to the indicated concentrations and allowed to rest at 37 ºC 
for 30 min before further manipulation. 
 
2.3 Flow cytometry 
 Platelet P-selectin (CD62P) expression, as a marker of α granule secretion and platelet 
activation, was measured by flow cytometry as previously described [19]. Briefly, platelets (250 
 106/mL) were pre-incubated with or without the indicated inhibitor for 10 min at 37 ºC. 
Platelets were then stimulated with sCD40L for 30 min at 37 ºC, fixed with 1% 
paraformaldehyde, washed and stained with saturating concentrations of anti-CD62P antibody 
for 30 min or its isotype-matched control IgG. Platelets were analyzed (20,000 events) on an 
Altra flow cytometer (Beckman Coulter) after gating their characteristic forward and side scatter 
properties. 
 
2.4 Platelet aggregation 
 Platelets were adjusted to 250 x 106 /mL and aggregation was monitored on a four-
channel optical aggregometer (Chronolog Corp.) under shear (1000 rpm) at 37 ºC. Platelets were 
pre-incubated with or without the indicated inhibitors for 10 min at 37 ºC prior to incubation 
with sCD40L for an additional 30 min under static conditions at 37 ºC. Platelet aggregation was 
then monitored following the addition of collagen (0.5 μg/mL) and recorded until stabilization of 
platelet aggregation. 
 
2.5 Immunoprecipitation of CD40 
 Platelets were stimulated as indicated and lysed into ice-cold modified RIPA lysis buffer 
(1% NP-40, 0.25% deoxycholic acid, 150 mM NaCl, 50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 
mM PMSF, 1 mM sodium-orthovanadate, 1 mM sodium fluoride, 1 μg/mL aprotinin, 1 μg/mL 
leupeptin, and 2 μg/mL benzamidin) for 1 h at 4 ºC. Lysates were sonicated on ice and pre-
cleared with 100 L of protein A agarose beads for 15 min at 4 ºC. Beads were then pelleted and 
the supernatant was incubated with an anti-CD40 antibody overnight at 4 ºC. Samples were 
treated with 100 L of protein A agarose beads for 1 h at 4 ºC. Beads were then precipitated by 
centrifugation, washed three times with ice-cold modified RIPA lysis buffer, resuspended in 2 
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Laemmli buffer and boiled for 5 min. Supernatants were analyzed by immunoblotting for the 
presence of TRAF2 and CD40 proteins. 
 
2.6 SDS-PAGE and immunoblotting 
 Proteins were resolved in 8% or 12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) gels and transferred to nitrocellulose membranes. The membranes 
were blocked with 5% non-fat dry milk for 1 h, washed three times with TBS/T (150 mM NaCl, 
20 mM Tris, pH 7.4, 0.1 % Tween-20) and incubated with the appropriate primary antibody 
overnight at 4 ºC. Following washing steps, membranes were labeled with horseradish 
peroxidase-conjugated secondary antibody for 1 h, washed and bound peroxidase activity was 
detected by enhanced chemiluminescence (PerkinElmer Life Sciences). To assess equal protein 
loading, membranes were stripped, blocked with 5% milk and blotted for β-actin. 
 
2.7 Statistical analysis 
 Results are presented as mean ± SEM of at least three independent experiments. 
Statistical comparisons were done using a one-way ANOVA, followed by a Dunnetts-t-test for 
comparison against a single group. Data with P < 0.05 were considered statistically significant. 
 
3. Results 
3.1 sCD40L induces TRAF2 association to CD40 and IκBα phosphorylation in platelets 
 We first confirmed our previous finding that sCD40L induces the association of TRAF2 
to platelet CD40 [19] and showed that pretreatment with a blocking anti-CD40L antibody 
entirely prevents TRAF2 binding to CD40 in response to sCD40L (Fig. 1A). We then evaluated 
the activation of the NF-κB signaling pathway downstream of platelet CD40 by assessing IκBα 
phosphorylation on residues Ser32/36, which leads to degradation and release of the active form of 
NF-κB. Our results show for the first time that sCD40L induces a time-dependent 
phosphorylation of IκBα in human platelets (Fig. 1B). Since the phosphorylation of IκBα at 5 
min was close to maximum, we chose this time point for subsequent experiments. Pretreatment 
with a blocking anti-CD40L antibody prevents platelet IκBα phosphorylation in response to 
sCD40L (Fig. 1C). 
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3.2 IκBα phosphorylation downstream of CD40 is independent of p38 MAPK 
 Signaling pathways downstream of CD40 have been shown to involve both NF-κB and 
p38 MAPK [20,21]. Indeed, we have previously shown that sCD40L enhances platelet function 
through activation of p38 MAPK [19], albeit the link between this MAPK and NF-κB activation 
remains uncharacterized. In order to delineate the cross-talk between these signaling cascades 
downstream of platelet CD40, we employed specific inhibitors of IκBα and p38 MAPK 
phosphorylation, BAY 11-7082 and SB203580 respectively. In platelets, inhibition of IκBα 
phosphorylation does not influence p38 MAPK phosphorylation following sCD40L treatment, 
and vice versa (Fig. 2A and B). These results indicate that platelet CD40 signals via two distinct 
pathways, one involving the NF-κB pathway and another involving p38 MAPK. 
 
3.3 IκBα is required for sCD40L-induced platelet activation and potentiation of aggregation  
 We have previously shown that sCD40L induces platelet CD62P expression and 
potentiates platelet aggregation in response to sub-threshold doses of platelet agonists [19]. In 
order to show the importance of IκBα in this process, the IKK inhibitor VII, which targets the 
kinase responsible for IκBα phosphorylation, was employed. Pretreatment of platelets with the 
IKK inhibitor VII not only decreases IκBα phosphorylation in a dose-dependent manner (Fig. 
3A), but also abolishes platelet activation in response to sCD40L stimulation, as assessed by 
CD62P expression (Fig. 3B). In functional studies, pretreatment of platelets with either BAY 11-
7082 or IKK inhibitor VII reverses the pro-aggregating effects of sCD40L (Fig. 4A and B). 
These results indicate that the NF-κB signaling pathway, which involves both IκBα and IKK, 
plays an important role in platelet CD40 signaling, activation and aggregation in response to 
sCD40L. 
 
4. Discussion 
 The presence of CD40L in platelets, which is cleaved to generate most of the sCD40L 
within the circulation, and its ability to induce an inflammatory response in the vascular system 
is well documented [5,14]. However, its modulation of platelet function remains a matter of 
debate. Andre and al. have shown that sCD40L binds to αIIbβ3 and stabilizes arterial thrombi in 
mice [22]. In contrast, we and others have shown that sCD40L induces platelet activation 
through CD40 [19,23,24,25]. Indeed, we have previously demonstrated that sCD40L exacerbates 
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platelet activation and aggregation through a CD40-dependent TRAF2/Rac1/p38 MAPK 
signaling pathway. We have also shown that elevated levels of sCD40L predisposed platelets to 
enhanced thrombus formation in response to vascular injury [19]. In this study, we further 
investigated the signaling pathways downstream of platelet CD40 in response to sCD40L. 
 In B lymphocytes, it is well documented that CD40 induces activation of the NF-κB 
signaling pathway through either TRAF2 or TRAF6 [26]. Having shown that sCD40L induces 
the association of TRAF2/CD40, but not TRAF6/CD40 [19] in platelets, we sought to evaluate 
whether CD40 ligation could trigger activation of the NF-κB signaling pathway in platelets. We 
showed for the first time that treatment of platelets with sCD40L activates the NF-κB signaling 
pathway, which was revealed by the phosphorylation of IκBα on Ser32/36. These results add 
insights to previous work [11], showing that NF-κB may be a novel mediator of platelet 
responses.  Although previous work has focused on the involvement of p38 MAPK in platelet 
CD40 signaling [19,23], the interrelation between this pathway and the NF-kB cascade remains 
undetermined. Craxton et al. [27] have shown that p38 MAPK regulates NF-κB activation in B 
cells, whereas p38 MAPK inhibition does not affect CD40-mediated NF-κB DNA binding, 
suggesting that NF-κB is not a direct target of the p38 MAPK pathway. In the present study, we 
show a divergence between the NF-κB and p38 MAPK signaling pathways downstream of 
platelet CD40. This branching phenomenon suggests that these pathways regulate different 
aspects of CD40-mediated platelet responses. For instance, the p38 MAPK pathway may be 
involved in actin polymerization, cytoskeleton reorganization and platelet spreading [28], while 
the NF-κB pathway may regulate de novo protein synthesis through its interaction with 
microRNAs [29], which have been shown to be present in platelets [30]. However, further 
investigations are needed to specifically address this issue.   
 Malaver et al. [11] have demonstrated the implication of NF-κB in platelet function and 
showed that blockade of the NF-κB pathway by BAY 11-7082 reverses platelet activation as 
well as aggregation triggered by thrombin, collagen and ADP. Since we have previously 
demonstrated that sCD40L induces platelet activation as assessed by α-granule secretion [19]; 
here we show that pretreatment of platelets with the IKK inhibitor VII, which inhibited IκBα 
phosphorylation, reversed sCD40L-induced platelet α-granule secretion, as assessed by CD62P 
translocation to the platelet membrane. Therefore, aside from activating NF-κB, IKK could 
regulate the activation of critical elements involved in the degranulation process, such as the 
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synaptosomal-associated protein 23 (SNAP-23). In fact, IKK2 regulates mast cell degranulation 
by phosphorylating SNAP-23 in a NF-κB-independent manner [31]. In functional studies of 
platelet aggregation, sCD40L stimulation of platelets potentiates aggregation by a mechanism 
involving the NF-κB signaling pathway, since inhibition of this pathway by either BAY 11-7082 
or the IKK inhibitor VII abolished sCD40L-induced potentiation of platelet aggregation. These 
results indicate that sCD40L via NF-κB, as well as p38 MAPK as previously demonstrated [19], 
primes platelets and predisposes them to enhanced aggregation responses in the presence of 
thrombotic stimulus. 
 In summary, this study shows for the first time that sCD40L is an important inducer of 
the NF-κB signaling pathway activation in platelets independently of the p38 MAPK pathway. 
This translates into platelet priming and enhancement of platelet activation and aggregation.  
Thus, the CD40L/CD40/NF-κB axis may ultimately represent a therapeutic target in the 
treatment of thrombo-inflammatory diseases. 
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Figure legends 
Figure 1: sCD40L induces TRAF2 association to CD40 and IκBα phosphorylation in 
platelets. (A) Platelets (500  106/mL) were left untreated or incubated with 1 μg/mL sCD40L 
for 15 min at 37 ºC in the presence or absence of a blocking anti-CD40L antibody (5 μg/mL). 
Total cell lysates were then immunoprecipated using an anti-CD40 antibody and immunoblotted 
for TRAF2 and CD40 expression. Blots are representative of three independent experiments. 
Histogram represents the mean of data of overlay blots, expressed as arbitrary units of optical 
density (n = 3; *P < 0.05 vs. baseline or sCD40L). (B) Time-dependent course of IκBα 
phosphorylation on Ser32/36 (p-IκBα Ser32/36) following sCD40L treatment. Lysates form 1000  
106 platelets/mL from untreated (Baseline) or sCD40L-treated (1 μg/mL) were resolved in 12% 
SDS-PAGE and assessed for p-IκBα Ser32/36. Blots are representative of three independent 
experiments. Histogram represents the mean of data of overlay blots, expressed as fold increase 
in optical density, as compared to baseline (n = 3, *P < 0.05 vs. baseline). (C) Dose-dependent 
effect of anti-CD40L treatment on IκBα phosphorylation. Platelets were left untreated or 
pretreated with the indicated dose of anti-CD40L for 5 min at 37 ºC prior to stimulation with 
sCD40L. Platelet lysates were then analyzed for p-IκBα Ser32/36. β-actin blots shown are from 
stripped p-IκBα Ser32/36 membranes. Blots are representative of five independent experiments. 
Histogram represent the mean of data of overlay blots, expressed as arbitrary units of optical 
density (n = 5, *P < 0.05 vs. baseline and †P < 0.05 vs. sCD40L alone). 
 
Figure 2: IκBα phosphorylation downstream of CD40 is independent of p38 MAPK 
phosphorylation. (A) Dose-dependent effect of BAY 11-7082 on IκBα and p38 MAPK 
phosphorylation. Platelets (1000  106/mL) were incubated with vehicle DMSO or the indicated 
concentrations of BAY 11-7082 for 5 min at 37 ºC and stimulated with sCD40L (1 μg/mL) for 5 
min. Platelet lysates where resolved in 12% SDS-PAGE and assessed for p-IκBα Ser32/36 (n = 4) 
and phospho-p38 MAPK (p-p38 MAPK) (n = 3). (B) Dose- dependent effect of SB203580 on 
IκBα and p38 MAPK phosphorylation. Platelets were incubated with vehicle DMSO or the 
indicated concentration of SB203580 for 10 min at 37 ºC prior to sCD40L stimulation (1 μg/mL) 
for 5 min. Platelet lysates where assessed for p-IκBα Ser32/36 (n = 4) and p-p38 MAPK (n = 4). β-
actin blots are from stripped membranes of either p-IκBα or p-p38 MAPK blots. Blots are 
representative of the indicated number of independent experiments. Histograms represent the 
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mean of data of overlay blots, expressed as arbitrary units of optical density (*P < 0.05 vs. 
baseline and †P < 0.05 vs. sCD40L alone). 
 
Figure 3: IκBα is required for sCD40L-induced platelet activation. (A) Platelets (1000  
106/mL) were incubated with vehicle DMSO or the indicated concentration of IKK inhibitor VII 
for 5 min at 37 ºC and stimulated with sCD40L for 5 min. Platelet lysates where resolved in 12% 
SDS-PAGE and assessed for p-IκBα Ser32/36. β-actin blot is from stripped membranes of p-IκBα 
blot. Blots are representative of four independent experiments. Histogram represent the mean of 
data of overlay blots, expressed as arbitrary units of optical density (n = 4; *P < 0.05 vs. baseline 
and †P < 0.05 vs. sCD40L alone). (B) Effect of IκBα inhibition on platelet activation in response 
to sCD40L. Platelets (250  106/mL) were left untreated or stimulated with sCD40L (1 μg/mL) 
in the absence or presence of the indicated concentration of IKK inhibitor VII. Platelet activation 
was assessed by flow cytometry for the expression of CD62P. Histogram represents the mean of 
data expressed as percent of CD62P positive platelets (n = 3; *P < 0.05 vs. baseline and †P < 
0.05 vs. sCD40L alone). 
 
Figure 4: IκBα is required for sCD40L-induced potentiation of platelet aggregation. (A and 
B) Effect of IκBα inhibition on the potentiation of platelet aggregation induced by sCD40L. 
Platelets were preincubated with the IκBα phosphorylation inhibitors BAY 11-7082 (10 M) or 
IKK inhibitor VII (2.5 M), or vehicle DMSO for 5 min at 37 ºC. Cells were then left 
unstimulated (control) or treated with sCD40L (1 μg/mL). Aggregation was then monitor in the 
presence of a priming dose of collagen (0.5 μg/mL). Histograms represent the mean of data of 
aggregation traces (n = 3; *P < 0.05 vs. Control). 
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The CD40/CD40L dyad was initially thought to be restricted to cells of the immune system and 
to occupy a crucial role in regulating adaptive immunity. Now, it is well known that these two 
molecules have a much broader expression pattern, encompassing cells of the circulatory and 
vascular systems. The broad expression pattern of this dyad shed light into its contribution not 
only to immune responses, but also to inflammatory reactions. Indeed, the implication of the 
CD40/CD40L in all the facets of atherosclerosis, which is considered to be a chronic 
inflammatory disease, as well as the tight correlation between circulating levels of sCD40L and 
ACS incidence support its role as an inflammatory modulator. As platelets express members of 
this dyad and occupy a significant role in the development and progression of cardiovascular 
diseases, multiple studies attempted to determine the impact of sCD40L on platelet function. 
However, the precise effect of sCD40L on the in vitro platelet function and in vivo thrombus 
formation, as well as the underlying signalling mechanisms remain unclear; hence the objective 
of this project. 
  The main results of these studies demonstrate that sCD40L potentiates platelet activation 
and aggregation in a CD40-dependent manner through two signalling pathways. The first 
signalling pathway involves TRAF2/Rac1/p38 MAPK, while the second involves TRAF2/NF-
κB. In addition, these results show that an increase in circulating sCD40L levels exacerbates in 
vivo thrombus formation in response to arterial injury, and leukocyte infiltration within the 
thrombus mass via CD40. 
 As aggregation is the main physiological function of platelets, we initially evaluated the 
effect of sCD40L on this important aspect of platelet function. Our results indicate that treatment 
of resting platelets with sCD40L alone induces a slight membrane translocation of P-selectin; 
however, it is unable to induce neither platelet aggregation nor activation of the αIIbβ3 integrin. 
This effect of sCD40L on platelets differs from those induced by other platelet agonists, such as 
collagen and thrombin, which trigger αIIbβ3 activation and platelet aggregation. In fact, sCD40L 
alone was unable to induce intra-platelet calcium influx and dense granule secretion, which are 
essential for αIIbβ3 activation and platelet aggregation. In contrast, sCD40L potentiates P-selectin 
expression, αIIbβ3 activation, and platelet aggregation in response to sub-threshold concentrations 
of platelet agonists, including collagen, thrombin and ADP. Therefore, these results indicate that 
sCD40L probably acts as a broad and potent primer that predisposes platelets to an enhanced 
response to physiological agonists. Aside from sCD40L, platelet priming has been shown to be 
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induced by other molecules, namely MMP-2, MDC, plasma protein growth arrest-specific 6 
(Gas-6), and stromal cell-derived factor-1α (SDF-1α).230, 604, 605 Similarly to sCD40L, these 
molecules potentiate platelet responses to activating stimuli without occupying a main role in 
primary haemostasis. These molecules play a significant role in pathological thrombus 
formation, which makes them attractive potential targets for novel antiplatelet therapies.606 
Moreover, the priming effect of sCD40L is seen in other cell types, such as proliferating B 
lymphocytes, in which sCD40L requires IL-4 co-stimulation for IgE production. Taken together, 
these findings indicate that sCD40L acts as important accessory element in platelet function. 
 To this date, the identity of the sCD40L receptor on platelets remains a matter of 
controversy, given that platelets express three receptors for CD40L (CD40, αIIbβ3, and α5β1).4, 308, 
310, 311 The results of our study using molecular and genetic approaches show that CD40 is the 
main receptor through which sCD40L mediates its potentiating effect on platelet responses. 
These results are consistent with previous studies demonstrating that sCD40L induces platelet 
activation, and secretion of ROS and RANTES through its interaction with CD40, the 
constitutively expressed CD40L receptor on the platelet surface.310, 360, 361 In addition, sCD40L 
has been shown to interact with the αIIbβ3 integrin on platelets.4, 307 However, this interaction was 
demonstrated by treating preactivated platelets (αIIbβ3 already in its active conformation) with 40 
μg/mL of sCD40L, which is 40 times higher than the concentration used in our studies. This 
suggests that CD40 is probably the high-affinity receptor for sCD40L, whereas αIIbβ3 is the low-
affinity one. Therefore, additional investigations are required to clarify this issue. Nonetheless, 
we could hypothesize that the increased levels of circulating sCD40L, as seen in ACS patients, 
prime quiescent platelets through CD40, as the αIIbβ3 integrin is in its inactive conformation. 
However, at the site of vascular injury, higher levels of sCD40L generated within the thrombus 
by activated platelets stabilize platelet aggregates via αIIbβ3 in its active conformation. However, 
this does not exclude the possibility that within a growing thrombus mass, CD40L expressed on 
activated platelets could interact with CD40 on adjacent platelets, thereby mediating CD40-
dependent signals. Indeed, our unpublished results indicated that this is most probably the case 
(discussed in more detail below). 
 CD40 signalling in immune and non-immune cells requires the recruitment and 
association of TRAF molecules with its cytoplasmic tail. To our knowledge, the expression of 
TRAF members in platelets and their association with platelet CD40 following sCD40L 
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stimulation have not been reported. Our results demonstrate for the first time that platelets 
express TRAF1, 2, and 6, and that only TRAF2 associates with CD40 following sCD40L 
stimulation, indicating that it may ultimately be responsible for the downstream signalling events 
arising from platelet CD40 activation. Despite their presence in platelets, neither TRAF1 nor 
TRAF6 associates with CD40, suggesting that they might instead have a role in TNF receptor 
and TLR signalling. However, TRAF1 might play a role in enhancing TRAF2-mediated CD40 
signals in platelets by promoting membrane localization of TRAF2.387, 388 On the other hand, the 
cytoplasmic domain of CD40 contains binding sites for both TRAF2 and TRAF6, and binding of 
either one is sufficient to induce activation of NF-κB in B lymphocytes.391 This is probably the 
case for platelets, as binding of only TRAF2 is sufficient to induce downstream signalling. 
However, unlike TRAF6, TRAF2 can activate both the canonical and non-canonical NF-κB 
signalling pathways, suggesting that in platelets TRAF2 binding potentially leads to activation of 
these two pathways. In addition, the almost complete lack of TRAF3 in platelets probably 
enhances TRAF2-mediated CD40 signals, since TRAF3 negatively regulates CD40 signalling by 
sequestering TRAF2 in a complex with cIAP1/2.402, 408 
 In B lymphocytes, it is well documented that CD40 induces activation of the NF-κB 
signalling pathway through either TRAF2 or TRAF6.444 In platelets, the members of the NF-κB 
signalling pathway have recently been characterized and shown to be involved in platelet 
activation; however, their role in platelet CD40 signalling is still unknown.607-609 As we have 
shown that sCD40L induces the association of TRAF2 but not TRAF6 with CD40 in platelets, 
we sought to assess whether CD40 ligation could trigger activation of the NF-κB signalling 
pathway in platelets. Our results demonstrate for the first time that treatment of platelets with 
sCD40L activates the NF-κB signalling pathway, specifically the canonical pathway, which was 
revealed by the phosphorylation of IκBα on Ser32/36. These results add new insights to previous 
work showing that NF-κB may be a novel mediator of platelet responses.608 Moreover, as 
mentioned earlier, it is probable that within a growing thrombus mass, CD40L expressed on 
activated platelets could interact with CD40 on adjacent platelets and induce signalling. Our 
unpublished results (Annex I, figure 1) demonstrate that platelet treatment with thrombin, which 
is also generated during thrombus formation, induces rapid expression of CD40L. This is in 
agreement with previous published studies demonstrating that CD40L is expressed on platelets 
upon activation; however, these studies failed to demonstrate whether the newly expressed 
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CD40L is capable of inducing CD40 signalling in platelets.2 Our results add new insights to 
these previous works by documenting that upon thrombin activation, TRAF2 associates with 
CD40 and IκBα is phosphorylated on Ser32/36 in a CD40L-dependent manner. This suggests that 
the newly expressed CD40L on platelets is capable of interacting with CD40 and subsequently 
trigger signalling, which contributes to platelet function upon thrombin stimulation. Whether the 
membrane or soluble form of CD40L generated by thrombin-stimulated platelets induces CD40 
signalling remains to be determined. However, it is unlikely to be the soluble form that interacts 
with CD40 in thrombin-stimulated platelets, given that IκBα phosphorylation and TRAF2 
association are detectable as early as 5 and 15 minutes, respectively, whereas platelets shed 
sCD40L within 1 to 2 hours of platelet activation and shedding also requires CD40 ligation.3 
  In search of the underlying molecular mechanisms by which sCD40L mediates its pro-
activating and pro-aggregating effects on platelets, we initially hypothesized that sCD40L might 
induce the secretion of weak platelet agonists, such as TxA2 and ADP, which could be 
responsible for the increase in platelet activation and aggregation in response to sub-threshold 
concentrations of agonists. Given that platelets secrete ADP from dense granule stores, we 
assessed dense granule release following sCD40L stimulation of resting platelets. Our results 
demonstrate that sCD40L alone does not affect dense granule secretion, as assessed by ATP 
release and mepacrine uptake. Additionally, we did not detect any changes in TxA2 release 
(unpublished results; Annex I, figure 2), as measured by enzyme-linked immunosorbent assay 
(ELISA), from resting platelets following sCD40L stimulation, suggesting that sCD40L does not 
influence COX-1 activation in platelets. At light of these results, we speculate that patients under 
aspirin regiment would not be protected from the sCD40L effects on platelet function. Moreover, 
Chakrabarti et al.360 have shown that platelets generate ROS following sCD40L stimulation; 
however, whether sCD40L potentiates platelet activation and aggregation via ROS production 
remains to be determined, since ROS have already been shown to contribute to platelet 
activation.359 On the other hand, the morphological changes observed in platelets by scanning 
electron microscopy reveal that sCD40L rather acts directly on platelets by inducing intracellular 
signals that trigger platelet shape change characterized by the formation of filopodia and 
lamellipodia, which predispose platelets to enhanced responses in thrombogenic environments. 
 In platelets, Rac1 and VASP regulate shape change, cytoskeletal reorganization, and 
spreading, via lamellipodia and filopodia formation, respectively.54, 610 VASP is mainly 
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phosphorylated on two principal residues, Ser239 and Ser157. Platelet inhibitors, such as NO and 
PGI2 induce phosphorylation of VASP on both residues, whereas platelet agonists, such as 
thrombin and collagen, trigger phosphorylation of VASP on Ser157, thereby promoting the 
anticapping activity of VASP and the subsequent actin polymerization and filopodia formation.54, 
611, 612 Our results demonstrate that sCD40L induces phosphorylation of VASP on Ser157, thereby 
providing evidence for its role as an inducer of shape change in platelets. The role of sCD40L in 
this process is further highlighted by its capacity to activate the small GTPase Rac1, which is 
involved in lamellipodia formation. Soluble CD40L-induced activation of Rac1 is 
physiologically significant, as specific inhibition of Rac1 considerably reduces sCD40L's ability 
to potentiate platelet aggregation and P-selectin expression. These results are in agreement with 
previous published findings demonstrating that CD40 signalling induces Rac1-dependent ROS 
production in WEHI 231 cells and endothelial cells.613, 614 Interestingly, inhibition of Rac1 
activation does not completely reverse sCD40L's ability to potentiate platelet aggregation and P-
selectin expression, probably due to VASP and NF-κB activation, which are possibly not related 
to Rac1 activation and may therefore be responsible for the residual effects of sCD40L on 
platelets. 
 In immune cells, CD40L is typically known to induce activation of MAPKs, such as 
p38.400 This seems to hold true for platelets. Indeed, our results confirm that stimulation of 
resting platelets with sCD40L induces the activation of p38 MAPK, and further highlight its 
involvement in platelet activation and aggregation, given that its inhibition abolishes the pro-
activating and pro-aggregating effects of sCD40L. Furthermore, our results demonstrate that p38 
MAPK is a downstream effector of Rac1, since its inhibition affects p38 MAPK activation. 
However, inhibition of Rac1 activation delays but does not completely inhibit p38 MAPK 
activation, which might explain in part the lack of complete reversal of sCD40L-induced 
potentiation of platelet aggregation and P-selectin expression following Rac1 inhibition. 
Nonetheless, the role of p38 MAPK in platelets seems to compliment that of Rac1, because it 
appears to be an important modulator of actin polymerization and platelet spreading, hence 
further confirming that sCD40L has an important role in inducing platelet shape change.615 
Moreover, extensive work has focused on the involvement of p38 MAPK in CD40 signalling; 
however, the association between this pathway and the NF-κB cascade remains a matter of 
debate.360, 616, 617 Craxton et al.618 have shown that p38 MAPK regulates NF-κB activation in B 
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cells, whereas p38 MAPK inhibition does not affect CD40-mediated binding of NF-κB to DNA, 
suggesting that NF-κB mediates its effects via both p38 MAPK-dependent and -independent 
pathways. Our results demonstrate a divergence between the canonical NF-κB and p38 MAPK 
signalling pathways downstream of platelet CD40, suggesting that these two pathways regulate 
different aspects of CD40-mediated platelet responses. For instance, the p38 MAPK pathway 
may be involved in cytoskeleton reorganization, as it has already been demonstrated to play an 
important role in actin polymerization and platelet spreading, whereas the NF-κB pathway may 
regulate de novo protein synthesis by modulating mRNA translation through its interaction with 
microRNAs (miRNAs), which have already been shown to be present in platelets.615, 619, 620 
Nonetheless, further investigations are required to clarify this issue. 
 Malaver et al.608 have implicated the canonical NF-κB pathway in platelet function and 
showed that blocking IκBα phosphorylation, which is responsible for its activation, reverses 
platelet activation and aggregation triggered by a wide array of platelet agonists, including 
thrombin, collagen and ADP. In the present study, we show that sCD40L induces platelet 
activation as assessed by P-selectin translocation to the membrane, which is indicative of α-
granule secretion, as well as activation of the canonical NF-κB signalling pathway. We then 
hypothesized that this pathway may be involved in platelet α-granule secretion. In fact, our 
results demonstrate that blockade of IKK, which phosphorylates IκBα, reverses sCD40L-induced 
α-granule secretion as assessed by P-selectin translocation. Therefore, apart from its role in 
activating the canonical NF-κB pathway, IKK could regulate key elements involved in the 
degranulation process, such as SNAP-23, which is involved in membrane and vesicle fusion. In 
fact, in mast cells, IKK2 regulates degranulation by phosphorylating SNAP-23 in a NF-κB-
independent manner.621 Whether this is the case in platelets merits further investigation, given 
that SNAP-23 is involved in platelet α-granule secretion.188 Furthermore, we evaluated the 
involvement of the canonical NF-κB signalling pathway in the effects of sCD40L on platelet 
function. Our results show that inhibition of the canonical NF-κB signalling pathway by 
preventing either IKK activation or IκBα phosphorylation abolishes sCD40L-induced 
potentiation of platelet aggregation. These results indicate that sCD40L, through both NF-κB and 
p38 MAPK, primes platelets and predisposes them to enhanced aggregation responses in the 
presence of thrombotic stimuli. In addition, the NF-κB signalling pathway does not influence 
activation of the p38 MAPK pathway, and vice versa. However, this does not remove the 
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possibility of a crosstalk between NF-κB and p38 MAPK, and that inhibition of either abolishes 
the sCD40L-induced platelet responses. 
 To date, it is still unclear whether the elevated levels of sCD40L seen in patients with 
ACS are a consequence of increased platelet activation or a predetermining cause of disease 
development (or possibly both). Our results demonstrate for the first time a direct correlation 
between enhanced levels of sCD40L and thrombosis. Infusion of sCD40L into mice prior to 
vascular injury exacerbates thrombus formation as compared to control mice, indicating that 
these mice were predisposed to enhanced thrombotic stimuli. These results add new insight to 
the work by Andre et al.4 that shows correction of thrombus instability, in a αIIbβ3-dependent 
manner, in CD40L deficient mice that were treated with 1.6 mg/kg of sCD40L. In our study, a 
different approach was used, as we aimed to mimic conditions in ACS patients where sCD40L 
levels are elevated. Under these conditions, injection of 0.25 mg/kg of sCD40L into mice results 
in plasma concentrations of approximately 50 ng/ml. These concentrations probably reflect the 
rapid clearance of a significant portion of the molecule by the liver or another metabolic organ. 
Nonetheless, circulating concentrations result in exacerbated thrombus formation in WT but not 
CD40-/- mice, indicating that elevated circulating sCD40L concentrations influence platelets 
through CD40 but not αIIbβ3, given that the integrin is in its inactive conformation. Moreover, 
this circulating concentration of 50 ng/mL of sCD40L that was achieved in our experimental 
model is noteworthy, since it is similar to the concentrations noted in multiple clinical studies, in 
patients with coronary and peripheral artery diseases.594, 595 In addition, sCD40L levels are 
further increased in individuals with high cardiovascular risk factors, such as diabetes, obesity, 
metabolic syndrome, hypertension, and smoking.622, 623 Furthermore, CD40-/- mice do not show 
defect in thrombus formation, therefore it is likely that CD40 is not required for platelet primary 
haemostasis, but rather has a pathological importance in atherothrombosis in the presence of 
elevated levels of sCD40L as seen in ACS patients. Nonetheless, the possibility that the αIIbβ3 
integrin may be in an active conformation in circulating platelets of ACS patients could not be 
excluded, which suggests that sCD40L may interact with αIIbβ3 on circulating platelets and 
induce "outside-in" signals through the integrin. However, the effects of sCD40L on platelets 
through its interaction with αIIbβ3 are seen at concentrations of 1.6 mg/kg, which are many folds 
greater than the concentrations seen in these patients and our study. In this regard, the 
CD40L/CD40 interactions in ACS patients and individuals with high cardiovascular risk factors 
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would prime and predispose platelets to an exaggerated response to thrombotic stimuli, whereas 
the CD40L/αIIbβ3 interaction would be implicated in thrombus stability at the lesion site where 
higher concentration of sCD40L are generated by activated platelets. 
 Expression of P-selectin on the platelet surface plays an important role in thrombus 
stabilization, as well as in platelet/leukocyte interactions and the recruitment of leukocytes to the 
site of vascular injury.310, 312, 360, 624 As sCD40L induces the expression of P-selectin on the 
platelet surface, we evaluated the extent of leukocyte infiltration within the thrombus mass. 
Although sCD40L has already been shown to promote platelet/leukocyte aggregate formation, 
we were the first to demonstrate in an in vivo setting that the increase in leukocyte infiltration 
within the thrombus of sCD40L-treated mice is CD40-dependent.310 The synergy between the 
increase in leukocyte (probably TF expressing leukocytes) infiltration and the enhanced platelet 
predisposition to activation and aggregation in response to vascular injury may explain the 
increased thrombus formation in the animals' in response to elevated levels of sCD40L. 
 The relative contribution of the soluble versus the membrane-bound form of CD40L in 
thrombus formation is still unknown. It is most likely that both forms are involved in the 
pathophysiological functions of the CD40/CD40L axis. In fact, our preliminary results  
(unpublished results) suggest that thrombin, which induces platelet membrane expression of 
CD40L, results in TRAF2 association with CD40 and activation of the canonical NF-κB 
signalling pathway in a CD40L-dependent manner. On the other hand, elevated levels of 
sCD40L, as seen under pathological conditions, predispose platelets to enhanced activation and 
aggregation in response to thrombotic stimuli. Nonetheless, the involvement of CD40L in 
atherogenesis, thrombus formation, platelet-mediated inflammation, and plaque instability makes 
it a potential target for the treatment of thrombo-inflammatory complications. In this regard, it be 
would relevant for future clinical studies to evaluate the level of platelet priming in ACS 
patients, who present elevated levels of sCD40L. This could be done by assessing the levels of 
TRAF2 association with CD40 or the activation of the NF-κB signalling pathway. Thus, a direct 
clinical association between the levels of circulating sCD40L and platelet function could be 
established for pharmacological targeting. 
 In summary, our studies show for the first time the in vitro and in vivo pathophysiological 
implication of sCD40L in different aspects of platelet function. We demonstrated that sCD40L 
potentiates platelet activation and aggregation in a CD40-dependent manner through two 
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divergent signalling pathways (Annex I, figure 3). The first signalling pathway involves 
TRAF2/Rac1/p38 MAPK, while the second involves TRAF2/NF-κB. In addition, our results 
show that an increase in circulating sCD40L levels exacerbates in vivo thrombus formation in 
response to arterial injury, and leukocyte infiltration within the thrombus mass in a CD40-
dependent manner. Therefore, these studies provide novel evidences for the regulation of platelet 
function by sCD40L and may explain in part the link between enhanced levels of sCD40L and 
the incidence of cardiovascular complications. The CD40/CD40L axis may eventually represent 
a therapeutic target for the treatment of thrombo-inflammatory diseases.  
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The results of our studies reveal a novel role for sCD40L in regulating platelet function and 
thrombus formation. In fact, the underlying cellular and molecular mechanisms induced by 
sCD40L, which affect platelet activation, aggregation, and thrombus formation, were 
unexplored. Interestingly, the most relevant results of our studies stem from the correlation 
between increased levels of circulating sCD40L and exacerbated in vivo thrombosis, which may 
explain in part the link between enhanced levels of sCD40L seen in ACS patients and disease 
complications. Moreover, the identification of the intracellular signalling pathways by which 
sCD40L affects platelet function provides important clues for the development of specific 
therapeutic targets for the treatment of thrombotic diseases. 
 However, as for any other pharmacological target, care should be taken in developing 
specific antagonists against the CD40/CD40L dyad in order to avoid unwanted side effects. For 
instance, blockade of either CD40 or CD40L could result in immune defects, such as the one 
seen in HIGM patients who lack effective development of an adaptive immune system in 
addition to increased cancer incidence due to a lack of an immune response against tumour cells. 
Therefore, a better understanding of the mechanisms by which this dyad affects platelet function 
would be necessary in order to develop effective pharmacological tools against specific 
signalling pathways involved in platelet CD40 signalling. A suggestive approach would be to 
target CD40-induced TRAF2 signalling specifically in platelets through either the use of peptides 
that interfere with TRAF2/CD40 interactions, or the use of vectors or nanoparticles that block 
CD40 or TRAF2. 
 Although our studies add significant novel insights into the cellular and molecular 
mechanisms by which sCD40L affects platelet function, they do not answer all the questions and 
issues related to CD40/CD40L interactions in platelets. For instance, future studies addressing 
the following issues could provide more insights into the role and the mechanisms of action of 
the CD40L/CD40 axis in platelets: 
1 -  What is the exact role of TRAF2 in platelet CD40 signalling, specifically in response to 
thrombin? 
2 -  What is the exact role of the canonical NF-κB signalling pathway in platelet CD40 
signalling? Is it involved in regulating de novo protein synthesis by modulating mRNA 
translation through its interaction with miRNAs or degranulation? 
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3 -  Is the non-canonical NF-κB signalling pathway activated by sCD40L, given that TRAF2 
is involved in the activation of both NF-κB pathways? If yes, what is its role in platelet 
function in response to sCD40L? 
4 -  What is the relative contribution of the p38 MAPK and NF-κB signalling pathways 
downstream of platelet CD40? 
5 -  Does sCD40L induce its effects on platelets through ROS generation? 
6 -  What is the relative contribution of CD40 and αIIbβ3 in platelet function in response to the 
membrane-bound or soluble forms of CD40L? 
7 -  Can elevated levels of sCD40L be used as a cardiovascular disease diagnostic marker, 
such as troponin? 
Answers to these questions will undoubtedly bring important contributions to our knowledge 
regarding the precise role of the CD40/CD40L axis in platelets, and consequently in thrombotic 
cardiovascular disease development. 
 In conclusion, our studies confirm the tight link between the CD40/CD40L axis, 
inflammation and thrombotic cardiovascular disease pathogenesis, and suggest that this dyad 
may ultimately represent a potential therapeutic target in the treatment of these diseases. 
Nonetheless, further investigations are required to better understand the role of this dyad and its 
molecular partners in disease development and progression.  
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Unpublished results 
 
This section includes data that were not published. 
Figure 1 
  
200 
 
Figure 1: Thrombin and sCD40L induce TRAF2 association with CD40 and IκBα phosphorylation in platelets. A. 
CD40 and CD40L expression on platelets following thrombin stimulation. Platelets (250 X 106/mL) were left 
untreated or stimulated with thrombin (0.1 U/mL) and assessed for CD40 and CD40L expression by flow cytometry. 
Histogram represents the mean of data expressed as percent of CD40 and CD40L positive platelets (n=3; *P<0.05 
vs. baseline). B. Platelets (500 X 106/mL) were left untreated or incubated with 1 μg/mL sCD40L or 0.1 U/mL 
thrombin for 15 minutes at 37ºC in the presence or absence of a blocking anti-CD40L antibody (5 μg/mL). Total cell 
lysates were then immunoprecipated using an anti-CD40 antibody and immunoblotted for TRAF2 and CD40 
expression. Blots are representative of 3 independent experiments. Histogram represents the mean of data of overlay 
blots, expressed as arbitrary units of optical density (n=3; *P<0.05 vs. baseline and †P<0.05 vs. sCD40L or 
thrombin alone). C. Dose-dependent effect of anti-CD40L treatment on IκBα phosphorylation. Platelets (1000 X 
106/mL) were left untreated or pretreated with the indicated dose of anti-CD40L for 5 minutes at 37ºC prior to 
stimulation with sCD40L (n=5) or thrombin (n=3) for 5 minutes. Platelet lysates were then analyzed for p-IκBα 
Ser32/36. β-actin blots shown are from stripped p-IκBα Ser32/36 membranes. Blots are representative of the indicated 
number of independent experiments. Histogram represent the mean of data of overlay blots, expressed as arbitrary 
units of optical density (*P<0.05 vs. baseline and †P<0.05 vs. sCD40L or thrombin alone). 
 
 
 
 
Figure 2 
 
   
Figure 2: Effects of sCD40L and thrombin on TxA2 secretion. Platelets (250 X 106/mL) were left untreated or 
treated with sCD40L (1 μg/mL) or thrombin (0.5 U/mL) and supernatants were assessed for 11-dehydro-TxB2 (the 
stable metabolite of TxA2) by ELISA. Histogram represents the mean of data expressed as pg/mL of 11-dehydro-
TxB2 (n=4; *P<0.05 vs. baseline). 
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Schematic representation 
 
This section includes a schematic representation of the signalling pathways downstream of 
platelet CD40 that were discovered in our studies. 
Figure 3 
 
 
Figure 3: Schematic representation of the two divergent signalling pathways downstream of platelet CD40. Upon 
sCD40L/CD40  interaction, TRAF2 associates with the cytoplasmic tail of CD40. TRAF2 then induces activation of 
IKK, which in turn is responsible for IκBα phosphorylation and its subsequent degradation and release of the active 
form of NF-κB. On the other hand, TRAF2 activates Rac1, which in turn activates p38 MAPK. It is still unknown 
how TRAF2 induces activation of VASP. Culmination of these signalling pathways leads to the observed effects of 
the CD40/CD40L dyad on platelet function. Image is produced by Hachem A.  
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